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ABSTRACT
Characterisation of Clonal Variants in a Human Lung Carcinoma Cell Line: 
Investigations into Control of Growth and Differentiation
Analysis of many human tumours reveals the presence of two or more heterogenous cell 
subpopulations. Lung cancer in particular exhibits a large degree of intrinsic 
heterogeneity. DLKP, a human lung cell line established from a tumour which was 
histologically diagnosed as a ‘poorly differentiated squamous carcinoma’, appears to 
consist of three morphologically distinct populations. In this study, three clones 
apparently corresponding to these populations were established from the parental DLKP 
cells. The growth patterns of these isolated populations in monolayer culture, soft agar, 
spinner flasks and serum-free medium were investigated and it was found that in all but 
the latter assay, the parental DLKP cells grew faster than each of the clones and that 
the growth of the clones themselves varied under the different assay conditions. One 
clone appears to behave similarly to a multipotent, stem cell-like population, capable 
o f giving rise to the two other clonal morphologies. Variation between the clones was 
also seen in their respective chromosome numbers and in their ability to adhere to 
extracellular matrix proteins.
An immunohistological characterisation of the DLKP cells and clones was carried out. 
While each cell line was found to be negative for the expression of keratin and all other 
epithelial markers examined, the presence of neuron-specific enolase, protein gene 
product 9.5 and neurofilament reactivity indicated a degree of neuroendocrine (NE) 
differentiation. These results suggest that the DLKP cell line should be classified as 
either variant small cell lung carcinoma (SCLC-V) or non-small cell lung carcinoma 
with NE differentiation (NSCLC-NE).
Studies employing the differentiation-inducing agents, 5-bromodeoxyuridine (BrdU) and 
retinoic acid (RA), resulted in induction of keratin expression in DLKP cells and in 
each of the clonal subpopulations. A similar effect was found in another keratin-
negative lung carcinoma cell line in response to BrdU and this agent also appeared to 
increase keratin expression in cell lines which inherently expressed keratin intermediate 
filaments.
Multidrug resistance (MDR) is a phenomenon which plays a significant role in the 
fatality of lung cancer. The proliferative capabilities of DLKP were compared with 
those of an MDR variant cell line, DLKP-A, and no significant differences were found. 
In addition, a clonal subpopulation of DLKP-A were transfected with a ribozyme 
capable of targetting and reducing the expression of p-glycoprotein, a membrane efflux 
pump involved in drug resistance. Drug resistance was successfully reversed in 
transfected cells to levels approaching those of parental DLKP sensitive cells.
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INTRODUCTION
1.0 INTRODUCTION
The lung functions as the principal organ of gas exchange in the body. It also carries 
out a range of nonventilatory functions including humidification, thermal regulation, 
mucociliary clearance and elimination of volatile substances.
The adult mammal lung contains over 40 different cell types, at least 8 of which are 
found in the epithelial lining of the tracheobronchial airways. These epithelial cells 
include ciliated cells, basal cells, brush cells, mucous goblet cells, serous cells, Clara 
cells, type I and type II cells and neuroendocrine cells, (the latter 5 of which function 
as secretory cells), and a variety of partially differentiated cell types. The distribution 
of these cells varies throughout the airways and marked species variation is also seen.
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1.1 LUNG DEVELOPMENT
The primordial lung arises as a bulb-shaped extension of the wall of the primitive 
endodermal digestive tract. This lung bud divides into 2 bronchial buds which proceed 
to differentiate into the bronchi. During the 5th week of human development, each 
bronchial bud enlarges to form the primordium of a primary bronchus. The primary 
bronchi subsequently subdivide into secondary bronchi and progressive branching then 
occurs such that by 24 weeks, approximately 17 orders of branches have formed and 
respiratory bronchioles have developed. A further 7 orders of airways develop after 
birth.
In humans, the development of the lung may be characterised in general by 4 stages, 
the last of which is completed at around 8 years of age.
The p s e u d o g la n d u la r  p e r io d  (5 to 17 weeks) is so-called because the lung resembles an 
exocrine gland during this time. The epithelium, which is derived from the pharyngeal 
endoderm, is separated from surrounding mesodermal elements by a basement 
membrane. The epithelial cells are tall columnar in appearance at the early stages of 
this period and become low columnar (cuboidal) later on. These epithelial cells are 
undifferentiated and contain large amounts of glycogen which is indicative of immature 
lung epithelial cells.
The first cell type to differentiate in human fetal lung is the neuroendocrine cell which 
appears in the larger bronchi of pseudoglandular lungs around 8 weeks of gestation. At 
first, these cells appear short and glycogen-depleted with a few dense core granules 
visible in the cytoplasm. These immature endocrine cells usually occur in clusters and 
occupy only the basal part of the epithelium at this stage.
Ciliated cells begin to appear after 10 weeks and differentiating mucus-secreting cells 
are present from week 13, along with submucosal glands. Basal cells also begin to 
differentiate at this stage, but mature basal cells are the last mature cell type to appear 
in the epithelium.
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The c a n a l ic u la r  p e r io d  (16 to 25 weeks) sees the emergence of the respiratory 
bronchioles. Type I alveolar epithelial cells appear at this stage as determined by 
thinning and stretching of the periphery of the cytoplasm of these cells. Differentiation 
of type II epithelial cells also takes place. This occurs when the undifferentiated 
cuboidal cells begin to develop osmiophilic inclusion bodies, organelles characteristic 
of type II cells, within the cytoplasm. Clara cells begin to mature in the 19th week of 
development.
By 24 weeks, each terminal bronchiole has given rise to 2 or more respiratory 
bronchioles, some of which have developed terminal sacs which are well vascularised.
The te r m in a l  s a c  p e r io d  (24 weeks to birth) sees the development of large numbers of 
terminal sacs. The epithelium of these primitive alveoli is very thin and capillaries 
begin to bulge into them. Terminal sacs are lined mainly by squamous type I cells, 
scattered among which are rounded, secretory type II cells. These are mature type II 
cells which contain large numbers of inclusion bodies and no glycogen. These cells 
secrete surfactant which forms a film over the epithelium and serves to counteract 
surface tension and facilitates expansion of the terminal sacs.
By the beginning of the a lv e o la r  p e r io d  (late fetal period to about 8 years), the lungs 
are capable of respiration as the alveolar epithelial membrane is thin enough to allow 
gas exchange. Before birth, the immature alveoli appear as small bulges in the walls of 
the terminal sacs and the respiratory bronchioles. After birth, the primitive alveoli 
enlarge and for up to a further 8 years, the number of alveoli continues to increase.
The sequence of appearance of the various epithelial cell types during development has 
been shown to be similar in other species including mouse (Have-Opbroek, 1991), 
hamster (McDowell e t  a l . , 1985) and monkey (Plopper e t a l., 1986).
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1.2 LUNG EPITHELIAL CELL TYPES
As mentioned in Section 1.0, up to 8 epithelial cell types have been identified in the 
adult lung and these are believed to arise from a common precursor stem cell (Figure 
1.2.1). Features of these epithelial cells will be discussed here.
C il ia te d  c e lls
The ciliated cells of the lung epithelium are terminally differentiated. Their primary 
function is to sweep layers of mucus, together with trapped particles of dust and dead 
cells, up towards the mouth where they are swallowed and eliminated. The cilia are 
approximately 0.25/im in diameter and are constructed from microtubule cytoskeletal 
filaments.
B a s a l c e lls
Basal cells are morphologically characterised as a small pyramidal element attached to 
the basal lamina (Lentz, 1971, McDowell and Beals, 1986) and were long considered 
to be the stem cell population of the lung epithelium. 2 different morphological types 
of basal cells have been described (Baldwin e t a l . ,  1991) (Figure 1.2.2). Additional 
analysis of these cells (Baldwin, 1994) revealed that the ‘typical’ basal cell is the most 
abundant and represents the established morphological description for basal cells. The 
‘atypical’ basal cell has an elongated shape and a spindle-shaped nucleus. Both cell 
types are attached firmly to the basement membrane by junctions. Any progenitoral role 
of the atypical basal cell has yet to be elucidated, as does its relationship to the typical 
basal cell.
A possible function for both basal cell types has been proposed by Evans and Plopper 
(1988), who outlined the role the basal cell may play in the adhesion of columnar 
epithelia to the basement membrane. While airway columnar cells (ciliated and 
nonciliated) form desmosomal attachments with neighbouring columnar and basal cells, 
they do not form hemidesmosomal attachments with the basement membrane (Tandler
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Figure 1.2.1 Unitarian theory of the origin of lung epithelial cells.
AFigure 1.2.2 Diagrammatic representation of A. typical and B. atypical 
basal cells.
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e t a l . , 1981). Basal cells may thus serve as a means of attachment of columnar cells to 
the underlying basement membrane.
As mentioned earlier, basal cells were once believed to be the stem cell population of 
the lung epithelium. However, during development, basal cells appear last and so are 
at least not the ontogenic precursors of secretory and ciliated cells (Plopper e t a l . ,  
1986, McDowell e t  a l . , 1985). In the adult lung, the stem cell compartment has yet to 
be identified. Donnelly and co-workers (1982) demonstrated that basal cells were 
capable of DNA synthesis and cell division, thus confirming their proliferative 
potential, but the pluripotentiality of these cells remains contentious.
Inayama e t a l . ,  (1988 and 1989), examined the ability of clones of tracheal basal cells 
to proliferate in  v i t r o  and to reepithelialise denuded tracheal grafts with a mucociliary 
epithelium. When cultured in  v i t r o ,  on feeder layers or on plastic, the basal cells were 
found to proliferate and underwent 15 to 20 population doublings. After 5 days in 
culture, the cells changed from colonies of tightly packed, small, round cells to colonies 
of mixed morphology containing larger cells with abundant cytoplasm. After 20 days 
in culture, all colonies contained a mixture of small and large cells with the larger cells 
usually predominating. Squamous differentiation was demonstrated by the presence of 
cross-linked envelopes in some of the cells. When inoculated into denuded tracheal 
grafts, the basal cells gave rise to a mucociliary epithelium.
Reports from Randell’s group (Liu e t a l . , 1994) also provide evidence for the role of 
basal cells as progenitor cells in the lung epithelium. In their studies, the binding site 
for G r if fo n ia  s im p l i c i f o l ia  1 (GS1)-B4 lectin and keratin 14 were used as markers for 
basal cells which were sorted by flow cytometry. The resulting population, which was 
>95% pure basal cells, was used to inoculate denuded tracheal grafts. A subfraction 
highly enriched with secretory and ciliated cells and depleted of basal cells was also 
analysed. Both fractions gave rise to a ‘poorly differentiated’ (PD) epithelial lining. The 
PD cells were structurally unlike basal, secretory or ciliated cells and contained lipid 
droplets and glycogen accumulations. These cells were positive for keratin 14. The PD 
epithelia established by both subfractions subsequently gave rise to a mucociliary
7
epithelium. These findings indicate that both basal and secretory cells ‘dedifferentiate’ 
into a PD cell that is an intermediate in the regeneration process of this model. 
However, it was noted that pure populations were not used and the model system 
employed is one of extreme mechanical injury which is often not the case in  v iv o .
In contrast to these observations, evidence against the role of lung basal cells as 
progenitor cells comes from Johnson and Hubbs (1990). These workers found that in 
an isolation of tracheal epitheal cells analysed by flow cytometry, secretory cells 
accounted for 86% of cycling cells while the remainder consisted of basal cells. The 
basal cell fraction also had a lower colony forming efficiency than secretory cells. A 
later report from this group (Johnson e t a l . , 1990) stated that the secretory cell-rich 
fraction could repopulate tracheal grafts with all major cell types, while the basal cell 
fraction merely generated basal and ciliated cells. Additional reports from Plopper e t 
a l.  (1986) and McDowell e t a l. (1985) also refute the progenitor role of basal cells in 
epithelial regeneration.
B ru s h  C e lls
Brush cells are non-ciliated epithelial cells, distinguished by the presence of unusually 
long, straight microvilli and epitheliodendritic synapses with nerve processes that reach 
in from the connective tissue (Weiss, 1983). These cells are located in the trachea and 
are counterparts to similar cells located in the nasal lining (which may be involved in 
sensory input for the sneeze reflexes).
Brush cells are not easily seen in all mamalian species, but are conspicuous in the 
tracheas of rats where they have been shown to possess glycogen granules as well as 
a preponderance of agranular recticulum in the cytoplasm.
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Mucous (Goblet) Cells and Serous Cells
The mucous cell (or goblet cell) is one of the 2 types of lung surface secretory cells 
known to secrete mucous, the 2nd type being the less abundant serous cell. Most 
mucous cells contain high molecular weight mucous acidic glycoprotein and 
electronlucent confluent granules. Serous cells possess much rough endoplasmic 
recticulum and in contrast to mucous cells, contain few electron-dense granules. They 
are believed to contain neutral mucin and also possibly a non-mucoid substance, 
probably lipid. In general, the mucous-secreting cells are columnar in shape but some 
goblet-shaped cells occur as cells become distended by their intracellular secretion 
which compresses the nucleus to the base of the cell.
The progenitor potential of secretory cells was briefly alluded to previously during the 
discussion on basal cells. Johnson e t a l . ,  (1990) found that isolated secretory cells had 
a higher colony forming efficiency than basal cells, accounted for the majority of 
cycling cells in the rat tracheal epithelium and were capable of repopulating tracheal 
grafts with all the major cell types. Studies on the effects of mechanical injury and 
vitamin A deficiency on adult tracheal epithelium (McDowell e t a l . , 1984 and Keenan 
e t  a l . , 1982) revealed that when the epithelium is injured, secretory cells divide to form 
a keratinising, metaplastic epithelium. When the injurant is removed, secretory cells 
divide and give rise to presecretory and preciliated cells, shortly after which, a 
complete mucociliary epithelium is reestablished. Liu and co-workers (1994) also found 
that isolated secretory cells regenerated a mucociliary epithelium on tracheal grafts via 
a poorly differentiated intermediary cell type.
Submucosal glands are responsible for producing most of the mucous present in adult 
human trachea and bronchi. Each gland is tubular with a duct opening into the airway 
lumen. A gland usually consists of 4 regions (Meyrick e t a l . ,  1969): (i) a narrow 
ciliated duct, the lining cells of which are continuous with the surface epithelium, (ii) 
an expanded collecting duct lined with cells of intermediate morphology, (iii) mucous 
cells and (iv) serous cells.
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C la ra  C e lls  ( n o n - c i l ia te d  b r o n c h io la r  c e lls )
In adult human lungs, Clara cells are found only in the epithelium of the terminal 
bronchioles, in contrast to the mucous or serous cells which are found mainly in the 
larger conducting airways of the trachea and bronchi (Plopper e t a l . , 1980). Clara cells 
contain electron-dense secretory granules and very little glycogen is present in adult 
cells. The apical membrane (facing into the lumen) of the Clara cell protrudes into the 
airway lumen and this periphery of the cell contains many secretory granules in position 
for release (Massaro e t  a l ., 1979).
Clara cells serve as stem cells in the bronchiolar epithelium. They divide to give rise 
to other Clara cells and also terminally differentiate into ciliated cells (Ayers and 
Jeffeiy, 1988). Hook and co-workers (1987) demonstrated that isolated Clara cells were 
capable of establishing a complete bronchiolar epithelial lining.
Clara cells contain the cytochrome P-450 monooxygenase pathway involved in the 
metabolism of foreign compounds and the concentration of cytochrome P-450 isozymes 
in these cells appears to exceed greatly that of other pulmonary cell types (Domin e t 
a l . ,  1986). The resulting activation of xenobiotic compounds implicates the Clara cell 
as a possible progenitor cell for the development of some pulmonary tumours.
The nature of the secretory product(s) produced and released by Clara cells is as yet 
unclear. The evidence for these cells having a significant secretory role in the lung is 
largely circumstantial and based mainly on ultrastructural and morphological 
characteristics. Clara cells contain ample rough endoplasmic recticulum, a well- 
developed Golgi apparatus and membrane-bound inclusions (storage granules), all of 
which are indicative of secretory cells. In addition, the cells appear to empty the 
contents of their secretory granules into the lumen of the airways (Kuhn and Callaway, 
1975) and elements of these secretions appear to be similar to those of other lung 
secretory cells (type II cells) (Ward e t a l . ,  1985).
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Alveolar Type I and Type II cells
Alveolar type I and type II cells are the main cells which comprise the bronchiolar 
epithelium (Penney, 1988). Type I cells are squamous in morphology, extremely 
flattened and thin, facilitating the exchange of gases in the alveoli. Type II cells, in 
contrast, have a cuboidal shape and contain characteristic lamellar inclusion bodies. 
Functions of type II cells include the synthesis, storage and secretion of surface active 
material (surfactant) (Chevalier and Collet, 1972), transepithelial solute transport to 
regulate the volume and composition of alveolar fluid (Goodman e t a l . , 1983) and re- 
epithelialisation of the alveoli after lung injury by differentiation into type I cells which 
are terminally differentiated (Adamson and Bowden, 1975).
Type II cells contain the cytochrome P-450 monooxygenase pathway involved in the 
metabolism of xenobiotics (Devereux e t a l . ,  1989), although the P-450 isozymes are 
present at lower concentrations than those of Clara cells. Nonetheless, type II cell 
damage has been demonstrated following metabolism of exogenous compounds (Wadell 
and Marlow, 1980). Under normal conditions, type II cells proliferate relatively slowly 
in the adult lung. The turnover is believed to occur approximately every 4-5 weeks 
(Kauffman, 1980). In response to alveolar lining injury however, type II cell 
proliferation increases dramatically (Smith and Brody, 1981) to replace damaged type 
I and type II cells. Because of their large surface area and relative inability to repair 
damage due to their low levels of energy-producing organelles such as mitochondria, 
endoplasmic recticulum and Golgi apparatus, the type I cells are often the major site 
of damage in the lung following a pulmonary insult. Subsequent to destruction of type
I cells, type II cells proliferate to restore the alveolar epithelium (Penney, 1988).
Considerable diversity exists amongst reports concerning the role of Clara cells and type
II cells in the development of pulmonary tumours in laboratory animals exposed to 
carcinogens. Several reports state that either type II cells (Rehm e t a l . , 1988 and 1991a 
and Khalil e t  a l . ,  1994) or Clara cells (Ward e t  a l . ,  1985, Rehm e t a l . ,  1991b and 
Belinsky e t  a l . , 1991) or both (Thaete and Malkinson, 1991), depending on the nature 
of the insult, are the origins of spontaneous and induced mouse and/or rat lung tumours.
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Both must be candidates for the originating cell(s) of pulmonary carcinomas in human 
due to their suseptibility to toxic and carcinogenic injury and their innate functions as 
progenitor cells of the lung epithelium.
N e u ro e n d o c r in e  C e lls
As mentioned earlier, neuroendocrine (NE) cells are the first differentiated cell type to 
appear in the developing lung. These cells belong to the diffuse endocrine system of the 
body that includes the polypeptide hormone-secreting enterochromaffin cells of the 
gastrointestinal tract and cells of the adrenal and thyroid glands.
Mature NE cells in human lungs are usually tall and pyramidal in appearance and 
contain numerous characteristic membrane-bound dense core granules. These granules 
contain a range of neural-related amines and peptides. Serotonin, neuron-specific 
enolase (NSE), bombesin-like peptides (gastrin-releasing peptide - GRP), calcitonin and 
calcitonin gene-related peptide have all been demonstrated in the NE cells of human 
fetal lungs. Both serotonin (Cutz, e t a l . , 1985) and NSE (Sheppard e t a l . , 1984) are 
present in immature NE cells at 8 weeks. GRP is the first peptide to appear and mRNA 
levels peak between 16-25 weeks (Spindel e t a l . , 1987). Calcitonin reactivity occurs 
later at 20-22 weeks (Sheppard e t a l . , 1984) but levels never reach those of GRP.
NE cells can occur singly in the lung epithelium or in clusters called neuroepithelial 
bodies (NEBs). The paucity of NE cells in the lungs of normal human adults led to the 
belief that the most crucial role of these cells is in fetal pulmonary development 
(Gosney, 1992). Hoyt e t a l . ,  (1991 and 1993), have demonstrated the proliferative 
effect of fetal pulmonary NEBs on local endoderm. Attempts to demonstrate 
proliferation of NE cells in normal adult lung have been largely unsuccessful. 2 reports 
of 3H-thymidine incorporation into normal NE cells (Linnoila, 1982 and Hoyt e t a l . , 
1988) indicated that these cells differentiate slowly from precursor cells or that 
differentiated NE cells can divide, although infrequently. The role of pulmonary NE 
cells in adult lung thus remains unclear. The demonstration of innervation and synaptic 
contact in some NE cells and NEBs (Lauweryns and Cokelaere, 1970) suggests a 
possible sensory role for these cells but no such function has been proven.
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The overlap in markers expressed in SCLC and NE cells (Hattori e t  a l . , 1968, Tateishi 
e t  a l . , 1978, Baylin e t  a l . , 1978 and Gazdar e t  a l . , 1980) led to the belief that NE cells 
were the specific precursor cells of SCLC (Pearse, 1969). However, the increasing 
demonstrations of markers common to several lung cancer subtypes has led to the 
common stem cell thoery for lung cancer. This theory is discussed in more detail in the 
next section.
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1.3 CLASSIFICATION OF LUNG CANCERS
Lung cancer is the leading cause of cancer death in the western world (Silverberg and 
Lubera, 1988). In 1982, the World Health Organisation revised the histological 
classification of lung tumours (World Health Organisation, 1982) which had originally 
been published in 1967 (Kreyberg, 1967). Malignant epithelial tumours are the most 
common lethal lung tumours. These have been broadly classed into non-small cell lung 
cancer (NSCLC) comprising squamous, adeno- and large cell carcinomas and small cell 
lung cancer (SCLC). The 2 classes account for approximately 75% and 25% of lung 
cancers respectively. NSCLC is usually treated by surgical resection, due to a poor 
response to anticancer drugs, with a 15% cure rate while chemotherapy, with or 
without radiotherapy, is the treatment commonly used for SCLC, with a 5% cure rate 
(Minna e t a l . ,  1989). The poor success rate in lung cancer treatment is due to several 
factors including early systemic spread, inability to detect early stages of the disease, 
ineffective treatment agents and the development of drug resistance following exposure 
to chemotherapeutic agents.
The WHO classification of lung tumours is based entirely on conventional light 
microscopic determination and subsequent treatment is frequently based solely on the 
resulting diagnosis. However, there is accumulating evidence that the current working 
criteria for tumour classification may be misleading. Heterogeneity within most 
individual tumours has been recognised for some time now (Weber, 1980, Fidler and 
Hart, 1982 and Owens e t a l . ,  1982). Evidence that expression of SCLC-related 
biochemical markers on NSCLC cells may result in improved response to chemotherapy 
(Ruckdeschel e t a l . ,  1991) suggests that knowledge of the biochemical composition of 
lung cancer cells may provide information about the clinical behaviour of these cells 
that is not apparent in routine histological analysis.
The classification of malignant epithelial lung tumours will now be discussed in more 
detail.
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SQUAMOUS CELL CARCINOMA
The 1982 WHO classification of lung tumours describes squamous cell carcinoma as 
a ‘malignant epithelial tumour with keratinisation and/or intercellular bridges’ and the 
presence o f trace amounts of intracellular mucin should not exclude tumours from this 
category. 3  histological degrees of differentiation of squamous cell carcinoma are 
described: (i) ‘well differentiated’ which exhibits orderly stratification, obvious 
intercellular bridges (desmosomes) and keratinisation with pearl formation, (ii) 
‘moderately differentiated’ with features intermediate between well differentiated and 
poorly differentiated and (iii) ‘poorly differentiated’ when keratin and/or bridges are 
present in a largely undifferentiated tumour or when these features are detected with 
difficulty.
Squamous cell carcinomas are the commonest form of lung cancer. They usually occur 
in the larger bronchi and are believed to arise from foci o f atypical squamous 
metaplasia. As with all cancer types, cytogenetic analysis has been carried out on 
squamous cell carcinomas (Buchmann, et al., 1991, Testa and Siegfried, 1992 and 
Rodenhuis and Slebos, 1992) in an attempt to indentify any specific chromosomal 
abnormalities or alterations that may have clinical significance in therapy and prognosis. 
It is hoped that this work may also elucidate some of the events involved in malignant 
transformation. However, because of the relatively low mitotic index of many primary 
NSCLC tumours and the often complex karyotypes, identification of consistent 
chromosomal abnormalities has proven difficult. Despite these complications, genetic 
aberrations have been reported including chromosome deletions and allelic losses 
(Weston et al., 1989, Shiseki et al. , 1994 and Sato et al. , 1994), near-triploid and near- 
tetraploid karyotypes (Testa and Seigfried, 1992), enhanced expression of ras oncogenes 
(Miyaki et al. , 1985) and differential expression of genes in normal lung and NSCLC 
tissue (Schraml et al., 1994).
The presence o f  additional copies of specific chromosomes and genes has been linked 
in theory to the overexpression of stimulatory growth factors and their receptors in 
NSCLC. Testa and Siegfried (1992) demonstrated partial gains in chromosome 7 of
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NSCLCs in the region where the epidermal growth factor (EGF) receptor gene is 
located (Spurr et al., 1984). Reports of increased expression of the EGF receptor 
protein and the EGF ligand itself in squamous cell lung cancers (Hendler and Ozanne, 
1984 and Ozanne et al. , 1986) and overexpression in cell lines (Sakiyama et al., 1986 
and Haeder et al., 1988) have led to speculative links between increased chromosome 
numbers and chromosome gains and overexpression of growth regulatory proteins, but 
no real link has yet been proven.
Several protein markers have been used in immunocytochemical studies to determine 
squamous differentiation. One such marker is transglutaminase. Transglutaminases are 
a group of enzymes that covalently link peptide-bound glutamine to primary amines 
such as lysine (Folk, 1985) and as such, these enzymes catalyse the formation of cross- 
linked envelopes during squamous differentiation (Green, 1977). The expression of this 
enzyme during squamous differentiation of tracheal epithelium has been demonstrated 
(Jetten and Shirley, 1986).
Specific keratin intermediate filament proteins are expressed in squamous differentiated 
cells and can be used as markers for this phenotype. Broers and colleagues (1988) 
demonstrated that highly differentiated human lung squamous carcinomas expressed 
high levels of keratins 4, 10 and 13. In addition, reduction o f squamous differentiation 
correlated with a loss of these specific keratins and an increase in keratins 7, 8 , 18 and 
19. A serum marker for patients with NSCLC has recently been evaluated (van der 
Gaast et al., 1994). Cyfra 21.1 is a fragment of keratin 19 (Pujol, et al. , 1993) and was 
shown to be a sensitive marker for squamous cell carcinoma.
Cholesterol sulfate (Rearick et al. , 1987a) and sulfotransferase (Rearick et al. , 1987b) 
have also been described as markers for squamous cell differentiation in lung epithelial 
cells.
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ADENOCARCINOMA
A second category o f NSCLC is adenocarcinoma. This tumour type is described in the 
WHO classification as malignant epithelial with tubular, acinar (glandular) or papillary 
growth patterns and/or mucous production by the tumour cells. In moderately 
differentiated adenocarcinomas, cells have rounded nuclei, coarse chromatin and large, 
prominent nucleoli. The cytoplasm is moderate in amount and may contain fine or 
coarse mucin-like vacuoles.
Adenocarcinomas are subdivided according to the WHO classification as follows: (i) 
adenocarcinoma which has a predominance o f glandular structures with or without 
papillary or solid areas and occurs predominantly in the larger bronchi, (ii) papillary 
adenocarcinoma with a predominance o f papillary structures, (iii) bronchioalveolar 
carcinoma in which cylindrical tumour cells grow upon the walls of preexisting alveoli 
and (iv) solid carcinoma with mucous formation which is a poorly differentiated 
adenocarcinoma lacking acini, tubules and papillae but with mucin-containing vacuoles 
with many tumour cells.
Chromosomal aberations similar to those o f squamous cell carcinomas have been 
detected in adenocarcinomas including increased numbers of chromosomes and partial 
gains of chromosomes (Testa and Siegfried, 1992) and amplification o f myc and ras 
protooncogenes (Slebos et al. , 1989, Rodenhuis et al. , 1987, Saksela et al., 1986 and 
Yokota et al., 1986). A putative tumour suppressor gene has been identified on 
chromosome 4 and Herzog et al. (1994) have demonstrated allelic loss of this gene in 
48% of lung adenocarcinomas.
As with squamous carcinomas, adenocarcinomas are often positive for EGF receptor 
expression (Haeder et al. , 1988).
Morphologically and biochemically, adenocarcinomas often demonstrate differentiation 
toward Clara cells and type II cells. Ultrastructural studies on adenocarcinoma lung cell 
lines (Gazdar et al., 1990 and Linnoila et al., 1992) have revealed cytoplasmic
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inclusions characteristic of Clara cells and type II cells and in addition, these cells also 
expressed the surfactant-associated proteins SP-A, SP-B and to a lesser extent SP-C. 
Adenocarcinoma cell lines also often produce and secrete Clara cell 10-kDa protein 
(Gazdar et al. , 1990).
LARGE CELL CARCINOMAS
The WHO classification of lung cancer (1982) describes large cell carcinomas as 
malignant epithelial tumours with large nuclei, prominent nucleoli, abundant cytoplasm 
and usually well-defined cell borders, without the characteristic features of squamous 
cells, small cell or adenocarcinomas. 2  variants o f large cell carcinomas are described; 
(i) giant cell carcinoma which consists of a significant number o f pleomorphic, 
multinucleated cells and (ii) clear cell carcinoma which comprises elements with clear 
or foamy cytoplasm without mucin and they may or may not contain glycogen.
Large cell carcinomas have no distinguishing features visible by light microscopic 
analysis. Giant cell carcinomas are very aggressive and highly malignant and are usually 
found at the later stages of malignancy (Yesner and Carter, 1982). Clear cell tumours 
are rare and most behave in a benign fashion.
Most large cell carcinoma cell lines grow as attached epitheloid cells without evidence 
o f squamous, glandular or papillary differentiation. However, immunocytochemical 
demonstration o f gastrin-releasing peptide reactivity in some large cells carcinomas 
(Hamid et al. , 1990) suggests a degree of NE differentiation in such tumours.
In vivo, large cell carcinomas may be categorised as 2 subtypes, a compact growth type 
and a loose structure type. Ishida et al. (1990) have proposed that the compact growth 
type represents a slightly more differentiated cell type due to the higher incidence of 
markers such as keratin, epithelial membrane antigen, secretory component, lactoferrin 
and carcinoembryonic antigen on these cells compared with the loose structure type.
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SMALL CELL CARCINOMA
Small cell carcinomas are a subtype of neuroendocrine tumour. Other subtypes include 
classic carcinoid and atypical carcinoid (or well-differentiated NE carcinoma) which are 
discussed later here.
3 categories of small cell carcinoma were described in the WHO classification (1982). 
(i) Oat cell carcinoma which is a tumour composed of uniform small cells, having dense 
round or oval nuclei, diffuse chromatin, inconspicuous nucleoli and very sparse 
cytoplasm. This tumour type is also reported to be associated with the secretion of a 
variety of substances including adrenocorticotropic hormone (ACTH), serotonin, 
antidiuretic hormone, calcitonin, growth hormone and oestrogens. (ii) Small cell 
carcinoma, an intermediate type which is also composed of small cells but with more 
abundant cytoplasm. Morphologically, these cells are less regular in appearance than 
those of oat cell carcinoma and may be polygonal or fusiform (spindle-shaped). 
Secretions similar to those of oat cell carcinoma are also prevalent in this category, (iii) 
Combined oat cell carcinoma, in which there is a definite component o f oat cell 
carcinoma with adeno- and/or squamous cell carcinoma.
Of the 3 NE tumour subtypes mentioned above (small cell carcinoma, classic carcinoid 
and atypical carcinoid), small cell carcinoma is the most aggressive. This carcinoma 
metastasises early in its course (Churg, 1988) and is not usually amenable to surgical 
resection. Chemotherapy and radiotherapy are the usual methods o f treatment but 
multiple drug resistance (MDR) is a problem which often results from this course of 
action (discussed in Section 1.7).
Small cell carcinomas exhibit many features found in neuroendocrine cells o f the lung 
epithelium. Original opinion was that these NE cells were derived from the neural crest 
rather then being endodermal in origin (Pearse, 1969) and that NE tumours, including 
SCLC, subsequently arose from these cells. However, the current working hypothesis 
is that NE cells and their tumours originate from undifferentiated, totipotent bronchial 
epithelial cells i.e. there is a common stem cell origin for all lung epithelial cells
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(Yesner, 1978 and Gazdar et al., 1981). This theory is discussed further at the end of 
this section.
Several aberations have been detected at the gene level in SCLCs. High expression of 
ras, myb, raf-\ and other myc family protooncogenes has been demonstrated in SCLC 
tumour tissue and cell lines (Nakano et al., 1984, Griffin and Baylin, 1985, Kiefer et 
al., 1987, Nau et al., 1985 and Rapp et al., 1988). Amplification and overexpression 
of the myc gene family appears to be a unique feature of SCLCs (Carbone and Minna, 
1992). Plummer et al. (1993), have shown a correlation between expression of c-myc 
and suppression of c-kit, a gene which encodes a tyrosine kinase growth factor receptor 
for hemopoietic stem cell factor, in SCLC cells. Chromosome 3p deletions have been 
found to be common in SCLC cells also (Graziano et al., 1991) and Levin et al. (1994) 
have identified several genetic alterations in SCLC.
As mentioned above, small cell lung cancers express a number of NE features in 
common with pulmonary NE cells. Both normal and tumour NE cells have been 
demonstrated to contain dense core vesicles or neurosecretory granules (Ghadially, 1988 
and Dardick, 1993). These granules can either store amines or take up precusor 
substances and decarboxylate them to amines (Pearse, 1969 and 1974) and hence cells 
with these properties have been termed APUD (amine precursor uptake and 
decarboxylation) cells. The enzyme L-dopa decarboxylase (DDC) is involved in this 
system and is used as a marker for APUD cells, both normal and malignant (Gazdar 
et al., 1988). Chromogranin A (CgA) is a high molecular weight protein present in NE 
granules and believed to be a secretory protein, although its function is not known 
(O’Connor et al., 1983). CgA production has been demonstrated in cell lines 
established from NE cell lines (Bergh et al., 1989) and this is considered to be a 
marker for NE differentiation.
Serotonin production within the dense core vesicles of NE cells and tumour cells has 
also been demonstrated (Lauweryns et al., 1973 and Newman et al., 1993).
Peptides such as gastrin-releasing peptide (GRP), leucine-enkephalin and calcitonin have 
been immunolocalised to pulmonary NE cells and their tumours (Wharton et al., 1978,
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Tsutsumi et al., 1983, Cutz et al., 1981, Becker et al., 1980, Gazdar, 1984, 
Shimosegawa and Said, 1991, Ghillani et al., 1989 and Woll, 1991).
Enolase enzymes are dimers composed of a , 0 or y subunits which convert 2- 
phosphoglycerate to phosophoenolpyruvate. The y, y- and a, 7 -enolases are expressed 
mainly in neurons and NE cells (Kato et al., 1982) and the 7 -subunit of enolase is 
therefore known as neuron specific enolase (NSE). High levels of NSE have been 
detected in NE-related tumours, including SCLC (Odelstad et al., 1981, Ishiguro et al., 
1983 and Tapia et al., 1981) and this enzyme is used as a marker for NE-like cells.
Neural cell adhesion molecule (NCAM) is a major cell-cell-contact protein in adult 
neuronal tissue (Edelman, 1986) and immunoreactivity for this protein has been 
demonstrated in almost 100% of all SCLC (Berendsen et al., 1988 and Schol et al., 
1988). Serum NCAM and NSE appear to have potential as in vivo tumour markers for 
SCLC (Jaques et al., 1993).
Another marker used in the evaluation of NE differentiation in cells is Leu 7 which is 
an antigen present on a subpopulation of large granular lymphocytes which have natural 
killer cell and antibody-dependent cell-mediated cytolytic functions (Abo and Balch, 
1981). Leu 7 immunoreactivity has been demonstrated in normal nervous tissue and also 
in tumours o f neuroectodermal origin (Caillaud et al., 1984 and Mechtersheimer et al.,
1991).
Protein gene product 9.5 (PGP 9.5) is a member of the family of ubiquitin carboxyl- 
terminal hydrolases (Wilkinson et al., 1989). First isolated from human brain (Jackson 
and Thompson, 1981), expression of the PGP 9.5 antigen has been demonstrated on 
neuronal and neuroendocrine tissue (Thompson et al., 1983) and on tumours of 
neuronal and neuroendocrine origin (Brook et al., 1988 and Reubi et al., 1990).
Additional markers reported to be present on NE-tumour cells are creatine kinase 
(Watanabe et al., 1988), somatostatin receptors (Reubi et al., 1990), protein 1A-1 
(unidentified protein) (Lan et al., 1993), neuroendocrine-specific protein (NSP) gene 
proteins (van de Velde et al., 1994) and pro-gastrin-releasing peptide (31-98) (Miyake
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et al., 1994). Recently, Bcl-2 expression was detected on 65% of small cell carcinomas 
examined by Ben-Ezra et al. (1994) and the authors hypothesise that this oncoprotein 
may play a role in the pathogensis of SCLC.
VARIANT SMALL CELL LUNG CARCINOMA
In 1985, Carney and colleagues described 2 major classes of SCLC cell lines: (i) classic 
SCLC lines which expressed elevated levels of 4 NE biomarkers examined, namely L- 
dopa decarboxylase, bombesin-like peptides, NSE and creatine kinase and (ii) variant 
SCLC (SCLC-V) lines which did not express one or more of the 4 NE markers (L-dopa 
decarboxylase and/or bombesin-like peptides) but did express elevated levels of NSE 
and creatine kinase. Also described were 4 morphological categories o f SCLC cell 
lines. Type 1 grew as tightly packed floating aggregates with central necrosis, type 2 
grew as relatively densely packed floating aggregates of amorphous cells lacking central 
necrosis, type 3 grew as very loosely adherent floating aggregates and type 4 grew 
attached to the substrate and consisted of polygonal overlapping cells, lacking an 
epithelioid appearance. There appeared to be a correlation between loss of NE marker 
expression and increased substrate adherence. The authors suggested that these findings 
may be clinically relevant and related to their previous findings that the loss of NE 
features observed in large cell variants derived from SCLC cell lines may be linked 
with the increased radiation and chemotherapy sensitivity observed in the large cell 
variants (Carney et al., 1983).
A higher cloning efficiency and a faster doubling time have been reported for SCLC-V 
lines compared with classic SCLC (Gazdar et al., 1985) and Broers et al. (1988) 
reported that while classic SCLC cell lines contain keratin and lack neurofilament 
proteins, most SCLC-V lines do not contain detectable amounts of keratins but partly 
express neurofilaments and vimentin. Most SCLC-V lines are also positive for NCAM 
and Leu 7 expression (Carbone et al., 1991). Higher levels of c-myc expression have 
also been found in SCLC-V lines (Little et al., 1983). Several SCLC-V cell lines have 
now been reported (Bepler et al., 1987c, Watanabe et al. , 1988, Doyle et al., 1990 and 
Yokose et al., 1991).
22
Transition o f classic SCLC cell lines to the variant phenotype after prolonged 
cultivation (months to years) has been reported (Gazdar et al., 1985 and Bepler et al., 
1987a) and it has been postulated that this in vitro phenomenon parallels the situation 
in vivo as a tumour progresses from a classic SCLC to a mixed morphology (Bepler et 
al., 1987b).
While all o f the SCLC markers described previously have been demonstrated in NE 
tumour cells, it is becoming increasingly clear that few markers are actually specific for 
SCLC. The first suggestion of this came in 1981 when McDowell et al. described non­
small cell neuroendocrine lung carcinomas which had been diagnosed by light 
microscopy as squamous, large cell or adenocarcinomas. Electron microscopic 
examination revealed dense core neurosecretory granules within the tumour cells. Since 
this report, much evidence of overlap in markers expressed by different lung tumour 
types has become apparent. Neal and co-workers (1986) suggested that up to 9% of 
non-small cell carcinomas of the lung contain neurosecretory granules. NCAM has been 
reported in 20-30% of NSCLC (Schol et al., 1988). NSE, chromogranin A, bombesin, 
L-dopa decarboxylase, Leu 7 and synaptophysin were all once believed to be exclusive 
to SCLCs but have been demonstrated in NSCLCs (Graziano et al., 1994, Kayser et 
al., 1988, Pahlman et al., 1986, Yokose et al., 1991, Gazdar et al., 1988, Hamid et 
al., 1990, Bergh et al., 1989 and Cole et al., 1985). Where 2 or more NE markers are 
present in cancer cells with otherwise NSCLC features, these cells have been termed 
NSCLC with neuroendocrine differentiation or NSCLC-NE (Linnoila et al., 1988a and 
1988b).
Studies by Gazdar et al. (1991) indicated that the drug sensitivity of NSCLC-NE cell 
lines was increased with respect to NSCLC and similar to that o f SCLC lines. This 
suggests that NSCLC-NE could possibly be successfully treated with chemotherapy. 
However, no clinical correlation has yet been demonstrated. Indeed, a trial involving 
individualised chemotherapy for NSCLC patients based on the identification of NE 
markers proved unsuccessful (Shaw et al., 1993). A retrospective study by Graziano 
and colleagues (1994) also found that the presence of markers for NSE, Leu 7 and 
chromogranin were not o f prognostic significance in a group of patients studied. 
However, there is evidence that the presence of the NE marker NCAM is indicative of
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a poor prognosis in NSCLC (Schol et al. , 1988). In addition, Sundaresan et al. (1991) 
reported that patients with NSCLC-NE had increased levels of metastases compared 
with NSCLC patients and therefore detection of NE markers on NSCLC may be 
clinically relevant.
OTHER LUNG EPITHELIAL CARCINOMAS 
PULMONARY CARCINOID TUMOURS
Carcinoid tumours are rare and make up only 1-6% of all primary lung tumours 
(Yousem, 1991). These tumours were originally believed to be derived from embryoinc 
neural crest precursor cells but are currently thought to arise from a pleuripotent 
bronchial epithelial cell, as are all epithelial lung cancers (see end of section for ‘stem 
cell theory’). Histologically, carcinoids are composed of sheets of small round cells 
with uniform nuclei and cytoplasm. Neurosecretory granules are often present (Hage, 
1973) and a distinction between SCLC which also contains neurosecretory granules may 
be made on the basis of the morphology o f the intracytoplasmic secretory granules 
(Hage 1980). In addition, Komminoth et al. (1991) were able to distinguish NCAM 
present on SCLCs from that of carcinoids by immunological examination of the 
polysialic chains of NCAM.
Immunocytochemical analysis has demonstrated numerous peptides contained within 
carcinoids including NSE, serotonin, insulin, growth hormone, neurotensin and 
bombesin (Linnoila et al. , 1988a and Barbareschi et al. , 1992).
Carcinoids are a less aggressive tumour type than SCLC and Barbareschi and co- 
workers (1992) found a decrease in NE features from typical carcinoid to SCLC which 
was paralleled by an increase in proliferative activity and by an altered expression of 
tumour suppressor gene products. This indicates that loss o f differentiation features may 
be related to an increase in aggressive growth in tumours.
24
PULMONARY BLASTOMA
Pulmonary blastomas occur infrequently ( <  1 % of all lung tumours) and usually consist 
of a mixture o f immature mesenchymal and epithelial elements. These tumours are 
believed to recapitulate the pseudoglandular stage of the developing lung (Francis and 
Jacobsen, 1983 and Spencer, 1961).
Yousem et al. (1990) carried out an immunohistochemical study to compare the lung 
antigens expressed by pulmonary blastomas and immature human lungs at 10-16 weeks 
gestation i.e. pseudoglandular lungs. The authors found extensive similarities in protein 
marker expression between the cells in their expression of keratin, epithelial membrane 
antigen, carcinoembryonic antigen, chromogranin-positive neuroendocrine cells and 
surfactant-producing and Clara cell antigen-expressing cells. Mesenchymal features 
present in both pulmonary blastomas and immature lung included smooth muscle and 
myofibroblastic differentiation. Chejfec et al. (1990) have also demonstrated 
neuroepithelial bodies and keratin, chromogranin, NSE, gastrin, calcitonin, bombesin, 
somatostatin and serotonin immunoreactivities in pulmonary blastoma.
BASAL CELL (BASALOID) CARCINOMA
Brambilla and colleagues (1992) classified a unique form of lung tumour as basal cell 
(basaloid) carcinoma. This tumour type presents an immunophenotype similar to that 
of basal bronchial epithelial cells with a low level expression o f keratins 5, 6 , 7, 8 , 13, 
16, 18 and 19, infrequent and inconsistent staining for NE markers, and absence of 
neuroendocrine granules and the presence of some squamous and/or glandular 
differentiation. The authors believe that this tumour type resembles multipotent basal 
cells with the potential for multidirectional differentiation along squamous, glandular 
or neuroendocrine pathways.
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‘STEM CELL THEORY'
The demonstration o f overlapping features between lung cancer types supports the 
concept of a common stem cell origin for lung epithelial carcinomas, a theory which 
was proposed almost 20 years ago (Yesner, 1978 and Fialkow, 1979). Gazdar et al. 
(1981) discussed the theory further and outlined how all the cells of the bronchial 
epithelium and the tumours which arise from them could have a common stem cell 
origin. Gazdar postulated that the transforming events which led to carcinogenesis affect 
undifferentiated or partially differentiated cells. Depending on the level of 
differentiation at which the transformation occurs, the resulting tumour will be 
differentiated or undifferentiated and will present as a squamous, large cell, 
adenocarcinoma or SCLC accordingly (see Figure 1.3.1).
Numerous reports of evidence for the presence of stem cell populations in tumour cell 
lines have been forwarded. Olsson et al. (1984), Spang-Thomsen et al. (1986) and 
Khan et al. (1991) described differences in nude mouse tumourigenicity, colony forming 
efficiency, reactivity with monoclonal antibodies and radiosensitivity between 
populations in cell lines, suggesting that stem cell-like populations were present. Others 
(Gazdar et al. , 1988 and Bergh et al., 1989) have suggested that the overlapping 
expression of markers between different tumour types is indicative of a common stem 
cell origin for lung epithelial tumours.
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1.4 HETEROGENEITY IN LUNG TUMOURS
The concept o f tumour heterogeneity was reviewed by Heppner in 1984. The author 
defined the term tumour heterogeneity as ‘those cases in which tumour cell differences 
are believed to be due to differences in cell lineage, i.e., due to the presence of 
distinctly different subpopulations capable of breeding true’, and stated that this did not 
contradict the single-cell origin of tumours as most organisms begin as single cells but 
soon become heterogenous. Heppner also stated that tumour heterogeneity may arise as 
a consequence o f those mechanisms that result in heterogeneity in normal tissue as well 
as tumour-specific mechanisms such as genetic instability. The characteristics in which 
diversity between subpopulations of tumour cells may be exhibited include cellular 
morphology, metastatic potential, karyotype, growth rate, antigen expression and 
response to chemotherapeutic drugs. Lung cancer is particularly noted for its 
heterogeneity. In 1959, Azzopardi described a SCLC as containing tubular structures, 
squamous nests, rosette formation, giant cells and mucin secretion.
Diversity among lung tumour cell populations is evident at the genetic level. Studies 
carried out on tumour heterogeneity based on differences in DNA content among cell 
subpopulations have demonstrated that NSCLC appear to exhibit a large degree of 
heterogeneity with most tumours analysed containing at least 2 subpopulations (Leith 
and Michelson, 1989). During tumour progression, cancer cells are believed to 
accumulate increasing random alterations (Nowell, 1986). These cytogenetic 
abnormalities are heterogenous, not only between lung tumours, but also within 
individual tumour cell populations (Morstyn et al., 1987 and Burholt et al., 1989a). 
Oncogenes such as c-ra/-l and c-myc have been implicated in the acquisition of a 
multidifferentiated phenotype by lung tumours. When Pfiefer and co-workers (1991) 
inoculated mice with normal human bronchial epithelial cells which had been 
transformed by the c-raf-l and c-myc protooncogenes, the resulting tumours contained 
desmosomes, microvilli and dense core granules, indicative o f squamous, glandular and 
neuroendocrine differentiation respectively.
While spontaneous gene mutations occur at high rates in tumour cells (Cifone and
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Fidler, 1981), the rates of variant formation in biochemical, immunological, enzymatic 
and biological properties found in cancer cells occur at much higher rates (reviewed in 
Nicolson, 1987). Histologic heterogeneity, i.e. the appearance o f different histological 
types in different areas of a tumour, was demonstrated by Mooi et al. (1990) to be a 
common occurrence in lung tumours as judged by electron microscopic examination. 
Lung cell lines may also exhibit morphological heterogeneity with many lines containing 
cells which grow attached to the substrate and in suspension (Khan et al., 1991 and 
Terasaki et al., 1984).
Heterogeneity in antigen expression by lung tumour cells has been described. Moss and 
colleagues (1991) reported that antibodies directed against NCAM and cytokeratins 
reacted differentially with cells in both lung tumour sections and in serous effusions. 
Gorgoulis et al. (1992) observed considerable intratumour heterogeneity in the 
expression of epidermal growth factor, transforming growth factor and epidermal 
growth factor receptor proteins in squamous cell lung carcinomas and Walker and 
Wright-Perkins (1992) demonstrated that a subline derived from a classic small cell 
cancer cell line expressed an antigen profile different to that of the parental cells.
Diversity in the metastatic potential o f lung carcinoma cells has also been observed. 
Brodt (1986) described 2 metastatic variants of a Lewis lung carcinoma which had 
different organ specificities and Young et al. (1987) reported on different in vivo 
metastatic potentials and in vitro migratory potentials of Lewis lung carcinoma clones. 
Overgrowth of primary tumours by metastatic subpopulations was demonstrated by 
Waghome et al. (1988) indicating diverse behavioural patterns amongst tumour cells.
Heterogeneity in tumour cell sensitivity to anticancer drugs is a major clinical problem. 
In a study using an artificially heterogenous small cell lung cancer xenograft, Aabo et 
al. (1994) found that the fractional size o f a resistant tumour subpopulation may 
determine the extent of any clinical response to a chemotherapeutic treatment. 
Differential sensitivities of clones from an individual tumour to anticancer drugs have 
been demonstrated by Barranco et al. (1988). Further studies from this group (1994) 
found a large histological variability from site to site within individual tumours and 
recommended the abandonment of all single site testing of tumours, as is the norm at
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the moment, and the implimentation of sample testing from 3-7 different sites within 
each tumour.
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1.5 GROWTH CONTROL IN LUNG CANCER CELLS
The processes involved in normal cellular proliferation and differentiation are highly 
co-ordinated and are influenced by several variables including extracellular matrix 
components, cell adhesion molecules and membrane junctional complexes between 
adjacent cells. A pivotal role in these processes is played by a diverse group of soluble, 
secreted regulatory molecules known as the polypeptide growth factors. Observations 
of growth factor mRNA and protein expression in embryogenesis (Peters et al., 1992), 
tissue injury (Adamis et al. , 1991) and disease (Thornton et al. , 1992) and regulation 
of proliferation and differentiation in vitro have all contributed to the understanding of 
the complexity and extent of growth factor networks.
Growth factors exert their effects by interacting with specific receptors on the surface 
of target cells. In general, these target cells are within a short extracellular distance 
from the growth factor-producing effector cells in contrast to the long distances over 
which endocrine hormones travel in the body. However, low concentrations of some 
growth factors can be found in serum (Antoniades, 1981). The binding of a growth 
factor to its receptor results in a cascade of intracellular events including protein 
phosphorylation, inositol-lipid breakdown, ion fluxes (reviewed inRozengurt, 1986) and 
changes in gene expression (Antoniades, 1992). Upon binding to its receptor, the 
growth factor is internalised by receptor-mediated endocytosis. Transport of the 
receptor-ligand complex to the lysosmal compartment results in degradation of the 
complex and subsequent down-regulation of the receptors and thus limits the response 
of the target cell to the growth factor-induced stimulation.
As their name infers, growth factors cause cells to enter and proceed through the cell 
cycle (reviewed in Aaronson, 1991). Firstly, ‘competence’ factors such as EGF, CSF-1, 
PDGF and FGF stimulate quiescent cells to enter the G, phase. The length of the Gj 
phase varies greatly between cells and a continuous signal must be present if the cells 
are to advance into the S phase of the cycle and become committed to DNA synthesis. 
This second phase o f the cycle is brought about by ‘progression’ factors. The absence 
of a progression factor such as IGF or insulin means that upon depletion or removal of
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the competence factor, the cell will return to G0 and will not enter S phase.
Growth factors may be grouped into families based on structural similarities (Heldin 
and Westermark, 1989). These families of factors interact with one or more specific 
transmembrane receptor types. Most growth factor receptors are protein tyrosine 
kinases which become activated after ligand binding. The ligand binds to an 
extracellular domain of the receptor and induces formation o f receptor dimers, which 
in turn leads to autophosphorylation and activation of an intracellular tyrosine kinase 
domain. This domain is highly conserved and is necessary for receptor signalling, while 
the transmembrane domain does not directly affect signal transduction but appears to 
anchor the receptor in the membrane.
The autophosphorylation sites in growth factor receptors are recognition sites for 
specific target proteins containing Src homology 2 (SH2) domains (Lowenstien et al.,
1992). These SH2 domains are highly conserved sequences of up to 100 amino acids 
found in many signalling molecules and oncogenic proteins. The interaction of SH2 
domains with autophosphorylated regions of growth factor receptors is believed to 
provide the link whereby diverse regulatory and enzymatic proteins can interact 
specifically with transmembrane receptors and thus transmit an external signal to the 
multiple intracellular signalling pathways.
The PDGF post-membrane signal transduction system serves as the prototype tyrosine 
kinase network (reviewed in Cantley et al., 1991). A range of substrates become 
phosphorylated by the PDGF receptor kinase following physical association with the 
activated receptor. These proteins include phospholipase C (PLC-7 ), 
phosphatidylinositol 3 ’ kinase (PI-3K), Ras guanosine triphosphatase (GTPase) 
activating protein (GAP) and Src and Src-like tyrosine kinases. PLC- 7  hydrolyses 
phosphatidylinositol 4,5-bisphosphate. This results in the formation of 2 second 
messengers: diacylglycerol which activates protein kinase C which in turn is thought 
to mediate the actions of a number o f tumour promoters, and inositol trisphosphate 
which causes the release of stored intracellular calcium. PI-3K phosphorylates the 
inositol ring of phosphatidylinositol, while GAP regulates the function of the Ras 
protein. Ras is a small guanine nucleotide-binding protein and is a requisite component
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of intracellular mitogenic signalling pathways. PI-3K is a negative regulator of Ras 
function and acts by stimulating its GTPase activity. Mutations of the ras gene can lead 
to an accumulation o f active Ras due to the inability of GAP to inactivate it. Raf, a 
serine/threonine kinase, also becomes phosphorylated following physical association 
with the PDGF receptor, although it lacks SH2 domains. The substrates of Raf are as 
yet unknown.
Observations of the decreased serum and growth factor requirements of transformed 
neoplastic cells compared with their normal counterparts (Temin, 1966 and Dulbecco, 
1970) along with the discovery that many oncogenes are identical or similar to growth 
factors, their receptors or elements of the signalling transduction pathways (Doolittle 
et al., 1983, Downward et al., 1984 and Mulcahy et al., 1985) has led to widespread 
interest in the role o f grwoth factors in tumourigenicity. It has also fuelled the belief 
that abnormal expression of growth factors, their receptors or their signalling pathways 
may result in the inappropriate growth of cells, thus contributing to tumourigenesis 
(reviewed in Cross and Dexter, 1991 and Goustin et al., 1986). An additional aspect 
of abnormal growth control is the phenomenon of autocrine growth whereby cells are 
stimulated by growth factors they have produced themselves. It has been proposed that 
the autocrine production of growth factors is an essential element of the tumourigenic 
process (Todaro et al., 1976 and De Larco and Todaro, 1978). In theory, the 
inappropriate expression of a growth regulatory protein could confer growth factor 
autonomy on cancer cells.
The first indication o f an interaction between cell growth and transformation came with 
the discovery that the normal counterpart of the oncogene v-sis of simian sarcoma virus 
is the cellular gene encoding the B-chain of platelet-derived growth factor (PDGF) 
(Doolittle et al., 1983 and Waterfield et al., 1983). It was subsequently demonstrated 
that transformation by the sis gene occurs by an autocrine mechanism via PDGF 
(Johnsson et al., 1985 and reviewed in Westermark and Heldin, 1991). Expression of 
PDGF has been demonstrated in most NSCLC cells examined (Safi et al., 1992, Bravo 
et al., 1991, Bergh, 1988 and Sariban et al., 1988). Soderdahl et al. (1988) reported 
the absence of PDGF proteins in SCLC cell lines but Bravo et al. (1991) reported the 
production of PDGF by SCLC cell lines and tissues. Antoniades et al. (1992)
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demonstrated the coexpression of PDGF and the PDGF receptor in primary human lung 
carcinomas suggesting a possible autocrine growth mechanism and Fitzer-Attas et al.
(1993) also localised PDGF receptors in lung carcinoma cells.
Epidermal growth factor (EGF) is found in normal human plasma and most human body 
fluids and the EGF receptor is present in a wide range of normal epithelial tissues 
(Kasselberg et al., 1985 and Gusterson et al., 1984). The EGF receptor is encoded by 
the c-erb B protooncogene (Downward et al., 1984). The EGF receptor is also the 
receptor through which transforming growth factor a  (TGFa) exerts its effects 
(Marquardt et al., 1984). When normal cells are exposed to EGF, various responses 
result which are associated with neoplastic transformation (reviewed in Stoscheck and 
King, 1986) including a partial loss of density dependent inhibition of growth, increased 
levels of phosphotyrosines in proteins, expression of c-fos and c-myc cellular 
protooncogenes and potentiation of growth in soft agar.
As mentioned earlier (Section 1.3), overexpression of the EGF receptor has been 
associated with NSCLC. Cherny et al. (1986) reported that expression of the EGF 
receptor was exclusive to NSCLCs as all SCLCs examined were negative while over 
80% of NSCLCs were positive for expression of the receptor. Veale et al. (1987) also 
demonstrated that expression of the EGF receptor was significantly upregulated in 
NSCLC tissue compared with normal tissue and that squamous carcinomas reacted 
significantly stronger with the antibody against the receptor than other types of NSCLC. 
There also appeared to be a correlation between high intensity o f receptor expression 
and advanced tumour stage, suggesting that the EGF receptor may be a useful marker 
for prognosis and determination of the degree of differentiation o f NSCLC tumours. 
Studies carried out by Gorgoulis et al. (1992) substantiated these findings with evidence 
that squamous cell lung carcinomas expressing the EGF receptor along with either or 
both of its ligands (EGF and TGFa) displayed pathologic features o f more aggressive 
disease. Garcia de Palazzo and co-workers (1993) reported that a mutated EGF receptor 
which had been identified in glioblastomas (Humphrey et al., 1990) may be a specific 
marker for squamous cell carcinomas as only malignant squamous epithelial cells 
expressed the mutant protein while adenocarcinomas did not.
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Many lung tumour cell lines have also been shown to express EGF, TGFa and EGF 
receptor proteins (Imanishi et al., 1989, Damstrup et al., 1992 and Soderdahl et al., 
1988). Soderdahl et al. (1988) also reported the absence of these 3 proteins from SCLC 
cell lines while Damstrup et al. (1992) found that a relatively high proportion of SCLC 
cell lines express EGF receptors.
Transforming growth factor /3 (TGF/3) consists o f a family of growth regulatory 
peptides which are considered to be prototypical growth inhibitors (reviewed in Barnard 
et al., 1990). In the normal human lung, bronchial epithelial cells appear to be the main 
location of TGF/3 (Mangan et al., 1994) and TGF/3 has been shown to growth inhibitory 
for most normal epithelial cells (Roberts and Spom, 1988 and Moses et al., 1990). In 
lung epithelial cells, growth inhibition by TGF/3 correlates with terminal squamous 
differentiation (Masui et al., 1986). In contrast, lung carcinoma cells are often 
insensitive to induction of differentiation or negative regulation by TGF/3 (Coffey et al., 
1988). In lung tumour cells, the belief that TGF/3 production was restricted to NSCLC 
cell lines (reviewed in Pelton and Moses, 1990) was disputed by Damstrup et al. (1993) 
who detected the expression of TGF/3 receptors and ligands in a high proportion of 
SCLC cell lines.
Norgaard et al. (1994) demonstrated that TGF/3 was capable of inhibiting the growth 
of SCLC cell lines. The growth inhibitory effect o f TGF/3 on normal lung epithelial 
cells and some lung tumour cell lines led to the consideration of the antitumour effects 
of this growth factor. Twardzik et al. (1989) reported antitumour effects of TGF/3 on 
A549 (lung adenocarcinoma cell line) tumours in vivo. However, a contrasting report 
from Robinson and Rose (1992) describes a lack o f in vivo antitumour activity of TGF/3 
on A549 tumours.
Another group of cellular regulatory molecules which have effects on cell proliferation 
are cytokines. This group includes interleukins, interferons and colony stimulating 
factors. These peptides and proteins were originally discovered as modulators of 
immune cell functions and proliferation but have since been shown to regulate non- 
immune cell growth (Berdel et al., 1992). As is the case with growth factors, cytokines 
influence cell behaviour by binding to surface receptors on target cells (Pelligrini and
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Schindler, 1993 and Taniguchi and Minami, 1993). The receptors are linked to a 
complex array of intracellular signalling pathways which modulate cell function.
In recent years, the growth inhibitory effects of several cytokines on cancer cells has 
led to a focusing on the antitumour effects of these molecules. Interleukin 1 (IL-1) has 
been shown to inhibit proliferation in cultured lung carcinoma cells (Nakane et al.,
1990) and primary human lung tumours in vitro (Hanauske et al., 1992) and to have 
antitumour activity in vivo (Iigo et al., 1990). Interleukin 2 (IL-2) has been examined 
clinically as an antitumour agent (reviewed in Foa et al., 1992) and responses are 
promising but have been limited by toxicity.
Interleukin 4 (IL-4) receptors have been found to be coexpressed with EGF receptors 
on approximately 33 % of NSCLCs and appear to be absent from SCLCs (Tungekar et 
al., 1991).
Interleukin 6  (IL-6 ) inhibits growth of lung cancer cell lines in vitro (Takizawa et al.,
1993) and systemic administration of this cytokine was found to mediate the regession 
o f pulmonary nodules in mice (Mule et al., 1992). Transfection of the IL- 6  gene into 
Lewis lung carcinoma cells led to the reversal o f a malignant towards a benign 
phenotype in vivo (Porgador et al., 1992).
Interferon- 7  (IFN-7 ) and tumour necrosis factor-a (TNF-a) have also been 
demonstrated to have anti-proliferative effects on lung carcinoma cell lines (Schuger et 
al., 1990).
The proliferative potentials of the neuropeptides and hormones found in lung cancer cell 
lines with NE differentiation has been explored, though not extensively. Bombesin, and 
its human analogue gastrin releasing peptide (GRP), have been shown to regulate 
epithelial cell proliferation in the lung during development and after injury (Mabry et 
al., 1988 and 1991) and also to act as autocrine growth factors for some SCLC cell 
lines (Cuttitta et al., 1985 and Mahmoud et al., 1991). NSCLC cells have been shown 
to secrete and respond to GRP also (Siegfried et al., 1994).
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Other neuropeptides have also been demonstrated to modulate cell proliferation 
(Zachary et al., 1987). Bradykinin, cholecystokinin, galanin, neurotensin and 
vasopressin may also have roles as autocrine growth factors in SCLC (Bunn et al., 1990 
and 1992, Sethi and Rozengurt, 1991 and reviewed in Sethi et al., 1992).
Increased understanding of the roles of cell signalling molecules in the development and 
progression of carcinomas has led to interest in the targetting of these pathways in an 
attempt to halt and reverse tumourigenicity. Considered modes of therapy include 
antibodies directed against growth factors and growth factor receptors, growth factor 
agonists and antagonists, negative growth factors, growth factor-linked toxins, 
disruption of signal transduction and gene therapy (Shaw et al., 1991 and reviewed in 
Kelly et al. , 1991). Clinical trials are underway already with suramin (Van Oosterom 
et al., 1990), an agent which inhibits the receptor binding o f various growth factors 
(Huang and Huang, 1988) but extensive research still remains to be carried out on these 
potential anticancer strategies.
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1.6 CELL ADHESION AND LUNG CANCER
Cells express an array of cell surface receptors which enable them to adhere to each 
other and to the extracellular matrix (ECM) in a highly specific manner, thus permitting 
the development and maintenance of tissue structure and function. Mammalian 
organisms are divided into a series o f  tissue compartments separated by the ECM which 
consists of the basement membrane (BM) and its underlying interstitial stroma 
(Yurchenco and Schittny, 1990). Epithelial basal cells are attached to the BM and on 
the opposite side, the interstitial stroma contains stromal cells, fibroblasts, 
myofibroblasts, smooth muscle cells and macrophages. The nervous system, muscle 
cells and blood vessels are also surrounded by a continuous basement membrane. Under 
normal conditions, and even during benign tissue remodelling, proliferative disorders 
and carcinoma in situ, the integrity of the BM is largely maintained and the cell 
populations on either side of the connective tissue do not mix. However, during the 
progression from in situ to invasive cancer, the tumour cells invade the epithelial BM, 
through to the interstitial stroma (reviewed in Liotta et al, 1991). It is usually this 
invasion of organ tissue and metastasis to other body tissues that causes cancers to be 
fatal.
1.6.1 Extracellular Matrix
As mentioned above, the ECMs penetrated by invasive cells can be classified into 2 
major categories: basement membranes and interstitial connective tissue.
1.6.1.1 Basement membrane
Basement membranes consist o f collagens, glycoproteins and proteoglycans and their 
basic composition is similar in different tissues. Type IV collagen is the major protein 
present, accounting for up to 60% o f BM proteins (Tryggvason et al., 1987). Laminin 
is the major noncollagenous glycoprotein present along with entactin (Timpl et al.,
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1983) and fibronectin (Steinman and Vaheri, 1978) and chondroitin sulfate and heparin 
sulfate are the predominant proteoglycans of the BM (Hassel et al., 1980). These 
molecules interact to form an acellular, amorphous, sheet-like structure that separates 
epithelium or endothelium from underlying mesenchymal tissue. This structure is highly 
resistant to cellular penetration and contains a large amount of binding proteins which 
allow cells to anchor and also provides traction for migration.
1.6.1.2 Interstitial connective tissues
While interstitial connective tissue also consists o f collagens, glycoproteins and 
proteoglycans, in contrast to BMs, the distribution of these components and their 
particular types can vary greatly among tissues. Again, collagens are the major proteins 
present with types I, II and III varying in abundance depending on location (Piez,
1984). The expression of other collagen proteins (types V-X) also occurs (Miller and 
Gay, 1987). Fibronectins (Hynes, 1986), vitronectin (Suzuki et al., 1984), osteonectin 
(Termine et al., 1981) and chondronectin (Hewitt et al., 1981) are the glycoproteins 
present in various connective tissues, while the proteoglycans present include 
chondroitin, heparin, dermatin and keratin sulfate (Poole, 1986).
1.6.2 Cell Attachment
Cell-cell and cell-matrix interactions are mediated to a large extent by cell surface 
receptors called integrins and families of adhesion molecules called cadherins and cell 
adhesion molecules.
1.6.2.1 Integrins
Integrins are membrane glycoproteins consisting o f  2 subunits, a and /?. Most integrins
are expressed on a wide variety of cells and most cells express several integrins 
(reviewed in Hynes, 1992 and Ruoslahti, 1991). Many integrins bind to ECM proteins 
and the specificity o f binding is determined, though not solely, by the identity of the 
a and /3 chains. For example, a,/3i and a7(Jt bind to laminin (among others) while otvP5 
binds vitronectin. However, the specificity of binding also depends on a given cell as
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a20l on platelets will not bind laminin (Staatz et al., 1989) while this integrin on other 
cell types can bind laminin (Elices and Hemler, 1989).
Some integrins bind to cell membrane proteins on the surfaces of other cells and thus 
mediate cell-cell adhesion, eg. a ,/?2 (also known as CDIIA/CD18) binds to intercellular 
adhesion molecules (ICAMs) (Springer, 1990) and aj3l binds to both an ECM protein 
and a cell membrane protein, fibronectin and vascular cell adhesion molecule (VCAM- 
1) respectively (Mould et al., 1990).
Other integrins found on platelets mediate the binding of platelets to each other via 
soluble molecules such as fibrinogen, thus playing a major role in blood clotting 
(Ginsberg et al., 1988).
The recognition site for integrin-binding on many ligands is an RGD (arginine, glycine, 
aspartic acid) tripeptide (Ruoslahti and Piersbacher, 1987). In addition to their roles in 
attachment, there is accumulating evidence that integrins may be capable o f transmitting 
external signals into cells. Tyrosine phosphorylation (Shattil and Brugge, 1991) and 
cytoplasmic alkilinisation (Schwartz et al. , 1991) have been observed following integrin 
binding of ligands and integrins have been shown to regulate processes such as cell 
proliferation and apoptosis (Agrez and Bates, 1994).
1.6.2.2 Cadherins
Cadherins are calcium-dependent transmembrane proteins and the activity o f these 
molecules involves interactions on both sides o f the cell membrane. On the intracellular 
side, cadherins interact with catenins, cytoplasmic proteins that link cadherin proteins 
to the actin-based cytoskeleton (Kemler, 1993 and Gumbiner, 1993). Extracellularly, 
cadherins act as cell-cell adhesion molecules.
The 3 main cadherins are E-cadherin, found on many types of epithelial cells (Takeichi,
1991), N-cadherin, found on nerve, heart and lens cells (Takeichi, 1991) and P- 
cadherin, found in the placenta and epidermis (Kemler et al., 1989). The muscle- 
specific M-cadherin (Donalies et al. , 1991) and the desmosomal proteins desmoglein
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and desmocollin (Buxton and Magee, 1992) are also members o f the cadherin family. 
The expression pattern of these molecules during embryogenesis suggests that they play 
an important role in this process (Takeichi, 1991). In adult tissues, E-cadherin is 
detected in epithelial cell types derived from all 3 germ cell layers but not in other cell 
types, and in polarised epithelial cells, it is expressed on the basolateral surface (Boiler 
etal. , 1985).
1.6.2.3 Cellular adhesion molecules
Cellular adhesion molecules (CAMs) are a family of cell surface proteins that mediate 
adhesion between cells o f the same type (homotypic intercellular adhesion). In contrast 
to cadherins, CAMs function via a calcium-independent mechanism. CAM molecules 
belong to the immunoglobin superfamily and the extracellular segments of these 
proteins are folded into several domains which are homologous to the immunoglobin 
domains characteristic o f antibody molecules. Neural cell adhesion molecule (NCAM), 
intercellular adhesion molecule (ICAM) (Montefort et al., 1993) and vascular cell 
adhesion molecule (VCAM) are all members of this family.
1.6.3 Tumour Invasion of the ECM
Benign tumours are characterised by a continuous BM surrounding the epithelial cells 
and separating them from the stroma. In contrast, malignant tumours actively invade 
the BM, enter the stroma and from there, gain access to the lymphatic and vascular 
systems.
3 main steps are involved in tumour cell interaction with die BM: attachment, matrix 
dissolution and migration. During the first step, the tumour cell attaches to elements in 
the BM such as type IV collagen, laminin and fibronectin via integrin and non-integrin 
receptors (Hynes, 1987, Humphries et al. , 1986 and Aznavoorian et al. , 1990). The 
second stage of the process begins within hours of attachment when the tumour cells 
begin to secrete degradative enzymes or induce the host to release proteinases to 
degrade the matrix (Gottesman, 1990). Lysis of the matrix proceeds close to the tumour 
cell surface where the amount of active enzyme outbalances the natural in situ
41
proteinase inhibitors (Brown et al., 1990). Translocation is the third step of invasion 
when the cell migrates across the BM in a pseudopodial manner (Luna et al. , 1989).
While these events may occur under non-malignant conditions such as angiogenesis and 
wound healing, cancer cells can manipulate ‘normal’ processes in order to invade tissue 
and metastasise. Loss or reduction of epithelial differentiation in carcinomas and the 
subsequent higher motility and invasiveness of cells is often as a result of reduced 
intercellular adhesion (Nigam et al., 1993). A substantial reduction in epithelial 
differentiation has been observed, particularly at invasion fronts where the cells break 
into the mesenchymal tissue (Gabbert et al., 1985). Often, the invading cells lose their 
epithelial appearance and become spindle-shaped and fibroblastoid. In fact, it has been 
suggested that tumour cell progression to an invasive state involves a process similar 
to the epithelial-mesenchymal conversion which takes place during development (Valles 
et al., 1991). Epithelial cells and mesenchymal cells are quite distinct, both 
morphologically and functionally. While epithelial cells express intercellular junctions 
and are polar and largely nonmobile, mesenchymal cells are generally loosely 
associated, nonpolar and surrounded by ECM. The latter phenotype resembles that of 
invading, metastatic cells (Liotta et al., 1991).
Alterations in the adhesion properties of invasive tumour cells, including lung cells, 
have been observed. Integrin expression on chemically transformed cells has been 
shown to be different to that of the parental untransformed cells. Dedhar and Saulnier 
(1990) reported increased expression of integrins which bind collagens and laminin and 
decreased expression of those which bind vitronectin on such cells. Increased expression 
of a laminin receptor has also been demonstrated on human carcinoma cells (Wewer et 
al., 1986). In addition, the distribution of integrins on transformed cells may alter, with 
a loss of preferential location to the basal membrane (Horan et al., 1985) and a high 
expression of laminin and fibronectin receptors in pseudopodial extensions which 
develop during cell migration (Guirguis et al., 1987).
In the normal lung, adhesion molecules including ICAM and several (8 integrin subunits 
have been detected on isolated type II cells (Guzman et al. , 1994) and the ability of 
bronchial epithelial cells to migrate on ECM components has also been demonstrated
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(Rickard et al., 1992). Hirasawa et al., (1994) found that integrins present on lung 
cancer cells bind the same ECM proteins as their normal counterparts and determined 
the arrays o f integrins expressed by a panel of lung cancer cell lines. Falcioni et al. 
(1994) studied the expression of f t ,  03, (34 and /?5 integrins in lung cancer and reported 
that while NSCLC expressed all 4 integrin types examined, SCLC expressed only the 
(Sj integrin which appeared to function as a laminin receptor on these cells. High levels 
of integrin expression were found on SCLC cells by Feldman and colleagues (1991) and 
the receptors appeared to mediate laminin binding by the cells. Laminin receptors have 
also been demonstrated on SCLC cells by Tagliabue et al. (1991) and Pellegrini et al. 
(1994) and laminin has been shown to induce anchorage-dependent growth and slight 
neuronal differentiation in SCLC cell lines (Giaccone et al. , 1992). Bohm et al. (1994) 
found that E-cadherin expression was reduced in most moderately differentiated, and 
reduced or absent in most poorly differentiated lung squamous cell carcinomas. In 
addition, all lymph node metastases and SCLCs had reduced E-cadherin expression 
(reviewed in Birchmeier and Behrens, 1994). BM components have also been shown 
to stimulate the growth of lung tumour cells in vivo (Topley et al. , 1993).
It is apparent therefore, that the adhesion properties of normal and tumour cells mediate 
both the immobilisation and migration of these cells and that alterations in adhesion 
properties play a role in the acquisition of a metastatic phenotype by tumour cells.
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1.7 DIFFERENTIATION-INDUCING AGENTS
By definition, cellular differentiation is the process by which ‘a cell acquires or displays 
a new stable phenotype without changing its genotype’ (Ham and Veomett, 1980). This 
process usually involves the induction of genes that characterise and are responsible for 
the differentiated state, and the repression of genes for cell proliferation (reviewed in 
Davila et al., 1990 and Sell and Pierce, 1994). The principle cells which differentiate 
are stem cells and progenitor cells (Figure 1.7.1). Stem cells are cells which are 
capable o f rapid cell growth and division and are mulitpotent i.e. have the potential to 
differentiate into two or more different cell phenotypes. These cells typically possess 
virtually unlimited proliferative potential but may remain quiescent under certain 
conditions. Progenitor cells, in contrast, are the progeny o f stem cells and possess more 
limited proliferation and differentiation potentials. These cells usually only give rise to 
one specific differentiated cell type. Genetic programmes regulate the destiny of cells 
during development and restrict the number of lineages that stem cells have the potential 
to form and thus, ‘determination’ is the process by which a cell becomes committed to 
differentiate to a specific lineage (Ham and Veomett, 1980).
A cell may differentiate to give rise to a phenotype which either retains or irreversibly 
loses its proliferative potential. Such cells are ‘nonterminally’ or ‘terminally’ 
differentiated respectively. The term ‘dedifferentiation’ refers to the process whereby 
a cell loses its differentiated phenotype, while ‘transdifferentiation’ occurs when a cell 
dedifferentiates and then redifferentiates into a new distinct cell type.
1.7.1 Models for Differentiation
Davila and colleagues (1990) have proposed a model for the control of proliferation and 
differentiation in mesenchymal stem cells (Figure 1.7.2). In this system, rapidly 
proliferating stem cells may undergo growth arrest as a result of growth factor 
deficiency or when they enter a predifferentiation state. The former state is reversible 
and does not lead to differentiation. The latter stage however, while also being 
reversible, can lead to a non-terminal differentiation state if the cells are not first
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Figure 1.7.1 A theoretical model of cell lineages. Stem cells are 
capable of unlimited self renewal (thick curved arrow) and give rise to 
transiently amplifying cells that retain some self renewal ability (thin 
curved arrow). Transiently ¡amplifying cells form most of the new cells 
in the tissue compartment (straight arrows). The most differentiated cells 
become incapable of further rounds of cell division.
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Figure 1.7.2 Model for the integrated control of proliferation and 
differentiation in mesenchymal stem cells showing that prior to terminal 
differentiation, cells must undergo predifferentiation growth arrest at a 
distinct biological state and then, non-terminal differentiation which is 
reversible.
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induced to reinitiate proliferation (Scott et al., 1982). The non-terminal differentiation 
state can be induced by factors including insulin, DMSO and serum factors while TGF/3 
and TPA inhibit this state (Sparks and Scott, 1986 and Yun and Scott, 1983). In 
addition, retinoic acid and TPA can induce dedifferentiation in these cells (Wier and 
Scott, 1986). Non-terminally differentiated cells acquire a completely differentiated 
phenotype and become less responsive to growth factors and in the final step in this 
model, the mesenchymal cells terminally differentiate and irreversibly lose their 
proliferative potential.
The fact that the proliferative potential of a cell diminishes with increasing 
differentiation means that two conceivable scenarios exist for the possible origins of 
cancer: from dedifferentiation of mature cells which retain the capacity to divide or 
from maturation arrest of immature stem cells. Sell and Pierce (1994) propose that the 
latter situation is that which gives rise to all cancers. The authors discuss a model in 
which normal cell renewal requires a determined stem cell to divide and the resulting 
daughter cells to comprise of one stem cell and one cell which differentiates, thus 
achieving steady state. During carcinogenesis however, a block occurs, the nature of 
which is as yet unknown, in the maturation process which allows neoplastic stem cells 
to accumulate, resulting in an increased number of cycling cells o f a restricted 
phenotype. In this model, an individual tumour will retain the basic phenotypic potential 
of the tissue-determined stem cell from which it arose, but will express this potential 
to different and varying extents compared with those seen in normal tissue.
The pathways involved in the haematopoietic differentiation system, and their disruption 
leading to leukemia, have been studied in depth (reviewed in Sawyers et al., 1991). 
Leukemia is defined as the uncontrolled proliferation or expansion of haematopoietic 
cells that do not retain the capacity to differentiate normally to mature blood cells. The 
pluripotent haematopoietic stem cell is the progenitor cell of all the cellular elements 
of the blood and lymph including platelets, red blood cells, neutrophils, macrophages, 
B lymphocytes and T lymphocytes (Figure 1.7.3). In the adult, pluripotent stem cells 
are located in bone marrow where they are present in low numbers and most of which 
are not actively cycling. Soluble factors known to induce proliferation and 
differentiation of committed progenitor cells include GM-CSF and IL-7 (reviewed in
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Figure 1.7.3 The cell lineages of the haematopoietic system
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Metcalf, 1989). One of the genes found to have a role in differentiation in this cell 
lineage is that coding for the retinoic acid receptor (RAR). This gene is disrupted in 
many cases of acute myeloid leukemia (de The et al., 1990a) and these cases can 
achieve complete remission of leukemia when treated with all-trans retinoic acid, 
probably because of induced differentiation o f the leukemic cells (Meng-er et al., 
1988). Bromodeoxyuridine is another agent known to induce differentiation of myeloid 
cells, causing promyelocytic cells to terminally differentiate into granulocytes or 
macrophages-like cells (Keoffler et al., 1983). Retinoic acid (RA) and 
bromodeoxyuridine (BrdU) as differentiation-inducing agents will now be discussed 
further.
1.7.2 Retinoic Acid
Members of the retinoid family of molecules have long been known to be potent agents 
for control of both cellular proliferation and differentiation. Wolbach and Howe (1925) 
first reported on the effects of vitamin A  deficiency on the proliferation and 
differentiation of epithelial cells. They found that normal differentiation of stem cells 
into mature epithelial cells failed to occur and abnormal cellular differentiation was 
evident with excessive accumulation o f keratin and increased cellular proliferation. 
Since these observations were made, the role and mechanism of action of retinoids in 
the control of cellular proliferation and differentiation has been intensively examined 
to the extent that over 2 0 0  different gene products have been shown to be influenced 
by RA (Chytil, 1992).
Cytosolic retinoic acid- and retinol-binding proteins (CRABP and CRBP respectively) 
have been identified (Chytil and Ong, 1983). The roles of these proteins are not clear 
but they may be involved in storage o f retinoids or in mediating retinoid metabolism 
(Yost et al., 1988). Two major families o f nuclear RA receptors, RA receptors (RARs) 
and retinoid X receptors (RXRs), have been demonstrated (Petkovich et al., 1987, 
Brand et al. , 1988, Krust et al. , 1989, Zelent et al., 1989 and Yu et al., 1991). These 
receptors display a structural organisation similar to that of the steroid hormone 
receptor family. Binding of RA to its receptor results in the formation of a homo- or 
heterodimeric complex which then binds to specific RA response elements in the
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genome, leading to alterations in gene transcription. RAR genes themselves have been 
found to be among the targets o f  these transcription factors (Hoffmann et al. , 1990 and 
de The et al. , 1989 and 1990b). A RA response element has also been identified in the 
laminin B1 gene (Vasios et al., 1989).
As mentioned above, retinoids play an important role in the proliferation and 
differentiation of epithelial cells. Normal adult lung has been shown to express RARs 
and RXRs (Mangelsdorf et al. , 1990) and normal bronchial epithelial cells show growth 
inhibition after RA treatment (Lechner et al., 1982). The accumulation of cholesterol 
sulfate (Rearick and Jetten, 1986) and cholesterol sulfotransferase (Rearick et al., 
1987b) during confluency-induced squamous differentiation of normal rabbit tracheal 
epithelial cells is inhibited by retinoids. Phorbol ester-induced squamous differentiation 
in normal human tracheobronchial epithelial cells is also inhibited by retinoids, as 
determined by cholesterol sulfate and transglutaminase levels (Jetten et al., 1989) and 
regulation of type II cell surfactant protein gene expression in human fetal lung has also 
been demonstrated (Metzler and Snyder, 1993). Ochiai (1992) found that 
undifferentiated human fetal bronchial cells could be induced by retinoids to undergo 
differentiation into a Clara cell type.
The ability of retinoids to inhibit squamous differentiation indicated a possible 
connection between squamous cell carcinoma and deregulated retinoid responsiveness. 
The link appears to have been made with the demonstration that most human lung 
cancer cell lines, both NSCLC and SCLC, exhibit resistance to RA treatment showing 
little growth inhibition, and also with the discovery of abnormalities in lung cancer cell 
RA receptor genes (Geradts et al. , 1993 and Zhang et al. , 1994).
While the proliferative response of lung carcinoma cells to RA appears altered to that 
of normal cells, retinoids maintain their ability to affect differentiation of cancer cells. 
Squamous differentiation in a SCLC cell line was induced by vitamin A deficiency 
(Terasaki et al., 1987). Doyle et al. (1989) reported that variant SCLC cell lines 
differentiated to a classic morphology following RA exposure and Feyles and co- 
workers (1991) observed upregulation of neurondocrine markers on SCLC cells cultured 
in RA.
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Expression o f keratin intermediate filament proteins in epithelial cells is also regulated 
by retinoids (Kim et al., 1984). Exposure of epidermal cells to retinoids results in the 
down-regulation of the terminal differentiation-associated keratins K1 and K10 
(Schweizer et al., 1987) and epidermal keratins K5, K6 , K14 and K16 (Stellmach et 
al., 1991).
1.7.3 Bromodeoxyuridine
The literature on BrdU-induced cellular differentiation is much less extensive than that 
of RA. BrdU is a thymidine (Td) analogue which competes with Td for incorporation 
into DNA and which is capable of modulating differentiation in a number of tissue 
types. Low concentrations of BrdU can reversibly block or inhibit differentiation in 
cells without significant alteration in cell proliferation (Rutter et al., 1973, Keoffler et 
al., 1983 and Tapscott et al., 1989).
It appears that BrdU must be incorporated into DNA to have its effect, possibly 
implicating the involvement of inhibition of expression of differentiation-specific genes 
(Harding et al. , 1978), but relatively little is known concerning the mechanism of action 
of this compound. Kidson and De Haan (1990) provided evidence supporting the 
inhibition o f differentiation-specific proteins by BrdU by comparing the effects of the 
Td analogues 5-iododeoxyuridine and 5-flurodeoxyuridine (IdU and FdU) on melanoma 
cell differentiation and proliferation with those of BrdU. IdU and FdU had no apparent 
effect on differentiation while BrdU significantly decreased the expression of a 
differentiation-specific protein in the melanoma cells. In a model of myogenic 
differentiation in a mouse myoblast line, BrdU blocked myogenic differentiation by 
specifically down-regulating the expression of the myogenic determination gene MyoDl 
(Tapscott et al., 1989). While BrdU was incorporated into the muscle structural genes, 
these genes were apparently transcribed normally. BrdU was thus blocking myogenesis 
at the specific level of a myogenic regulatory gene.
The mechanism behind the selective inhibition of such genes by BrdU remains to be 
explained. Lin and Riggs (1972) demonstrated enhanced binding of lac suppressor by 
the lac operon in BrdU-substituted DNA compared with unsubstituted DNA, suggesting
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that BrdU may exert its effect by altering the binding of regulatory proteins. Hill et al. 
(1974) proposed that BrdU causes an altered reading of the DNA template resulting in 
abnormal mRNA that is unable to code accurately for differentiation-associated proteins. 
The ability of BrdU to block cellular differentiation is related to the degree of DNA 
substitution and the effect is usually reversible following removal of BrdU and 
replacement with Td (Ashman and Davidson, 1980). This indicates that BrdU is not 
acting as a mutagen but is specifically blocking differentiation pathways.
BrdU has been shown to induce schwannian differentiation in neuroblastoma (Sugimoto 
et al. , 1988 and Esumi et al., 1989) and terminal differentiation in leukemic (Yen and 
Forbes, 1990) cell systems. In the latter system, BrdU has been shown to induce the 
early events of the metabolic cascade leading to onset of terminal differentiation along 
either myeloid or monocytic pathways. Decreased c-myc expression was demonstrated 
in these BrdU-treated cells and this oncoprotein is also down-regulated during terminal 
differentiation induced by agents such as RA and DMSO.
BrdU suppresses differentiation in a differentiated hamster melanoma cell line and 
promotes invasiveness by increasing the levels and subtypes of integrins expressed and 
elevating the levels of metolloproteinases present in the cells (Thomas et al., 1993). 
Malignant melanoma cells treated with BrdU differentiate into cells which can no longer 
proliferate anchorage-independently in soft agar (Valyi-Nagy et al., 1993). Feyles et 
al. (1991) examined the effects o f BrdU on a SCLC cell line and discovered that 
substrate-adherent growth was induced, along with an epitheloid morphology and 
increased expression of neuroendocrine markers.
It thus seems likely that induction or inhibition of differentiation by BrdU depends on 
the cell type involved and the target genes.
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1.8 MULTIPLE DRUG RESISTANCE
Clinical treatment regimes for cancer currently comprise principally of surgical 
resection, chemotherapy or radiation treatment, or a combination of these. Surgery is 
the usual course of action for NSCLC because such tumours are often amenable to 
resection and also because of the lack of effective drugs available against this cancer 
type. SCLCs in contrast, have a reasonable response rate to chemotherapy, and in 
particular to combination chemotherapy where several drug types are administered. 
Chemotherapy combined with radiation therapy proves to be even more beneficial in 
some cases to the extent that it is recommended that surgery should not be performed 
routinely on most patients with SCLC (Cook et al., 1993). VP-16, adriamycin and 
vincristine have among the most effective single-agent responses of the anticancer drugs 
used (Cook et al. , 1993) and studies involving these drugs found that 2-drug and 3-drug 
combination chemotherapeutic regimes were increasingly superior to those of single 
agents (Bunn et al., 1977 and 1992). However, the phenomenon of multiple drug 
resistance (MDR) is often a major problem in the treatment of cancers and one of the 
main reasons for the high fatalities associated with the disease.
While nearly 90% of SCLC tumours initially respond to chemotherapy, the majority of 
responders will relapse with drug-resistant disease. The innate drug resistance of 
NSCLC tumours is thus mirrored by the acquired drug resistance of SCLCs, but it is 
not clear if the mechanisms involved in each are similar. Following the acquisition of 
MDR, cells may be resistant to a wide range of drugs that are structurally and 
mechanistically unrelated to each other. VP16 is an etopiside which inhibits 
topoisomerase II activity leading to increased DNA damage, adriamycin is an 
intercalating agent which also inhibits topoisomerase n  activity and blocks DNA 
synthesis and RNA transcription and vincristine is a tubulin inhibitor which disrupts 
spindle formation during cell division.
Despite the diversity in the modes on action of these drugs, MDR cells may be resistant 
to all three. Mechanisms of drug resistance include reduced levels or activity of 
topoisomerase II leading to reduced DNA damage (Binaschi et al. , 1992), increased
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production of target reductase enzymes (Curt et al., 1983) and increased expression of 
P-glycoprotein, a membrane efflux pump which removes various hydrophobic 
compounds from the cytosol, thus preventing their intracellular accummulation 
(Gottesmann, 1993).
1.8.1 Phenotypic Alterations in MDR Cells
In vitro studies have been important in contributing to the understanding of MDR 
mechanisms and in the development of circumvention strategies. Many MDR variant 
cell lines have been established by culturing cells in increasing concentrations of drug, 
with the resulting cells exhibiting MDR features such as the overexpression of P- 
glycoprotein (Jensen et al., 1993) and the reduction in activity of topoisomerase II 
(Long et al., 1991). Other phenotypic alterations have been observed in several MDR 
variant cell lines including overexpression o f a putative membrane transporter, MRP, 
and alterations in enzymes of glutathione metabolism (Clynes et al., 1993). Biedler et 
al. (1975 and 1981) noted alterations in cell morphology, in vitro growth behaviour and 
reduced in vivo oncogenic potential during selection of drug-resistant sublines with 
actinomycin D, vincristine and adriamycin. An increase in the number of EGF receptors 
of up to 10-fold has been observed in some MDR lines (Meyers et al., 1986) possibly 
suggesting an alteration in growth control in these cells compared with their sensitive 
counterparts. These in vitro results appear to correlate with in vivo observations of 
morphological changes following chemotherapy where SCLCs were found to have 
altered pathologically towards NSCLC phenotypes (Abeloff and Eggleston, 1981).
Multidrug resistant neuroblastoma cells show altered intermediate filament protein 
expression compared with sensitive control cells and the alterations vary with different 
selection agents (Biedler et al., 1991). The changes in intermediate filament expression 
appear to correlate with differentiation of the neuroblastoma cells along 2  distinct 
pathways. Retinoic acid was found to promote further differentiation along the same 
pathways. High levels of P-glycoprotein are expressed in MDR neuroblastoma cells 
(Biedler et al., 1991) and also in the more differentiated cells of normal human tissues 
such as kidney or colon and in the more differentiated human tumours (Cordon-Cardo 
et al., 1990 and van Kalken et al., 1991). There therefore may be a relationship
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between P-glycoprotein expression and cellular differentiation. Treatments with 
differentiation-inducing agents such as RA have also been shown to result in increased 
expression of P-glycoprotein (Mickley et al., 1989 and Bates et al., 1989). Biedler
(1994) suggests that while the development o f MDR has obvious negative effects, 
positive effects may also occur from the induction o f tumour cell differentiation and a 
subsequent reduction of tumourigenic potential.
1.8.2 Ribozyme Approach to Reversal of MDR
One of the more novel approaches to the reversal of MDR utilises MD/?l-specific 
ribozymes. Ribozymes are RNA molecules which have enzymatic, catalytic activity. 
Naturally occurring ribozymes are capable of self-catalysed cleavage (Cech, 1987) and 
the cleavage reactions are believed to result from RNA conformations bringing reactive 
groups into close proximity (reviewed in Symons, 1992). These catalytic RNAs have 
been found in several systems from bacteria to plants to humans (Cech, 1988 and Cech 
and Bass, 1986) and do not appear to require an exogenous energy source. The first 
ribozymes discovered were self-catalysing (Kruger et al., 1982). These molecules are 
therefore limited to a single turnover and are modified during the reaction. Other 
ribozymes exist however, which act in trans with a potential for unlimited turnover.
Models for the design o f ribozymes have been proposed (Haseloff and Gerlach, 1988) 
for use in the in vitro manipulation o f RNAs. Ribozymes can be designed to target 
specific RNA molecules thus reducing the expression of a particular protein. Ribozymes 
which target MDR1 gene transcripts which encode P-glycoprotein have been created and 
have been successful in increasing drug sensitivity in MDR cells (Kobayashi et al. , 
1994 and Kiehntopf et al., 1994), but to date, no reported reversal o f drug resistance 
in a lung cell line has been accomplished by ribozyme transfection.
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1.9 AIMS OF THESIS
DLKP is a human lung cancer cell line which was established by Dr.Geraldine Grant 
during the course of routine primary culture of human lung tumours. The DLKP cell 
line was derived from a lymph node metastasis o f a primary lung tumour from a 52- 
year old patient who smoked approximately 40 cigarettes for most of his adult life (Law 
et al., 1992). The tumour was histologically diagnosed at the time as a ‘poorly 
differentiated squamous cell carcinoma’ and in a subsequent review of the original 
histology, the tumour was described as a ‘poorly differentiated and necrotic carcinoma 
without obvious keratinization, but of larger size and with more cytoplasm than typical 
"oat" small cell carcinoma’, and poorly differentiated NSCLC was deemed the most 
appropriate diagnosis.
The karyotype of DLKP has been determined (Law et al., 1992) and cytological 
analyses have been carried out (Gilvarry et al., 1990). In addition, multiple drug 
resistant variants of DLKP have been established (Clynes et al. , 1992) as models for 
MDR in NSCLC cells.
1.9.1 Isolation and Characterisation of DLKP Clones
Law et al. (1992) found that at passage 5, the DLKP cell line contained 2 chromosomal 
subpopulations with 65% of the cells being hyperdiploid (56 chromosomes) and 35% 
being hypertetraploid (95-115) chromosomes. It was also observed during routine 
culture o f these cells that at least 3 morphologically distinct subpopulations were 
present. These heterogenous populations were evident in DLKP cultures which had been 
passaged up to 100 times. As most lung tumours contain heterogenous populations, it 
was thus possible that the DLKP cell line could serve as a model to closely examine 
such heterogeneity. It was decided to attempt to isolate the different morphological cell 
types o f DLKP in a cloning procedure in an effort to study the individual growth 
characteristics of tumour cell subpopulations in isolation and also the growth effects of 
such populations on each other.
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As outlined in Section 1.3, properties such as metastatic potential and response to 
chemotherapy are also often heterogenous within lung tumours and a model containing 
subpopulations with these characteristics would be useful in investigations into these 
properties of cancer cells which cause the disease to be fatal.
If the DLKP cells were to serve as models for in vivo phenomena such as tumour 
heterogeneity, tumour growth and progression and drug resistance etc., it would be 
important to characterise the cells as fully as possible in order to allow extrapolations 
and comparisons to be made with in vivo situations. An extensive characterisation study 
was therefore carried out on DLKP with chromosomal, growth, physiological and 
biological features of the cells examined to establish their relationship to normal and 
other tumour lung cells in vivo and in vitro.
1.9.2 Search for Specific Markers of DLKP Clones
Studies on the isolated DLKP clonal subpopulations would be aided by the identification 
of markers specific to one or more of the clones. Distinct individual clonal 
morphologies can vary slighlty under different conditions, are not always objectively 
discernible and do not facilitate quantitative analyses. Specific markers however, would 
be measurable and would allow precise identification of the individual clonal 
populations. The DLKP clones were therefore included in the characterisation studies 
carried out on DLKP and in addition, monoclonal antibodies were raised to DLKP in 
an attempt to identify specific markers for the clones.
1.9.3 Examination of Interconversion and Differentiation of Clones
The inter-relationship between the isolated clonal subpopulations of DLKP became 
interesting when it was observed that, in terms of morphological appearance, the clones 
appeared to be interconverting. The cell(s) of origin o f lung cancer is as yet unknown, 
as is the true stem cell(s) of the lung epithelium. It was possible that if the distinct 
DLKP morphologies represented distinct phenotypes, the interconverting clones could 
be used as a model to examine the progression o f lung cancer cell types, including those 
with stem cell-like properties, and their adaptation to their environment. In addition,
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manipulation of the interconversions by differentiation-inducing agents could give 
insight into the cellular origins of lung cancer and normal differentiation in vivo by 
elucidating pathways of differentiation open to the individual and/or collective DLKP 
clones.
Comparison o f the growth and differentiation characteristics of DLKP cells with their 
MDR variants could also contribute to the understanding of lung cell differentiation as 
MDR cells are often more differentiated than their sensitive counterparts (Section 1.6), 
as well as revealing some o f the effects of the acquisition of the MDR phenotype on 
aspects of lung cell biology.
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MATERIALS AND METHODS
2.1 WATER
Ultrapure water was used in the preparation of all media and solutions. This water was 
purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP) to a 
standard of 1 2  - 18 megaohms/cm resistance.
2.2 GLASSWARE
Most solutions pertaining to cell culture and maintenance were prepared and stored in 
sterile glass bottles. These bottles (and lids) and all other glassware used for any cell- 
related work were prepared as follows:- all glassware and lids were soaked in a 2 % 
(v/v) solution of RBS-25 (AGB Scientific) for at least lhr. after which they were 
scrubbed and rinsed several times in tap water. They were then washed by machine 
using Neodisher detergent which is an organic, phosphate-based acid detergent, rinsed 
twice with distilled water, once with ultrapure water and sterilised by autoclaving.
2.3 STERILISATION
Water, glassware and all thermostable solutions were sterilised by autoclaving at 120^0 
for 20 min. under pressure of lbar. Thermolabile solutions were filtered through a 
0.22/xm sterile filter (Millipore, millex-gv). Low protein-binding filters were used for 
all protein-containing solutions.
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2.4 MEDIA PREPARATION
The basal media used during routine cell culture were prepared according to the 
formulations shown in Table 2.4.1. 10X media were added to sterile ultrapure water, 
buffered with HEPES and NaHC03 and adjusted to a pH of 7.45 - 7.55 using sterile 
1.5M NaOH and 1.5M HC1. The media were then filtered through sterile 0.22/xm bell 
filters (Gelman; G.1423S) and stored in 500ml sterile bottles at 4°C. Sterility checks 
were carried out on each 500ml bottle of medium as described in Section 2.5.6.
The basal media were stored at 4°C up to their expiry dates as specified on each 
individual 10X medium container. Prior to use, 100ml aliquots of basal media were 
supplemented with 2mM L-glutamine (Gibco; 043-05030) and 5% foetal calf serum 
(Sigma; F7524, Batch #13H 3389) and this was used as routine culture medium. This 
was stored for up to 2 weeks at 4°C, after which time, fresh culture medium was 
prepared.
Table 2.4.1 Preparation of basal media
DMEM 
(Gibco 042-02501M)
Hams F12 
(Gibco 042-01430M)
MEM
(Gibco 074-01700N)
10X Medium , 500ml 500ml Powder
Ultrapure H20 4300ml 4700ml 4300ml
1M HEPES' 
Sigma H9136
100ml 100ml 100ml
7.5% NaHCOj 
BDH 30151
45ml 45ml 45ml
* HEPES = N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid)
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2.5 CELL LINES
All cell culture work was carried out in a class II down-flow re-circulating laminar flow 
cabinet (Nuaire Biological Cabinet) and any work which involved toxic compounds was 
carried out in a cytoguard (Gelman). Strict aseptic techniques were adhered to at all 
times. The laminar flow cabinet was swabbed with 70% industrial methylated spirits 
(IMS) before and after use, as were all items used in the cabinet. Each cell line was 
assigned specific media and waste bottles and only one cell line was worked with at a 
time in the cabinet which was allowed to clear for 15min between different cell lines. 
The cabinet itself was cleaned thoroughly each week with industrial detergents (Virkon; 
Antec. International, TEGO; TH.Goldschmidt Ltd.), as were the incubators.
The cell lines used during the course of this study, their sources and their basal media 
requirements are listed in Table 2.5.1. Basal medium was supplemented with 5-10% 
serum and 2mM L-glutamine. Lines were maintained in 25cm2 flasks (Costar; 3050) 
or 75cm2 flasks (Costar; 3075) at 37°C and fed every two to three days.
2.5.1 Subculture of Adherent Lines
During routine subculturing or harvesting of adherent lines, cells were removed from 
their flasks by enzymatic detachment. Waste medium was removed from the cells which 
were then rinsed with a pre-warmed (37°C) trypsin/EDTA (TV) solution (0.25% trypsin 
(Gibco; 043-05090), 0.01% EDTA (Sigma; EDS) solution in PBS A (Oxoid; BR14a)). 
The purpose of this was to sequester the naturally occurring trypsin inhibitor which 
would be present in any residual serum. Fresh TV was then placed on the cells 
(2ml/25cm2 flask or 4ml/75cm2 flask) and the flasks were incubated at 37°C until the 
cells were seen to have detached ( 5 - 1 0  min). The trypsin was deactivated by addition 
of a equal volume of growth medium ( i.e. containing 5% serum) and the entire 
solution was transferred to a 30ml sterile universal tube (Sterilin; 128a) and centrifuged 
at 1,000 r.p.m. for 5 min. The resulting pellet of cells was resuspended in pre-warmed 
(37°C) fresh growth medium, counted (Section 2.5.3) and used to re-seed a flask at the 
required cell density or to set up an assay.
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Table 2.5.1 Cell lines used during the course o f  this study
Cell line Basal medium Cell type Source
DLKP
(and all its 
derivatives)
ATCC1 Human lung poorly differentiated 
squamous carcinoma
Dr.Grant
NCTCC
SK-MES-1 MEM2 Human lung squamous carcinoma ATCC3
SK-LU-1 MEM Human lung adenocarcinoma ATCC
A549 ATCC Human lung adenocarcinoma ATCC
H82’ RPMI 1640 Human lung SCLC-V ATCC
H69* RPMI 1640 Human lung SCLC-C ATCC
HTB 120" RPMI 1640 Human SCLC-C ATCC
SK-N-SH MEM Human neuroblastoma ATCC
HL60* RPMI 1640 Human leukemic line ATCC
RPMI 2650 | MEM Human nasal squamous line ATCC
HEP-2 ATCC Human laryngeal epithelial line ATCC
Sp2* RPMI 1640 Mouse hybridoma line ATCC
T84 ATCC Human colonic epithelial line ATCC
Fibroblasts ATCC Normal human lung fibroblasts Dr. Woodman 
NCTCC
703D4/704A1" [ DMEM Mouse hybridomas ATCC
EP16* RPMI 1640 Mouse hybridoma ATCC
* These cells grow in suspension, all others are adherent.
'ATCC consists of a 1:1 mixture of DMEM and Hams F12.
2MEM medium was supplemented with 1 % (v/v) MEM Non-essential amino acids (NEAA) (Gibco; 043- 
01140) and ImM sodium pyruvate for all lines 
3ATCC = American Type Culture Collection
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2.5.2 Subculture of Suspension Lines
While cell lines that grew in suspension did not require enzymatic detachment, it was 
occassionally necessary to detach some cells which had adhered loosely to the flask 
surface by giving the flask a sharp tap with the hand. The cell suspension was removed 
from the flask to a sterile tube, centrifuged as in Section 2.5.1 and the cells were 
treated identically to adherent cells from this stage on.
2.5.3 Cell Counting
Cell counting and viability determinations were carried out using a trypan blue (Gibco; 
525) dye exclusion technique. An aliquot of trypan blue was added to a sample from 
a single cell suspension in a ratio of 1:5. After 3 min. incubation at room temperature, 
a sample o f this mixture was applied to the chamber of a haemocytometer over which 
a glass coverslip had been placed. Cells in the 16 squares of the four outer corner grids 
of the chamber were counted microscopically, an average per comer grid was calculated 
with the dilution factor being taken into account and final cell numbers were multiplied 
by 1 0 4 to determine the number of cells per ml (volume occupied by sample in chamber 
is 0 . 1 cm x 0 . 1cm x 0 .0 1 cm i.e. 0 .0 0 0 1 cm3 therefore cell number x 1 0 4 is equivalent 
to cells per ml). Non-viable cells were those which stained blue while viable cells 
excluded the trypan blue dye and remained unstained.
2.5.4 Cell Freezing
To allow long term storage of cell stocks, cells were frozen and cryo-preserved in 
liquid nitrogen at temperatures below -180°C. Once frozen properly, such stocks should 
last indefinitely.
Cells to be frozen were harvested in the log phase of growth (/. e. actively growing and 
approximately 50 - 70% confluent) and counted as described in Sections 2.5.1 - 2.5.3. 
The pelleted cells were re-suspended in serum and an equal volume o f a DMSO/serum 
(1:9, v/v) solution was slowly added dropwise to the cell suspension to give a final
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concentration of at least 5x10s cells per ml. 1.5ml aliquots o f  this suspension was 
placed in cryovials (Greiner; 122 278) which were then quickly placed in the vapour 
phase of liquid nitrogen containers (approximately -8QPC) for 2 .5 - 3.5 hr. After this 
time, the cryovials were transfered down into the liquid nitrogen where there were 
stored until required.
2.5.5 Cell Thawing
Immediately prior to the removal of a cryovial from the liquid nitrogen stores for 
thawing, a sterile universal tube containing growth medium was prepared for the rapid 
transfer and dilution o f thawed cells to reduce their exposure time to the DMSO 
freezing solution which is toxic at room temperature. The suspension was then 
centrifuged at 1,000 r.p.m. for 5 min., after which , the DMSO-containing supematent 
was removed and the pellet was re-suspended in fresh growth medium. A viability 
count was then carried out (Section 2.5.3) to determine the efficacy of the freezing/ 
thawing procedures and the thawed cells were placed into tissue culture flasks with the 
appropriate volume of medium (10ml/25cnf flask and 15ml/75cmi flask) and allowed 
to attach over night. After 24 hr, the cells were re-fed with fresh medium to remove 
any residual traces o f DMSO.
2.5.6 Sterility Checks
Sterility checks were routinely carried out on all media, supplements and trypsin used 
for cell culture. Samples of basal media were inoculated into Columbia (Oxoid; 
CM331) blood agar plates, Sabauraud (Oxoid; CM217) dextrose and Thioglycollate 
(Oxoid; CM 173) broths which should between them detect most contaminants including 
bacteria, fungus and yeast. Growth media (i.e. supplemented with serum and L- 
glutamine) were sterility checked at least 2  days prior to use by incubating samples at 
37°C which were subsequently examined for turbidity and other indications of 
contamination.
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2.6 MYCOPLASMA ANALYSIS
Mycoplasma examinations were carried out routinely (at least every 3 months) on all 
cell lines used in this study. These analyses were performed by Una Gilvarry, Cathy 
Halligan and William Nugent.
2.6.1 Indirect Staining Procedure
In this procedure, Mycoplasma-negâtive NRK cells (a normal rat kidney fibroblast line) 
were used as indicator cells. As such, these cells were incubated with supematent from 
test cell lines and then examined for Mycoplasma contamination. NRK cells were used 
for this procedure because cell integrity is well maintained during fixation. A 
fluorescent Hoechst stain was utilised which binds specifically to DNA and so will stain 
the nucleus of the cell in addition to any Mycoplasma DNA present. A Mycoplasma 
infection would thus be seen as small fluorescent bodies in the cytoplasm of the NRK 
cells and sometimes outside the cells.
NRK cells were seeded onto sterile coverslips in sterile Petri dishes at a cell density o f  
2X103 cells per ml and allowed to attach over night at 37°C in a 5% C 0 2, humidified 
incubator. 1ml of cell-free (cleared by centrifugation at 1,000 r.p.m. for 5 min) 
supematent from each test cell line was then inoculated onto a NRK Petri dish and 
incubated as before until the cells reached 2 0 -5 0 %  confluency ( 4 - 5  days). After this 
time, the waste medium was removed from the Petri dishes, the coverslips were washed 
twice with sterile PBS A, once with a cold PBS/Camoys (50/50) solution and fixed with 
2ml of Camoys solution (acetic acid:methanol-1:3) for 10 min. The fixative was then 
removed and after air drying, the coverslips were washed twice in deionised water and 
stained with 2ml of Hoechst 33258 stain (BDH) (50ng/ml) for 10 min. From this point 
on, work proceeded in the dark to limit quenching of the fluorescent stain. Following 
three rinses in PBS, the coverslips were mounted in 50% (v/v) glycerol in 0.05M  citric 
acid and 0.1M disodium phosphate and examined using a fluorescent microscope with 
a UV filter.
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2.6.2 Direct Staining
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an enriched Mycoplasma culture broth (Oxoid; CM403) - supplemented 
with 16% serum. 0.002% DNA (BDH; 42026), 2/ig/ml fungizone (Gibco; 042 05920), 
2x10s units penicillin (Sigma; Pen-3) and 10ml of a 25% (w/v) yeast extract solution - 
to optimise growth of any contaminants and incubated at 37°C for 48 hr. Sample of 
this broth were then streaked onto plates of Mycoplasma agar base (Oxoid; CM401) 
which had also been supplemented as above and the plates were incubated for 3 weeks 
at 37°C in a C 02 environment. The plates were viewed microscopically at least every 
7 days and the appearance of small, ‘fried egg’-shaped colonies would be indicative of 
a mycoplasma infection.
2.7 ESTABLISHMENT OF DLKP CLONES
The three DLKP clones were established from a limiting dilution assay, one from a 
single procedure and two from a re-cloning procedure.
2.7.1 Limiting Dilution Assay
A single cell suspension of DLKP cells (passage 3) was plated onto 3 x 96-well tissue 
culture plates (Falcon; 3072) at a cell density of 5 cells per ml. The plates were 
incubated at 37°C in the presence of 5% C 02 in a humidified atmosphere. After 5 days, 
each well was examined microscopically and those wells identified as containing a 
single cell or single colonies made up of two or three cells were marked. The remaining 
wells contained no cells, had more than one colony or contained cells lying close to 
each other but it was not clear if  they were clones or not. All such wells were 
disregarded.
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2.7.2 Culture of Clonal Populations
The marked wells were fed every 6  - 7 days until they became confluent. The cells 
were then removed from their wells by trypsinisation. This involved the aspiration of 
waste medium from each well and the addition o f 50/xl of TV (Section 2.5.1). The 
plates were then incubated at 37°C for approximately 5 min. After this time, the cells 
had not completely detached from the well surfaces but agitation and resuspension with 
a micropipette was successful in completing detachment. Each clonal population was 
then directly transferred into an individual well in a 24-well plate (Greiner; 662160) 
without centrifugation. Each well contained 1ml of growth medium which was sufficient 
to inactivate the trypsin and centrifugation and subsequent resuspension may have led 
to the loss o f some cells.
These wells rapidly became confluent (after 6 - 7  days) and the clones were then 
transferred into 6 -well plates (Costar; 3516) in a similar manner to that of the previous 
transfer. When these wells became confluent, the cells were transferred to 25cm2 flasks 
and then to 75cm2 flasks. The cells were harvested as normal (Section 2 .5 .1) for these 
manipulations.
2.7.3 Recloning Procedure
The recloning procedure was identical to that of the above procedure, except that a 
lower initial cell density of three cells per ml was used to seed the 96-well plates to 
further reduce the possibilities of obtaining more than one cell per well.
2.8 CHROMOSOMAL ANALYSIS
Colcemid is a compound which disrupts spindle formation and so prevents cells from 
advancing through the cell cycle and halts them at metaphase. This agent is used in 
cytogenetic studies to allow examination of metaphase chromosomes when they are less 
densly aggregated than at other times of the cell cycle. For these studies, colcemid 
(Gibco; 890-30141D) was reconstituted to a working stock of 0.2/xg/ml in sterile PBS 
A and stored at 4°C.
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Each line analysed was harvested and inoculated into 2x75cm2 flasks at a density of 
4X104 cells per ml. This inoculum level was such that each cell line would have entered 
the log phase of growth 24 hr later, thus optimising the number of metaphase cells 
which could then be collected.
24 hr after seeding, colcemid was added to each flask to give a final concentration of 
0.02/xg/ml and the flasks were incubated at 37°C for 2 hr. Metaphase cells, which were 
rounded and loosely attached, were then harvested by shaking each flask vigorously and 
decanting the supematent. Each flask was rinsed thoroughly with sterile PBS A, the 
washings were pooled with their respective supematents and all were centrifuged in 
clean, glass centrifuge tubes at 1,000 r.p.m. for 5 min. The pellets were resuspended 
in 5 - 10 ml of pre-warmed 0.075M KC1, a hypertonic solution which caused the cells 
to swell and become fragile, and incubated at 37°C for 20 min. The samples were 
centrifuged again as before and the resulting pellets were resuspended in Camoys 
fixative (Section 2.6.1) which was added slowly, dropwise and the cells were incubated 
at 4°C for 1 hr. After this time, the cells were centrifuged as before and resuspended
in fresh fixative. This was repeated three times. After the final centrifugation, the cells
were resuspended in 1ml o f Camoys fixative.
Using a pasteur pipette, drops o f cell suspension were dropped onto clean glass slides 
and when they had dried (seconds), the slides were stained for 5 min with a 5% Giemsa 
(BDH; 35014) solution in pH 6 . 8  Gurr buffer (BDH; 33199), rinsed in Gurr buffer and 
examined microscopically. The number of chromosomes present per spread was 
determined by counting by eye.
2 .9 GROWTH ASSAYS
A range o f growth assays was carried out using a variety of conditions and end points.
2 .9 .1  Monolayer Assay
Cells which were in the log phase of growth were fed 24 hr prior to harvesting for the 
assay. Cells were harvested and resuspended vigorously in growth medium (i.e. serum
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supplemented) after centrifugation to ensure that a single cell suspension was obtained. 
The cell suspension was diluted in growth medium to a concentration o f lx l0 4 cells per 
ml and this was then plated onto 96-well plates at 100/xI per well i.e. lxlO3 cells per 
well using a multi-channel micropipette (supplied by Brownes). These cells were 
allowed to attach over night at 37°C, in a C 0 2, humidified incubator. Plates were 
wrapped in ‘Parafilm’, as were all unsealed tissue culture plates and dishes during 
incubation periods in the course of these studies, to prevent evapouration.
When the cells had attached, medium was removed from the wells by inverting and 
tapping the plates over an open vessel which had been swabbed with IMS. The wells 
were then rinsed three times with sterile PBS A, ensuring to remove as much PBS as 
possible after the final rinse.
For the serum dose response assays, medium containing the appropriate concentration 
of serum was plated as required. Plates were then incubated at 37°C in a 5% C 0 2 
incubator for 6  days. After this time, the medium was removed from the plates and they 
were rinsed with PBS A as before. Growth was determined by crystal violet dye elution 
assay (Section 2.9.2).
2.9.2 Crystal Violet Dye Elution Assay
Following removal of waste medium and rinsing three times with PBS A, a 0.2% 
solution of crystal violet (BDH; 34024) in PBS A which had been filtered through a 
Whatman No. 1 filter (Whatman; FB105-32) immediately prior to use, was dispensed 
onto the assay plates at 100/xl per well. Plates were incubated at room temperature for 
1 0  min, the dye was removed and the plates were rinsed thoroughly in tap water and 
then inverted and allowed to dry on tissue paper.
When completely dry, lOO/il of 33% glacial acetic acid was placed in each well to elute 
the dye and the plates were tapped gently to ensure that the dye had gone evenly into 
solution. The absorbance of each well was determined on an ELISA plate reader at a 
wavelength of 570nm which was specific for maximum absorbance of the crystal violet 
dye and at 620nm which was a reference wavelength.
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2.9.3 Serum-Free Subculture Assay
The serum free medium (SFM) used in these assays was adapted for use with DLKP 
cells by Paula Meleady (NCTTC) from a SFM developed for CHOK1 cells (Chinese 
hamster ovary line) by Mendiaz et al. (1986) which had been further refined by 
Dr. Joanne Keenan (NCTTC). The medium consisted of basal Hams F12 medium which 
was supplemented with a number of trace elements, insulin and transferrin (see Table 
2.9.1).
Routinely growing cells were harvested by trypsinisation but because they were to be 
cultured in SFM, serum-supplemented growth medium, which contains a naturally 
occurring trypsin inhibitor, could not be used to inactivate the trypsin. Instead, purified 
trypsin inhibitor (Sigma; T6522) was used. A  volume of trypsin inhibitor at 
1.388mg/ml will inactivate an equal volume of the 0.25% trypsin solution used here. 
When the cells had been centrifuged, they were resuspended in SFM and inoculated into 
25cm2 vented flasks (Costar; 3056) at a density of 2.5x10s cells per flask and incubated 
at 37°C in a C 02 incubator. Vented flasks and a C 0 2 incubator were used as opposed 
to sealed flasks and a normal incubator as this was believed to aid in buffering the cells, 
one of the functions normally carried out by serum.
Subculturing o f these cells was similar to that of serum-supplememted, adherent cells 
(2.5.1), except that trypsin inhibitor was used to inactivate the trypsin, a slightly higher 
speed o f 1,500 r.p.m. was employed to pellet the cells and cells were always re-seeded 
into fresh flasks, which was not necessarily the case in serum-supplemented 
subculturing.
The extent o f proliferation of cells under SFM conditions was determined by 
haemocytometer cell counts (Section 2.5.3).
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Table 2.9.1 Supplements in serum free medium
Supplement Final concentration (/iM)
FeS04 5.0
H2Se03 3.0xl0 2
CuS04.5H20 l.oxia3
MnS04.5H20 l.oxia3
Na2Si03 5 .oxia2
N H 4V O 3 5 .0xia3
(NH4)6M o7024.4H20 l.oxia3
NiCl2.6H20 5.0X104
ZnS04.7H20 5 .0X10-2
SnCl2.H20 5.OXIO4
CaCl2 6.0xia2
Linoleic acid 3 .0xia2
NEAA l.oxia2
Transferrin 5.0/xg/ml
Insulin 10.0/ig/ml
L-glutamine 2mM
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2.9.4 Soft Agar Assay
The agar for these assays was prepared as follows:-
1.548g of agar (Bacto Difco) was dissolved in 100ml of ultrapure water and autoclaved. 
This agar was then melted in a microwave oven immediately prior to use and incubated 
in a water bath at 44°C.
Agar medium (AgM) was prepared as follows and equilibrated to 44°C:-
2xDMEM* 50ml
HEPES (lmM) 2ml
NaHC03 1ml
Pen/Strep 1ml (Gibco; 15070-022)
Growth medium 14ml
*2xDMEM was prepared as follows 
lOxDMEM 20ml
Ultrapure water 76ml
HEPES (lmM) 4ml
(adjust to pH 7.4 with 1M NaOH)
The thermo-labile components L-glutamine (1ml) and serum (10ml) were added last to 
the AgM. 50ml of the melted agar was then added to AgM, mixed well and quickly 
dispensed onto 35mm sterile Petri dishes (Lux Scientific Corp.; 5217). The plates were 
allowed to set at room temperature and the remaining AgM was returned to the water 
bath and the temperature was reduced to 41°C.
The cells to be assayed were harvested and resuspended in medium without serum, 
ensuring tha a single cell suspension was obtained. The cells were diluted to give a 
concentration of 2x10* cells per ml in a total o f 5ml. 5ml of agar (41°C) was added to 
each cell suspension, mixed well and 1.5ml was quickly dispensed onto each pre-set 
agar plate, in triplicate, giving a final cell concentration of 1.5x10* cells per plate. The 
plates were placed on trays which contained a small volume of water to prevent the agar 
from drying out and incubated at 37°C, 5%COz for 10 days.
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After this time, colonies were counted using an inverted microscope (CK Olympus, 
Tokyo) at 40x. The Petri dishes used had grids marked on their bases which aided in 
the counting process. Colonies greater than 20/im in diameter were scored using an eye­
piece graticule. 10 areas were viewed per plate and the total number of colonies present 
was extrapolated from this.
The percentage colony forming efficiency (CFE) was determined by expressing the 
number of colonies formed as a percentage of the number of cells plated.
2.9.5 Spinner Flask Assay
Clean spinner flasks (Techne) were coated with a siliconising agent, 
dimethyldichlorosilane solution (BDH; 33164) to prevent cell attachment and allowed 
to dry in a fume hood. The flasks were then rinsed at least three times with ultrapure 
water and autoclaved. Flasks were rinsed again with sterile PBS A prior to use to 
remove any residual silicone.
Cells were harvested and inoculated into the spinner flasks at a concentration of 2x10s 
cells per 50ml per flask. The flasks were placed on magnetic stirrer boxes in a 37°C 
constant temperature room and the stirrers caused a magnetic rod inside the flasks to 
rotate, thus keeping the cells in suspension. The rods were rotated at a speed of 35rpm.
Every 7 days, the cells were decanted from the flasks, an aliqout was counted using a 
haemocytometer and the remainder were used to re-seed the flasks at the original 
density of 2x10s cells per flask. For the first 5 weeks of the assay, cells were not fed 
between counts as there appeared to be sufficient medium present to maintain their 
growth. However, over the course of the first 5 subcultures, the rate of growth o f the 
cells was found to be increasing and it was necessary to add a further 50ml o f medium 
to each flask 4 - 5  days after re-seeding.
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2.9.6 Growth Factor Assay
Growth factor assays were carried out on 96-well plates. These assays proceded as 
described in Section 2.9.1 up to the point where the attached cells were rinsed with PBS 
A. After this, 50/d of DMEM containing twice the final concentration of L-glutamine 
and also twice the final concentration of background serum or insulin, depending on 
which was being used in the assay, was plated onto the cells using a multi-channel 
micropipette. Growth factor stocks (see Table 2.9.1) were diluted in Hams F12 medium 
to twice the final concentration of their respective biologically active ranges, as 
recommended by the suppliers, and 50/il aliquots were plated onto the cells also. All 
growth factors were aliquoted and stored at -2(fC at high stock concentrations to 
minimise loss of activity.
Plates were incubated at 37°C, 5% C 02 for 6 days, after which growth levels were 
determined by CVDE assay as outlined in Section 2.9.2.
Table 2.9.1 List of growth factors used in these studies
Growth factor Supplier Cat.No.
TGF0 R & D Systems 100-B
EGF Promega G5021
Insulin Sigma 11882
Serotonin Sigma H4511
Histamine Sigma H7125
PDGF-AA Promega G5181
PDGF-BB R & D Systems 220-BB
IL-la R & D Systems 220-LA
IL-6 R & D Systems 206-IL
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2.9.7 3H-Thymidine Incorporation Assay
All experiments involving radioactivity were carried out in a designated cabinet in a 
laboratory allocated specifically to such work. When solutions or vessels containing 
radiolabel were being handled, 2 pairs of gloves were worn and all waste solutions and 
materials were deactivated in a strong detergent solution such as RBS. Waste was 
disposed of according to University guidelines.
Cells were seeded into 96-well plates at a density of lxlO3 cells per well in growth 
medium and allowed to attach over night. The next day, waste medium was removed 
and the cells were rinsed 3 times with sterile PBS A. Medium without serum was then 
plated onto the cells and the plates were incubated over night again at 37°C, 5% C02. 
The purpose of this was to serum starve the cells, inducing quiescence and halting them 
at the G0 phase of the cell cycle. Subsequent addition of growth factors should then 
either induce the cells to proceed through the cell cycle and thus stimulate DNA  
synthesis or inhibit DNA synthesis in those cells still cycling or have no effect if the 
cells do not express the appropriate growth factor receptors.
100/xl of fresh medium containing the growth factors to be tested were then plated and 
incubated for 4 hours at 37°C, 5% C 02. 5/xl of 3H-thymidine was added (100/xCi) to 
each well and the plates were incubated for a further 24 hr.
Waste medium was then removed, the plates were rinsed once with PBS A and 200/d 
1M KOH was added to each well to lyse the cells. After incubating at 37°C for 1 hr, 
the contents of each well was mixed thoroughly, 100/d aliquots were added to 5ml 
scintillation fluid (Ecolite; ICN 882475) and the number of disintegrations per minute 
were determined using a scintillation counter.
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2.10 CONDITIONED MEDIUM ASSAY
Medium in which cells have been growing can be termed ‘conditioned medium’ (CM), 
so-called to recognise that cells may release substances into their medium including 
waste products of metabolism, growth factors and other secretory products. This CM 
can be collected and analysed to examine various aspects of the biology of a particular 
cell. In these studies, CM was analysed for growth stimulatory properties.
2.10.1 Collection of Conditioned Medium
Cells were harvested from 75cm2 flasks and seeded into tissue culture roller bottles 
(Falcon; 3027) at concentrations of 2x10s cells per ml in 100 ml growth medium. The 
roller bottles were incubated at 37°C on a roller bottle apparatus which rotated the 
vessels at a speed of 0.25 r.p.m. for the first 24 hr to allow cell attachment and at 0.50 
r.p.m. after this time. The medium was replaced every 2 - 3  days until the cells were 
approximately 50% confluent. The medium was then removed, the cells were rinsed 
twice with sterile PBS A and then incubated for 1 hr with 100ml PBS A to remove as 
much serum-containing medium as possible. After removal of the PBS A, 100ml of 
Hams F12 supplemented with 2mM L-glutamine but without serum was placed into the 
roller bottles which were incubated over night as usual.
This 100ml Hams F12, called CM1, was then discarded and replaced with fresh Hams 
F12 (with L-glutamine), CM2, and the cells were incubated and allowed to condition 
this medium for 48 hr. CM2 was then decanted, centrifuged at 1,000 r.p.m. for 10 min 
to remove any cell debris and was stored at 4°C. A fresh 100ml of Hams F12 was 
placed in the roller bottles, incubated for a further 48 hr and harvested in the same 
manner as CM2. CM2 and CM3 were then combined and stored at 4°C until assayed.
CM was collected from cells cultured in 75cm2 flasks in the same way.
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2.10.2 Ultrafiltration of Conditioned Medium
The membranes used in the ultrafiltration procedures were a YM3 (An 06177A) which 
had a molecular weight cut-off of l,000kD. The membrane was pre-treated by rinsing 
for 1 hr in ultrapure water, with 3 changes of water in that time, to remove residual 
sodium azide which was used as a preservative. The membrane was then placed in an 
ultrafiltration cell and rinsed again by running 100ml of PBS A or ultrapure water 
through the system 3 times. Pressure of 50psi was provided by N2 gas.
The sample to be filtered was then placed in the ultrafiltration cell and pressure of 50psi 
was applied. The sample was stirred continuously by a magnetic bar to prevent protein 
accumulating on the membrane. The volume of the sample was reduced the required 
amount, 10-fold for these studies, and that which was retained by the membrane was 
called a lOx sample. The lOx sample was stored at 4°C until required.
At the end of the procedure, the membrane was rinsed with ultrapure water or PBS A, 
removed from the cell, soaked in water for a further 30 min and stored in a 1.5M NaCl 
solution at 4°C until required again. Each membrane could be used up to 5 times.
2.10.3 Conditioned Medium Assay
Cells were plated on 96-well plates, allowed to attach over night and rinsed as outlined 
in Section 2.9.1. 100/d of CM was then applied to the appropriate wells. Controls for 
these assays consisted of Hams F12 (as this was the medium used to collect CM) which 
had been incubated for 24 hr at 37°C to mimic any alterations that may have occurred 
to Hams F12 components during the incubation periods with the cells.
The plates were incubated at 37°C, 5% C 0 2 for 6 days and then the cells were 
examined using the CVDE assay (Section 2.9.2).
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2.11 EXTRACELLULAR MATRIX ADHERENCE ASSAYS
Collagen type IV (Sigma; C5533), fibronectin (Sigma; F2006) and laminin (Sigma; L- 
2020) were reconstituted in PBS A and collagen and fibronectin stocks were stored at 
-20°C while laminin stocks were stored at -80PC.
2.11.1 Coating of Plates
Each ECM protein was diluted to 50/xg/ml with PBS A and 250/zl aliquots were placed 
into the wells of a 24-well plate and the plates were tapped gently to ensure that the 
base of each well was completely covered with solution. The plates were then incubated 
at 4°C over night. The ECM solutions were then removed, the wells were rinsed twice 
with sterile PBS A and 0.5ml of a 0.1% BSA/PBS A solution was dispensed into each 
well. The plates were incubated at 37°C for 15min and then rinsed twice again with 
PBS A.
2.11.2 Adherence Assay
The cells were harvested and resuspended in Hams F12 medium without serum. The 
cells were then plated at lxlO4 cells per well in triplicate and incubated at 37°C for 
either 15 or 30 min. Controls wells were those which had been coated but contained no 
cells. At each time point, the medium was removed from the wells and the attached 
cells were rinsed gently with PBS A. The cells were then stained with crystal violet dye 
for 10 min, after which, the plates were rinsed and allowed to diy.
The dye was eluted with 200/d 33% glacial acetic acid and 100/il aliquots were 
transferred to 96-well plates and the absorbance was determined on an ELISA plate 
reader (Section 2.9.2). Exent o f attachment to the different substrates was determined 
by comparing the absorbancies in wells containing cells with those which had been 
coated but contained no cells.
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2.12 TOXICITY ASSAY
Due to the nature of the compounds tested in the assays, precautions were taken to limit 
the risks involved in their handling and disposal. All work involving toxic compounds 
was carried out in a Gelman ‘Cytoguard’ laminar air flow cabinet (CG Series). 
Adriamycin, vincristine and VP 16 waste was disposed of by hyperchlorite inactivation, 
autoclaving and inceration, respectively.
Cells were harvested and plated into 96-well plates at densities of lxlO3 cells per 100/xl 
per well in growth medium and allowed to attach over night at 37°C, 5% C 02. After 
this time, drug dilutions were prepared at twice their final concentration and 100/xl 
aliquots were dispensed directly onto the 96-well plates, giving final concentrations of 
lxdrug.
The plates were incubated for 6 days and cell survival was determined by CVDE assay 
(Section 2.9.2).
2.13 PREPARATION OF CELLS FOR ELECTRON MICROSCOPY
Cells were harvested by trypsinisation and washed by centrifuging and resuspending 3 
times in PBS A. The pellets were then resuspended gently in a 10% glutaraldehyde/PBS 
A solution (v/v) and stored at 4°C overnight. The cells were centrifuged again (1,000 
r.p.m., 5 minutes) and the pelleted cells were sent to Dr.Daved Dinsdale, Leicester, 
England for electron microscopic analysis.
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2.14 ELECTRICAL RESISTANCE STUDIES
Cell monolayers were cultured on tissue culture plate inserts which could be removed, 
assayed and replaced at will to enable continuous assessment of the electrical resistance 
exhibited by the monolayers. The base of the insert was a transparent, porous 
membrane which allowed the monolayer to be viewed microscopically and also allowed 
the free movement of solutes between the insert and the outer well.
2.14.1 Preparation of Cell Monolayers
Cells were harvested and seeded into inserts (Falcon; 3180) which were suspended in 
the wells of a 12-well plate (Falcon; 3043). Cells were seeded at densities of lxlO6 cells 
per insert to enable rapid formation of a confluent monolayer. The well contained 1ml 
of growth medium while the insert contained 0.5ml. The plates were incubated at 37°C, 
5% C 02 for the duration of the assay.
2.14.2 Determination of Electrical Resistance
The electrical resistance measurements were carried out by Stephen Keely, 
Pharmacology Department, University College Dublin using the facilities of Dr. Alan 
Baird. An Endohm apparatus was employed to determine resistance across the 
monolayers.
The measurements were carried out in a laminar flow cabinet and the apparatus was 
swabbed thoroughly with IMS before use. An insert was removed from its 12-well plate 
using a sterilised tweezer and placed in the chamber of the Endohm which contained 
4 - 5 ml medium. An electrode was placed into the insert and a current of electricity 
was passed through the monolayer. The Endohm then registered the resistance presented 
by the monolayer to the electric current. The insert was then returned to its well. This 
procedure was repeated every 3 - 4  days until the resistance of the positive control cell 
line was seen to plateau.
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2.15 IMMUNOCYTOCHEMISTRY
The immunocytochemical techniques carried out here followed standard procedures with 
only slight adaptations in the cell preparations which were analysed.
2.15.1 Preparation and Fixation of Cells
The cell preparations varied and depended on the cellular location of the antigen of 
interest, whether the cells grew in suspension or were adherent and whether the cells 
being studied were normal, untreated cells or had been exposed to differentiating 
agents.
The fixation procedure, however, remained constant, regardless of the cell preparation. 
For fixation, cells were rinsed 3 times with PBS A and then incubated at -2CPC for 7 
min. in pre-chilled methanol. The methanol was then removed from the cells and the 
cells were air-dried over night and stored at -20°C until required. This method was 
successful for every antibody used in this study.
2.15.1.1 Cytospin cell preparations
This procedure was employed if the cell being examined grew in suspension.
Cells were harvested, centrifuged at 1,000 r.p.m. for 5 min and resuspended in PBS 
A. The cells were rinsed a further 2 times in PBS A and were finally resuspended in 
cytospin buffer (Table 2.15.1). The cells were then cytospun onto clean glass slide 
using a cytocentrifuge. The cells were spun at 500 r.p.m. for 6 min, after which, they 
were allowed to air dry and were fixed as outlined in Section 2.15.1.
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Table 2.15.1  Components of cytospin buffer
Component g/L
NaCl 8.00
KC1 0.40
CaCl 0.14
MgCl 0.10
MgS04 0.10
Na2HP04 0.06
kh2po4 0.06
NaHC03 0.35
Glucose 1.00
Ultrapure water 1,000ml
2.15.1.2 Multiwell slide cell preparations
Multiwell glass slides (Dynatech) were utilised in most cases when the cells to be 
examined were adherent. These slides were used in preference to cytospins because they 
enabled cells to be cultured and analysed in situ, allowing cell morphology and antigen 
localisation to be examined after the immunocytochemical procedure. Each slide 
contained 8 or 10 wells, each of which could be analysed with a separate antibody, thus 
reducing the number of slides to be manipulated and the volumes of washing buffers 
required. In addition, cytospin preparations do not allow cell recovery after 
trypsinisation which may damage some cell surface antigens.
The multiwell slides were prepared as follows
Each slide was soaked in RBS detergent for 1 hr, then scrubbed, rinsed thoroughly with 
ultrapure water and wrapped in aluminium foil. The slides were then sterilised by 
baking for at least 2 hr at 180°C.
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Cells were harvested and seeded onto the wells of the sterilised slides at densities of 
lxlO4 cells per 50/xl per well. Each slide was placed into a sterile Petri dish which was 
sealed with ‘Parafilm’ and incubated at 37°C, 5% C 02 until the confluency required was 
achieved. The cells were then fixed in methanol (Section 2.15.1).
2.15.1.3 Tissue culture plate cell preparations
This method of cell preparation was employed for the analysis of BrdU- and RA-treated 
cells. The differentiation assays were carried out in 6-well tissue culture plates and 
because of the low cell numbers involved and the possibility of damaging antigens by 
transferring the cells to glass slides or making cytospin preparations, the 
immunocytochemical analyses on these cells was carried out in situ.
Following removal of waste medium, each well was rinsed with PBS A and fixed with 
methanol (Section 2.15.1).
2.15.1.4 EP16 and 703D4/704A1 Hybridomas
Most of the antibodies used in the immunocytochemical studies were commercial 
products, sold in purified form. Three of the antibodies, however, were aquired from 
hybridomas which were bought from the ATCC and cultured in the laboratory. These 
were the Epl6, 703D4 and 704A1 monoclonal antibodies. In order to obtain these 
antibodies, the hybridomas were cultured in their respective growth media (Table 2.5) 
as outlined for suspension cells in Section 2.5.2. Hybridomas secrete their antibodies 
into the medium, therefore, the cells were fed with fresh medium wich was then 
collected 3 - 4  days later. The supematents were cleared by centrifugation and could 
then be used neat in immunocytochemical studies as primary antibodies. The 
supematents were aliquoted and stored at -20PC until required.
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2.15.2 Immunocytochemical Procedure
The avidin-biotin-peroxidase complex (ABC) immunoperoxidase technique (Hsu et al. , 
1981) combined with the diaminobenzidine (DAB) visualisation procedure was 
employed here to indicate primary antibody binding. The ABC method involves 
application of a biotin-labelled secondary antibody, followed by the addition of avidin- 
biotin-peroxidase complex which results in a high staining intensity due to the formation 
of an avidin-biotin lattice which contains several peroxidase molecules. The peroxidase 
enzyme reacts with a DAB solution to give an insoluble, brown-coloured precipitate. 
Therefore, observation of a brown precipitate following this procedure is indicative of 
primary antibody reactivity.
The immunocytochemical procedure used was as follows :-
(note:- the word ‘slide’ will be used to describe all cell preparations (Sections 2.15.1.1 
-2.15.1.3)).
Frozen, fixed cell preparations were allowed to equilibrate to room temperature. A 
grease pen (DAKO; S2002) was used to encircle cells on cytospin slides and in tissue 
culture dishes to contain the various solutions involved. This was not necessary on the 
multiwell slides as the wells were indented and capable of holding a drop of solution. 
The cells were incubated for 5 min with a 3% H20 2 solution in ultrapure water to 
quench any endogenous peroxidase activity that may have been present in the cells and 
would give rise to false positive results. The slides were then rinsed with distilled water 
and placed in Tris-buffered saline (TBS) (0.05M Tris/HCl, 0.15M NaCl, pH 7.6) for 
5 min. Following this, the slides were incubated for 20 min at room temperature with 
normal rabbit serum (DAKO; X902) diluted 1:5 in TBS, to block non-specific 
background. This was then tapped off, 50/il of optimally-diluted primary antibody was 
placed on the cells and the slides were placed on a tray containing moistened tissue 
paper and incubated at 37°C for 2 hr. The primary antibodies, their sources and 
dilutions are listed in Table 2.15.1. The slides were then rinsed in TBS, x3 in 10 min, 
and then incubated for 30 min with biotinylated rabbit anti-mouse immunoglobins 
(DAKO; E354). The slides were rinsed as before and incubated with streptABComplex/ 
Horse Radish Peroxidase (HRP) (DAKO; K377) for 30 min at R.T., after which they
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were rinsed and incubated with a DAB solution (DAKO; S3000) for 10 - 15 min.
The slides were then counterstained with a 2% methyl green solution, dehydrated in 
alcohol and mounted in DPX (BDH; 36029) mounting solution.
Table 2.15.1 Primary antibodies used in immunocytochemical studies
Antibody D ilu tion /
Concentration
Supplier Catalogue
No.
Cam 5.2 25/ig/ml Becton Dickinson
Pan keratin 1/100 Sigma C2562
Keratin 8
Keratin 10 Undiluted DAKO 47048
Keratin 14 1/200 Sigma C8791
Keratin 17 1/400 Sigma C9179
Keratin 18 1/200 Sigma C8541
EMA *
EP16 Neat CM NCTCC
Desmoplakin Neat CM Gift'
Transglutaminase 1/20 Biogenesis 5560-6006
703D4/704A1 Neat CM NCTCC
NSE * Immunon 401400
PGP 9.5 * Ultraclone
Leu 7 * Becton Dickinson
Neurofilaments 1/20 Immunotech 0168
NCAM 1/10 DAKO M779
5-HT 1/5 DAKO M0758
GFAP Undiluted DAKO U7038
--------------------------------------------------P7TÖ7
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Table 2.15.1 Primary antibodies used in immimocytochemical studies (contd.)
Antibody Dilution/
Concentration
Supplier Catalogue
No.
Chromogranin A Undiluted DAKO U7030
Vimentin * DAKO
LCA * DAKO M701
P-glycoprotein 0.25/xg/ml Centicor Diagnostics
or2 integrin 1.8mg/ml Gift2
1 Gift from Dr.David Garrod, University of Manchester, England.
2 Gift from Dr.Fiona Watt, Imperial Cancer Research Fund, London, England.
2.16 MONOCLONAL ANTIBODY PRODUCTION
Hybridomas which secreted monoclonal antibodies were produced by immunising mice 
with DLKP cells, harvesting the mouse spleen cells and fusing them to mouse myeloma 
Sp2 cells to immortalise the antibody-producing cells.
2.16.1 Immunisation Procedure
Two Balb/c mice were injected 3 times in 7 weeks with lxlO7 DLKP cells in 1ml of 
PBS A per injection. A final booster injection o f cells was administered in week 8, 3 
days prior to the fusion.
A sinus bleed was carried out at the end of week 7 to determine if the mice were 
producing anti-DLKP antibodies. Approximately 0.25ml of blood was collected and 
allowed to clot in an Eppendorf at 4°C for 2 - 3 hr. The blood was then centrifuged at
10,000 r.p.m. to pellet the red blood cells and the serum was decanted and stored at - 
20°C until its reactivity with DLKP cells was analysed by ELISA as described in 
Section 2.16.4.
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2.16.2 Fusion
Of the 2 mice immunised, the animal whose sinus bleed had demonstrated greater 
reactivity with DLKP cells was chosen and sacrificed by cervical dislocation. The 
animal was swabbed with 70% IMS and brought into a laminar flow cabinet where it 
was disected using sterilised instruments and its spleen was removed. The spleen was 
homogenised by forcing it through a sterile tissue dissociation sieve (Sigma) using the 
plunger from a 20ml syringe. The resulting cell suspension was collected into a 50ml 
sterile centrifuge tube and any large clumps present were allowed to settle. The 
supematent was then transferred to a fresh tube and the cells were centrifuged at 1,000 
r.p.m. The cells were resuspended in DMEM Hybrimax (Sigma; D5660) without serum 
and centrifuged again (note:- the DMEM referred to throughout these antibody 
procedures is DMEM Hybrimax. This medium contains no HEPES buffer which is 
toxic to hybridomas). Red blood cells were lysed by resuspending the cells in 10ml pre­
warmed (37°C) red cell lysis buffer (Sigma; R1129) and after 5 min, an equal volume 
of DMEM was mixed well into the suspension to wash the cells. The cells were 
centrifuged at 1,000 r.p.m. for 5 min, a viability count was carried out (see Section 
2.5.3) and the cells were washed a further 2 times in DMEM (without serum).
The Sp2 myeloma cells were prepared for cell fusion by harvesting from a 75cm2 flask 
rinsing twice in serum-free DMEM and counting.
A universal of 50% (w/v) PEG-1500 (Boehringer; 783641) and a universal containing 
20ml of serum-free DMEM were incubated at 40PC. The isolated splenocytes and the 
Sp2 cells were mixed in a 10:1 ratio in a 50ml centrifuge, using 4.5xl07 splenocytes 
(a minimum of lxlO7 were required). The pooled cells were washed twice with serum- 
free DMEM and the cells were pelleted at 2,000 r.p.m. After ensuring that all 
supematent had been removed, 1ml of pre-warmed PEG solution was gently added to 
the cells with a plastic pipette and the cells and PEG were mixed by aspirating up and 
down. After 30 sec., the pipette was removed and the cells were gently swirled for a 
further 75 sec., after which, 0.5ml of plating medium i.e. DMEM containing HAT 
(Sigma; H0262) and 10% serum, was added slowly down the side of the universal while
87
swirling gently. A farther 8ml plating medium was added slowly over the next 5 min. 
while continuously swirling the cells and the cells were then centrifuged at 500 r.p.m. 
for 5 min. The supematent was then removed, the cells were resuspended in 10ml 
plating medium and incubated at room temperature for 15 min. 90ml plating medium 
was then added to the 10ml cell suspension and the cells were plated into 96-well plates 
at lOO^ tl per well. A further 100/xl plating medium was then added to each well and the 
plates were incubated undisturbed for 12 days at 37°C, 5% C 02.
2.16.3 Screening of Hybridomas
After the 12 day incubation period, the plates were viewed microscopically for colony 
formation and positive wells were marked. Over the next 10 - 14 days, those 
supematents which changed colour from pink/purple to orange/yellow, indicating cell 
growth, were removed and stored at -20PC and the cells were re-feed. The supematents 
were screened for reactivity with DLKP cells as follows:-
DLKP cells were plated onto 96-well plates at 2x10* cells per well and allowed to 
attach over night. The plates were then washed 3 times with PBS A and fixed with 70% 
acetone at room temperature for 5 min. The acetone was then removed, the plates were 
air dried and the non-specific activity was blocked by incubating the cells with 1% 
BSA/TBS (see Section 2.15.2) for 1 hr. 100/xl supematent (or diluted serum from sinus 
bleed) was then incubated with the cells at 37°C for 1.5 hr, the plates were washed 3 
times with TBS/0.1 % Tween 20 (Sigma; P1379) and incubated at 37°C for 1.5 hr. with 
1/10,000 dilution of anti-mouse IgG/IgM secondary antibody (Pierce). The plates were 
washed as before and then incubated with a substrate solution (lmg/ml p-nitrophenyl 
phosphate (PNPP) (Sigma; 104-0) in O.IM-glycine, 0.001M-MgC^.6H20 , 0.001M- 
ZnCl2, pH 10.4) at 37°C for 0.5 - 1 hr. Absorbances were read on an ELISA plate 
reader at 405nm and positive reactivity was determined by comparing supematent- 
containing wells with those which had been incubated with PBS A instead of 
supematent.
Positive clones were cultured further into 25cm2 and 75cm2 vented flasks and were 
gradually weaned off the HAT-containing medium (which selectively killed unfused Sp2 
myeloma cells) into DMEM without HAT. Unfused splenocytes were unable to
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replicate and so their numbers gradually diminished.
2.16.4 Isotype analysis
Isotype classifications were determined using a Serotec kit (MMMT RC1). The 
principle of the kit is based on red cell agglutination. A positive, agglutinated result is 
produced when a highly specific antibody recognises and binds to the particular isotype 
to which it is directed. This binding forms a lattice of agglutination when the reagents 
fall to the bottom of a microtitre plate. A negative result is produced when the reagent 
cells are put into a class of antibody which they do not recognise.
Dilutions of hybridoma supematent were made and 30/tl aliquots were incubated with 
30/xl aliquots of each specific isotyping reagent at room temperature for 1 hr. After this 
time, the plates were examined to determine which well contained agglutinate and the 
isotypes of the antibodies were revealed accordingly.
2.17 WESTERN BLOT ANALYSIS
Proteins for western blot analysis were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Resolving and stacking gels were prepared as outlined in 
Table 2.17.1 and poured into clean 10cm x 8cm gel cassettes which consisted of 1 glass 
and 1 aluminium plate, separated by 0.75cm plastic spacers. The resolving gel was 
poured first and allowed to set. The stacking gel was then poured and a comb was 
placed into the stacking gel in order to create wells for sample loading. Once set, the 
gels could be used immediately or wrapped in aluminium foil and stored at 4°C for 24 
hr.
Equal cell numbers were lysed in loading buffer (2.5ml 1.25M-Tris/HCl, l.Og SDS, 
2.5ml mercaptoethanol (Sigma; M6250), 5.8ml glycerol and 0.1% bromophenol blue 
(Sigma; B8026) made up to 25ml with distilled water) and boiled for 5 min. 20/xl 
samples were loaded onto the stacking gels, as were molecular weight protein markers, 
and the gels were run at 250 volts, 45 mAmps. for approximately 1.5 hr.
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Table 2.17.1 Preparation o f electrophoresis gels
Resolving gel (12%) Stacking gel
Acrylamide stock’ 5.25ml 0.8ml
Distilled H20 6.45ml 3.6ml
1.875M-Tris/HCl, pH 8.8 3.0ml -
1.25M-Tris/HCL, pH 6.8 - 0.5ml
10% SDS 
(Sigma; L4509)
150/d 50/d
10% Ammonium persulphate 
(Sigma; A1433)
50/d 17/d
TEMED 
(Sigma; T8133)
9/xl 6/d
' Acrylamide stock = 29. lg acrylamide (Sigma; A8887) and 0.9g NN’-methylene bis-acrylamide (Sigma; 
N7256) made up to 100ml with distilled water.
When the bromophenol blue dye front was seen to have reached the end of the gels, 
electrophoresis was stopped, the electrophesis apparatus was disassembled and the gels 
were removed and equilibrated for 10 min. in transfer buffer (24mM-Tris and 192mM- 
glycine in 250ml water, pH 8.3 without adjusting). 3 - 4  sheets of Whatman 3mm filter 
paper (Whatman; 1001824) were soaked in transfer buffer and placed on the cathode 
plate of a semi-dry blotting apparatus to act as a buffer reservoir. A sheet of 
nitrocellulose filter paper (Amersham; Hybond-C), also pre-soaked in transfer buffer, 
was placed on the filter paper and the gel was placed on top of this. Additional pre­
soaked sheets of filter paper were placed on the gel and after trapped air bubbles had 
been removed by rolling a glass pipette over the stack of filter paper, the protein was 
transferred from the gel to the nitrocellulose filter at 15volts and a current of 0.34 
mAmps. for 20 min. The nitrocellulose paper was then removed and incubated in 
blocking buffer (3% non-fat dried milk (Cadbury; Marvel skimmed milk) in TBS pH
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7.5/0.1% Tween 20) for 1 hr at room temperature, to block non-specific binding. All 
incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus to ensure even exposure of the nitrocellulose blot to all reagents.
After blocking, the blot was rinsed with PBS A and incubated in 10ml primary antibody 
(conditioned medium from hybridomas) at 4°C, overnight. The blots were then washed 
3 times in TBS/0.1% Tween 20 for 20 min and incubated for 1.5 hr. in secondary 
antibody (1/9,500 dilution of rabbit anti-mouse IgG (Sigma; A1902). The blots were 
then washed as before and developed by incubating in 10 - 20ml substrate buffer (70/d 
BCIP (Boehringer; 1383 221) and 67.5/xl NBT (Boehringer; 1383 213) in 20ml of 
lOOmM-Tris, lOOmM-NaCl and 50mM-MgCl2 in distilled water at pH 9.5).
2.18 DIFFERENTIATION STUDIES
Differentiation studies were carried out using 5-bromodeoxyuridine (BrdU) (Sigma; 
B5002) and all-trans retinoic acid (RA) (Sigma; R2625). All manipulations involving 
these agents were carried out in subdued light, as both were light sensitive.
2.18.1 Reconstitution of BrdU and RA
BrdU powder was dissolved in ultrapure water to a stock concentration of lOmM, was 
sterilised by filtering through a sterile 22/xm filter (Millipore) and was aliquoted into 
sterile Eppendorfs and stored at -2CPC for up to 1 year.
RA was reconstituted in 95% ethanol to a stock concentration of lmM and was 
aliquoted into cryovials and stored at -8QPC.
2.18.2 Differentiation Assays - Adherent Cells
Cells were plated into 6-well plates at densities of 5X103 cells per 2ml per well and 
allowed to attach, spread and begin to form colonies by incubating at 37°C, 5% C 02, 
for 48 hr. The medium was then removed from the cells and replaced with BrdU or RA 
which had been diluted to the required concentrations with normal growth medium
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appropriate to the cell type involved. Plates were wrapped in aluminium foil and 
incubated as before. Medium was replaced every 2 - 3  days over the course of the assay 
and all waste medium was retained for disposal by incineration dug to the hazardous 
nature of BrdU and RA.
At the conclusion of each assay, the plates were rinsed 3 times with PBS A, fixed with 
methanol and analysed by immunocytochemistry as outlined in Section 2.15.
2.18.3 Differentiation Assays - Suspension Cells
Cells were plated into 6-well plates and incubated as described in Section 2.18.2. In 
order to change the medium in these plates, it was necessary to remove the cells and 
their supematents to sterile universals and centrifuge at 1,000 r.p.m. for 5 min to pellet 
the cells. The cells were then resuspended in 2ml of the appropriate medium and 
returned to their wells.
When the assays were completed, the suspension cells were removed and 
cytocentrifuged and any cells which had adhered during the course of the assay were 
fixed as described in Sections 2.15.1 and 2.15.3.
2.19 RIBOZYME TRANSFECTIONS
A plasmid which contained the ribozyme MDR 1 gene and a gene coding for geneticin 
resistance (received as a gift from Dr.Kevin Scanlon, City of Hope Medical Centre, 
Los Angeles) was used to transfect clonal subpopulations of DLKP and DLKP-A, 
DLKP-I and DLKP-A-2B respectively. A calcium phosphate transfection technique was 
employed.
2.19.1 Transfection of Cells
Cells were harvested and seeded into 10cm diameter sterile Petri dishes at a density of 
5x10s cells per dish. The dishes were wrapped in ‘Parafilm’ and incubated overnight 
at 37°C, 5% C 02. 10/ig DNA was diluted in 410/xl sterile water and stored overnight
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at 4°C.
The next day, the DNA solution was incubated at 37°C for 1 hr. and 480/xl of 2xHBS 
(280mM-NaCl, 1.5mM-Na2HP04, 50mM-HEPES, pH 7.12, filtered through a 22/zm 
filter and stored at 4°C) was incubated in a sterile tube at room temperature. The rest 
of the procedure was carried out in a laminar flow cabinet. 60/xl 2M-CaCl2 was added 
dropwise into the tube containing the DNA, being continually mixed using a vortex 
mixer. This was immediately added to the HBS, dropwise with continuous mixing, and 
then allowed to stand for exactly 30 min. The DNA-CaPO4 mixture was then added 
dropwise to the dishes of cells which were swirled gently to ensure even mixing. The 
cells were then incubated at 37°C for 4 hr. After this time, a fine, opalescent precipitate 
was seen to cover the cells. The medium and precipitate were aspirated off the cells and 
5ml 10% glycerol in lxHBS was placed on the cells. After exactly 3 min., the glycerol 
was removed, the cells were rinsed twice with serum-free medium and then fed with 
fresh growth medium. The dishes were then incubated at 37°C, 5% C 02, for 2 days.
2.19.2 Selection of Plasmid-containing Cells
2 days after being transfected, the cells were fed with geneticin-containing medium i. e. 
growth medium with 400/xg/ml geneticin (Sigma; G9516). Untransfected, control cells 
were also fed with this medium each time the transfectants were fed in order to indicate 
when any untransfected cells would be dead. Therefore, it could be assumed that when 
all control cells were dead, any cells remaining in transfected dishes should countain 
the plasmid and its geneticin-resistance gene. Geneticin levels were increased to 
600/xg/ml after 11 days, and 17 days after the transfection, all control cells were dead.
2.19.3 Culture of Transfected Clones
When the control cells were found to have died after exposure to geneticin, the 
remaining transfectants were cloned in a limiting dilution assay in 96-well plates 
(Section 2.7.1). As a result of this, 5 DLKP-I and 2 DLKP-A-2B transfected clones 
were obtained. These were cultured further from 96-well plates into 6-well plates and 
into 25cm2 and 75cm2 flasks and frozen stocks were prepared (Section 2.5.4).
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2.20 DNA EXTRACTION
A crude method of extraction was used to obtain DNA from transfected cells 
A 70% confluent, 25cm2 flask of cells was harvested by trypsinisation and pelleted by 
centrifugation as normal (Section 2.5.1). The cells were resuspended in 10ml sterile 
PBS A and centrifuged again and this was repeated twice. The cells were then 
resuspended in 1 - 2ml PCR buffer (50mM-KCl, 10mM-Tris/HCl (pH 8.3) 2.5mM- 
MgCl2, 0.1mg/ml gelatin, 0.45% Nonidet P-40 (Sigma; N0896), 0.45% Tween 20 - 
autoclave and store at -20°C and before use, thaw and add 0.6/xl of 10mg/ml Proteinase 
K (Sigma; P2308) per 100/xl of solution) in sterile eppendorfs and incubated in a water 
bath at 55°C for 1 hr. The eppendorfs were then incubated at 95°C for 10 min. to 
inactivate the proteinase K and the samples were stored at -20°C until required.
DNA concentration was calculated by determining its optical density (OD) at 260nm 
and using the following formula:-
OD260nm x Dilution factor x 50 = mg/ml DNA
2.21 RNA EXTRACTION
The labile nature of RNA required that strict procedures were followed in the course 
of work involving RNA. This procedures included the wearing of gloves at all times 
that RNA-containing vessels were being used, the baking of all glassware and foil used 
to make up solutions and weigh compounds and most solutions and plastics were treated 
with 0.1% diethyl pyrocarbonate (DEPC) which is a strong inhibitor of RNases.
RNA was then extracted from cells as follows :-
Cells were grown in 135mm diameter Petri dishes to approximately 80% confluency. 
Five dishes of each cell line were grown at 37°C, 5% C 02. Waste medium was then 
removed, the cells were washed twice with DEPC-PBS A and were lysed in 5ml of a 
4M-guanidinium thiocyanate (GnSCn) solution (50g guanidinium thiocyanate (Sigma; 
G6639), 0.5g N-lauroyl sarcosine (Sigma; L5125) and 5ml of lM-sodium citrate (RDH; 
32320), pH 7.0 - brought up to 100ml with DEPC-water and filtered through a 0.45^m
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filter and supplemented with 700/d/ml j3-mercaptoethanol and 330/xl/ 100ml antifoam A 
(Sigma; A5758) prior to use).
Lysates from the 5 dishes were pooled and centrifuged at 1,000 r.p.m. for 5 min. 5.5ml 
of a 5.7M-cesium chloride solution (95.8g CsCl (Sigma; C3032) and 2.5ml of 1M- 
sodium citrate, pH 7.0 in 100ml water, filtered through a 0.22/xm filter, treated with 
0.1 % DEPC and autoclaved) was placed into polyallomer ultracentrifuge tubes and the 
cell lysates were then layered onto these CsCl cusions. These were then centrifuged at
27,000 r.p.m. for 21 - 24 hr. at 15°C in a swinging bucket centrifuge. The tubes were 
then brought into a laminar flow cabinet and the supematent was removed from the 
tubes, leaving approximately 1ml of CsCl in the bottom of the tube, below which lay 
the RNA pellet. The tube was inverted and the bottom of the tube was cut away using 
a heated scalpel blade. The pellet was rinsed with 95% ethanol and resuspended in 
200/il DEPC-water. The solution was transferred to an eppendorf and the bottom of the 
tube was rinsed with a further 200/d water which was added to the eppendorf. 40/d of 
3M-sodium acetate was added to the RNA solution to give a final concentration of 
0.3M-sodium acetate, and 2 volumes of ice-cold absolute ethanol were also added. The 
eppendorfs were stored at -80°C overnight and the RNA was then pelleted at 4°C at 
maximum speed in a microfuge. The resulting pellet was washed with 70% ethanol, the 
supematent was removed and the pellet was resuspended in 50/d DEPC-water.
RNA concentration was calculated by determining its OD at 260nm and using the 
following formula:-
OD260nm x Dilution factor x 40 =  /xg/ml RNA
The purity of the RNA extraction was calculated by determining its OD at 260nm and 
280nm. An A260 : ratio of 2 is indicative o f pure RNA and only those samples with
ratios between 1.8 and 2.1 were used.
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2.22 POLYMERASE CHAIN REACTION
A standardised polymerase chain reaction (PCR) procedure was followed in this study. 
The eppendorf tubes used (Eppendorf; 0030 121023) and the sterile water were DEPC- 
treated. All reagents had been aliquoted and were stored at -2Qf'C and all reactions were 
carried out in a laminar flow cabinet.
Each PCR tube contained the following 
24.5/xl water
5/tl lOx buffer* (lOOmM-Tris/HCl, pH 9.0, 50mM-KCl, 1% Triton X-100)
3/xl 25mM-MgCl2*
8/xl dNTPs (1.25mM each of dATP, dCTP, dGTP and gTTP) (Promega; U1240)
1(jl1 each of first and second strand target primers (250ng//d)
1/xl each of first and second strand endogenous control primer (250ng//xl)
0.5/xl of 5U//d Taq DNA polymerase enzyme*
5/xl DNA or cDNA 
‘(Promega; N1862)
A drop of autoclaved mineral oil was placed in each reaction tube to prevent 
evaporation and the DNA was amplified by PCR (Techne; PHC-3) as follows:- 
95°C for 1.5 min - to denature double-stranded DNA 
30 cycles: 95°C for 1.5 min. - denature
55°C for 1 min - anneal 
72°C for 3 min. - extend 
72°C for 7 min. - extend
The reaction tubes were then stored at 4°C until analysed by gel electrophoresis as 
described in Section 2.24.
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2.23 REVERSE TRANSCRIPTASE REACTION
Reverse transcriptase (RT) reactions were carried out in laminar flow cabinets using 
micropipettes which were specifically allocated to this work.
cDNA was formed using the following procedure 
1/xl oligo (dT)12'18 primers (l/ig//il) (Promega; C1101)
1/xl total RNA (l/xg//xl)
3/xl water
were mixed in an eppendorf, heated to 70°C for 10 min and then chilled on ice. To this, 
the following were added
4/xl of a 5x buffer (250mM-Tris/HCl pH 8.3, 375mM-KCl and 15mM-MgCl2)
2[xl DTT (lOOmM) (Gibco; 510-8025 SA)
1/xl RNasin (40U//xl) (Promega; N2511)
1/xl dNTPs (lOmM of each dNTP)
6/tl water
1/xl Moloney murine leukemia virus-reverse transcriptase (MMLV-RT) (40,000U//il) 
(Gibco; 510-8025 SA).
The solutions were mixed and the RT reaction was carried out by incubating the 
eppendorfs at 37°C for 1 hr. The MMLV-RT enzyme was then inactivated by heating 
to 95°C for 2 min. The cDNA was stored at -20°C until required for use in PCR 
reactions as outlined in Section 2.22.
2.24 ELECTROPHORESIS OF PCR PRODUCTS
A 3% agarose gel (NuSieve;GTG) was prepared in TBE buffer (5.4g Tris, 2.75g boric 
acid, 2ml 0.5M-EDTA pH 8.0 in 500ml water) and melted in a microwave oven. After 
allowing to cool, 0.003% of a lOmg/ml ethedium bromide solution was added to the 
gel which was then poured into an electrophoresis apparatus (BioRad). Combs were 
placed in the gel to form wells and the gel was allowed to set.
10/xl loading buffer (50% glycerol, lmg/ml xylene cyanol, lmg/ml bromophenol blue,
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ImM EDTA) was added to each 50/d PCR sample and 10 - 20/xl was run on the gel at 
80mVolts for approximately 1 hr. When the dye front was seen to have migrated the 
required distance, the gel was removed from the apparatus and examined on a 
transilluminator.
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RESULTS
3.1 CLONAL VARIATION IN DLKP
During routine culture of the DLKP cells , it appeared that at least 3 morphologically 
different populations were present within the cell line. The largest population 
(‘A’; —65%) were squamous in appearance with distinct cell boundaries and were 
relatively large in size with a high cytoplasmic to nuclear ratio. The second population 
(‘B’;~30% ) were smaller (approx. 1/4 area of ‘A’ cells) and grew in colonies with 
indistinct cell boundaries. The third population (‘C’; ~5%) were of intermediate size 
with an irregular, fibroblastoid-like morpholgy and did not appear to form colonies. It 
was not clear at this stage whether the 3 speculative populations were (i) merely 
different stages of the cell cycle of one parental cell type - although this seemed 
unlikely as specific colonies of the different populations A, B and C, when present in 
a culture, appeared to be constant rather than transient, (ii) a mixture of different cell 
types - this also seemed unlikely as the different morphologies were still present in 
cultures at high passage numbers (>  passage 80) where one would expect the faster 
growing cell type in an initially mixed population to have overtaken and out-grown its 
slower counterparts or (iii) various differentiation states of one (or more) parental cell(s) 
- this would seem the most likely situation. Clonal subpopulations were isolated from 
the DLKP cell line in an attempt to isolate, if possible the morphologically diverse 
populations seen in culture.
3.1.1 Isolation of DLKP Clones
Clones of the DLKP cell line were obtained by limiting dilution assay (Section 2.7.1). 
Initial attempts to clone using cloning rings proved to be practically difficult and prone 
to fungal contamination, although this technique has often been successful for other 
workers. The endpoint for both techniques is the same as in each case, the presence of 
a true single colony is determined by eye. However, the limiting dilution assay 
procedure is only suitable for cells such as DLKP which are not density dependent and 
can proliferate at low seeding densities. To clone cells without this capability, methods 
such as cloning rings or cloning in soft agar may be more suitable.
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In a limiting dilution assay, very low seeding densities are used to facilitate isolation 
of clonal populations and for the DLKP cells, 5 cells/ml (or 1 cell/2 wells of a 96-well 
plate) was the density used. Seeding densities higher than this were not successful in 
obtaining single colonies of cells. The number of clones obtained using this method is 
therefore not usually high.
The lowest obtainable passage number of DLKP cells, passage 3, were used in the 
cloning assay in an attempt to obtain clones with characteristics as close as possible to 
cells in the original tumour. The first cloning assay resulted in 5 clones, each of which 
appeared to be a homogenous population. The clones were named DLKP 1-5. DLKP-1, 
-3 and -5 had morphologies similar to that described as ‘A’ in Section 3.1 while DLKP- 
2 and -4 had morphologies similar to ‘B’ and ‘C’ respectively. However, due to the 
frequent manipulations (feeding, trypsinising etc.) and the suseptibility of unsealed 
plates to contamination, unfortunately clones DLKP-1 and -5 became contaminated with 
fungus and had to be discarded. As is the case in all routine cell culture carried out 
here, no anti-bacterial or anti-fungal agents were used at any stage in the cloning 
process to avoid deleterious effects on the cells and/or their behaviour.
In order to ensure the clones were true clonal populations, DLKP-2 (passage 12), -3 
(passage 16) and -4 (passage 20) were recloned as in the original cloning assay except 
that a lower seeding density, 3 cells/ml (or 1 cell/3 wells) was used. DLKP-2 and -4 
were recloned successfully and named DLKP-2A and DLKP-4A respectively. DLKP-3 
however, did not redone successfully at this density. Following seeding into the 96-well 
plates, wells containing 1 cell were marked as usual and fed with the same medium as 
the other reclones, but the DLKP-3 cells failed to proliferate. Parental DLKP cells 
(passage 15) were cloned at the same time as the recloning and this resulted in a clone, 
DLKP 7, with an apparently homogenous population, similar to that of morphology ‘A ’ 
described in Section 3.1. At a later stage, the nomenclature of the 3 clones was changed 
to avoid any possible confusion with other DLKP variants such as DLKP-A. Names 
were chosen which reflected the morphology and/or behaviour of each clone; DLKP 
2A was renamed DLKP-I (intermediate), DLKP 4A was changed to DLKP-M 
(mesenchymal-like) and DLKP 7 became DLKP-SQ (squamous) (see Figure 3.1.1). 
From now on, the clones will be refered to as DLKP-I, -M or -SQ.
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While initially each clone appeared to be a homogenous population, after about 20-25 
passages in culture, interconversion between the clones was observed. After this time, 
colonies with DLKP-I morphology began to appear in cultures of DLKP-M and DLKP- 
SQ (approximately 5-10% of total population) and similarly, colonies of DLKP-SQ 
morphology, and to a lesser extent DLKP-M morphology, could be seen in cultures of 
DLKP-I (approximately 5-10% and <5% of total population respectively. No 
interconversion was observed between DLKP-M and DLKP-SQ). It was therefore 
necessary to establish large stocks of each clone and to strictly confine experiments with 
the cells to specific passage numbers. Unless otherwise stated, all work here was 
carried with the clones at passage numbers from 20 to 35.
101
Figure 3.1.1 Morphological appearance of A. DLKP (I=DLKP-I-like, M=DLKP-M-like and 
SQ=DLKP-SQ-like morphologies), B. DLKP-I, C. DLKP-M and D. DLKP-SQ cultured in 
DMEM:Hams F12 (1:1), supplemented with 5% serum. xlOO.
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3.1.2 Analysis of Chromosome Distribution in DLKP and Clones
The clones, DLKP-SQ, -I and -M appeared morphologically different to each other but 
as yet, no physiological or behavioural differences had been explored. The chromosome 
distribution in DLKP (passage 5) had previously been determined by Law et al., (1992) 
in a cytogenetic analysis of the cell line. Law concluded that 2 chromosomal 
populations were present in DLKP; one (65% of cells) consisting of hyperdiploid cells 
with a modal number of 56 chromosomes and the other (35% of cells) being a 
hypertetraploid population with a chromosome distribution between 95 and 115.
In order to determine if chromosomal as well as morphological differences existed 
between the DLKP clones, or if any of the clones represented either of the 2 
chromosome populations observed by Law, the chromosomal distributions of the cells 
were compared (see Section 2.8). DLKP cells at passage 22 were used here (note, 
passage 5 used by Law) to compare with DLKP-SQ, -I and -M which were used at 
passages 29, 26 and 32 respectively (Figure 3.1.2).
A range of chromosome populations was seen in all lines with prominent populations 
evident in each case (Table 3.1.1). The largest DLKP chromosomal population was 
hypertetraploid with 40% of the cells containing 100-110 chromosomes. A single peak 
was also evident at 30-39 chromosomes. 36% of DLKP-I cells were roughly tetraploid 
(90-100 chromosomes) and DLKP-M exhibited the closest to normal complement with 
60% of cells being hyperdiploid (50-60 chromosomes). DLKP-SQ cells had the most 
varied chromosome numbers. 36% of the cells had chromosome numbers between 90 
and 100 while 27% had numbers between 100 and 110.
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Figure 3 .1 .2  Range o f chromosomal populations determined in A . DLKP, B . DLKP-I, 
C . D LKP-M  and D . DLKP-SQ.
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3.1.3 Analysis of Growth of DLKP and Clones
As mentioned in Section 3.1, the 3 morphological cell types present in DLKP and 
apparently represented by DLKP-I, -M and -SQ can be seen in cultures of DLKP up 
to passage 80 and above. The ratios of the cell types also appear to remain constant. 
It therefore seems that a balance exists between the growth potentials of each of the 
clones and it presumably is of benefit to the mixed parental population that this balance 
is maintained. Because of this, it was of interest to study the growth capabilities of 
these isolated clonal populations in comparison to each other and the parental DLKP 
cells in an attempt to understand the growth properties of individual tumour 
subpopulations and what role they may play in tumour formation, growth and 
progression.
3.1.3.1 Growth in serum
The growth curves of DLKP, DLKP-SQ, -I and -M in monolayer culture were 
determined in the presence of 0%, 1% and 5% serum (see Section 2.9.1). At each 
serum concentration, the parental DLKP cells proliferated faster than any of the clones 
(Figure 3.1.3). Of the clones themselves, DLKP-I were the fastest growers in this assay 
having growth curves almost equal to those of DLKP. DLKP-SQ and DLKP-M grew 
relatively poorly in the first few days of culture, appearing to be density dependent, but 
after this this slow start, their growth rates increased also.
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DAYS IN CULTURE
Figure 3.1.3 Growth of DLKP and clones 
in a monolayer assay in A. 0% serum, B. 
1% serum and C. 5% serum.
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3.1.3.2 Growth in serum-free medium
Analysis of the growth of cells in defined serum-free medium (SFM) is often of greater 
interest and more informative than their growth in serum-containing media as a more 
precise knowledge of the growth requirements of the cells is gained. The SFM used in 
these experiments was an adaptation of that used by Mendiaz et al., (1986). The only 
mitogen present in this medium is insulin which is supplemented with transferrin, non- 
essential amino acids, trace elements and L-glutamine (see Section 2.9.3).
When DLKP and the clones were placed in SFM, all cells were seen to attach rapidly 
(within 1 hr.) to the surface of the flask. After 5-6 days, the appearance of each of the 
4 lines differed from each other (Figure 3.1.5). In the case of DLKP, most of the cells, 
although attached to the flask surface, had not spread but remained rounded and so the 
squamous morphology they exhibited in serum-supplememted medium was not evident. 
However, about 25% of the cells were growing as colonies which resembled the 
morphology of DLKP-I colonies under normal culture conditions (i.e. medium +  5% 
serum). The DLKP-I cells began to form colonies within 3-4 days of transferral to 
SFM, and these colonies were also very similar to those of DLKP-I in serum-containing 
medium. DLKP-M cells in SFM also resembled their serum-supplemented counterparts. 
These cells were elongated with neurite-like processes present on some cells, and no 
colony formation occurred. The entire DLKP-SQ population, when placed in SFM, 
remained rounded in appearance, failed to form colonies and resembled the round 
phenotype present in DLKP-SFM cultures.
The proliferation of the cell lines was determined every 6 - 7  days. The numbers of 
DLKP-SQ and -M cells failed to increase above seeding densities at any stage, 
regardless of how often they were fed or how long the cultures were maintained for. 
In contrast, DLKP and DLKP-I grew well under the SFM conditions and were cultured 
for up to 10 passages at a time. The extent of growth of the 2 lines varied, but in 
general, the numbers of DLKP-I cells were higher than DLKP (Figure 3.1.4).
As described above, the morphologies of DLKP and DLKP-I when cultured in serum-
108
free medium were different to their normal, serum-supplemented counterparts. 
Increasing numbers of cells growing in suspension appeared with time in both cell lines. 
In order to compare the morphologies of the cells grown in serum-containing and 
serum-free media and to determine if culture in serum-free medium affected the 
morphologies of the DLKP and DLKP-I cells, samples of each cell line were placed 
into flasks containing serum-supplemented medium after 5 and 10 passages in serum- 
free medium. The cells were allowed to attach and after 6-7 days, when reasonably 
large colonies had formed, the morphologies of the cells were examined under the 
microscope. No change in morphology was apparent in cells which had been cultured 
for 5 passages in SFM compared with their morphologies prior to serum-free culture 
(Figure 3.1.6). However, changes were apparent in those cells which had been cultured 
for 10 passages in SFM (Figure 3.1.6). The DLKP cells had become more homogenous 
with the majority of cells ( >  90%) being squamous in appearance, similar to the DLKP- 
SQ morphology. Relatively few colonies of DLKP-I-like morphology, and no cells of 
DLKP-M-like morphology were evident. The morphology of the DLKP-I cells had also 
altered after 10 passages in SFM. The population had become more heterogenous, with 
large numbers of DLKP-SQ-like cells evident.
Culture in serum-free medium therefore seemed to influence the morphologies of the 
2 cell lines and drive them towards a squamous-like morphology similar to DLKP-SQ. 
However, since DLKP-SQ cells failed to proliferate in serum-free medium, the 
squamous-like cells appearing in serum-free culture are not identical to DLKP-SQ.
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Figure 3.1.4  Growth o f DLKP and D LK P -I in SFM . Flasks were inoculated with 2.5x10s cells 
and growth was determined every 7 days by counting. Flasks were then re-seeded at original 
inoculating densities.
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Figure 3.1.5 Appearance of cells when cultured in SFM: A. DLKP, passage 5 in SFM, B. DLKP-I, 
passage 6 in SFM, C. DLKP-M, passage 1 in SFM and D. DLKP-SQ, passage 1 in SFM. xlOO.
Ill
Figure 3.1.6 Appearance of DLKP cells in serum-containing medium after A. 5 passages (xlOO 
magnification) and B. 10 passages (x200) in SFM and appearance of DLKP-I cells after C. 5 passages 
(xlOO) and D. 10 passages (x200) in SFM. xlOO.
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3.1.3.3 Growth in soft agar
Many tumour cells have the ability to form 3-dimensional colonies in soft agar and this 
characteristic reflects their malignant clonogenic potential. The ability of DLKP and 
each of the clones to form colonies in 0.3% soft agar assays was determined (see 
Section 2.9.4). Colonies greater than 20/xM in diameter were counted and a large 
difference in the CFEs of the lines was observed (Table 3.1.2).
The parental DLKP cells proved to have the highest CFE with a value of 37.58% ±  
7.72%. Of the 3 clones, DLKP-SQ had the best CFE (26.78% ±  0.44%), with DLKP- 
M having an intermediate CFE value of 13.08% ±  0.27% and DLKP-I having 
effectively no ability to form colonies in soft agar (2.45% ±  2.04%). The poor growth 
of DLKP-I cells in agar is surprising, given their rapid growth in monolayer and in 
serum-free medium.
During the course of this assay, the cells (normally maintained at 37°C) were suspended 
in agar at 41°C. Therefore, a relatively heat-sensitive cell type may perform deceptively 
poorly in this assay and fail to form colonies as a result their exposure to increased 
temperatures. To examine this possibility with regard to the low CFE of DLKP-I 
compared with the other cell lines, the following experiment was carried out:- 
suspensions of DLKP, DLKP-I, -M and -SQ cells were incubated in a water bath at 
42°C for 15 min. (note soft agar assay conditions less severe; agar was pre-warmed to 
41°C, transfered to a laminar flow and would have been cooling towards room 
temperature when cells were suspended in it). The cells were then placed in normal 
tissue culture flasks and incubated at 37°C, as in routine cell culture. After 5 days, the 
flasks were examined microscopically and all 4 lines appeared to be growing normally 
(Figure 3.1.7). All lines were subsequently passaged successfully and no deleterious 
effects of the temperature treatment were apparent in any of the lines, including DLKP-
I. Therefore, these cells did not appear to be more adversely affected than the other 3 
lines by increased temperatures up to 42°C.
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Cell line Largest chromosomal % Total cells
population counted
DLKP* 100-110 40
DLKP-I 90-100 36
DLKP-M 50-60 60
DLKP-SQ 90-100 36
100-110 27
Table 3.1.1 Chromosomal distribution in DLKP and clones (n =  50, *n =  75).
CeU line CFE (%)
DLKP 37.58 ±  7.72 ;
DLKP-I 2.45 ±  2.04
DLKP-M 13.08 ±  0.27
DLKP-SQ 26.78 ±  0.44
Table 3.1.2 Colony forming efficiency (CFE) of DLKP and clones in soft agar. Colonies 
greater than 20/iM  in diameter were counted microscopically and expressed as a percentage o f the 
total number of cells plated. The results shown are mean results from 2 separate experiments.
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Figure 3.1.7 Morphologies of A. DLKP, B. DLKP-I, C. DLKP-M and D. DLKP-SQ cells when 
cultured following incubation at 42°C for 15 min. xlOO.
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3.1.3.4 Growth in suspension
It had been observed during routine culture that a small percentage of DLKP cells 
( — 1 %) grew in suspension in normal culture flasks at any given time. Whenever these 
cells were decanted and placed in new culture flasks, all cells were seen to attach to the 
flask. It therefore seemed that growth in suspension was possible for some, if not all, 
DLKP cells and that these suspension cells could also attach to a substrate.
The ability of DLKP and clones to grow in suspension in spinner flasks was examined 
as outlined in Section 2.9.5. Flasks were coated with a siliconising agent to prevent cell 
attachment to the flask surface and magnetic stirrers rotated a rod inside each flask 
which kept the cells in suspension.
The DLKP cells were found to be the most efficient of the 4 lines at growing in 
suspension in spinner flasks (Figure 3.1.8). DLKP-SQ were found to grow better than 
the other 2 clones, paralleling the result in soft agar. All lines grew in clumps up to 
~  1mm in diameter.
To determine if the lack of substrate adherence and enforced growth in suspension 
affected the morphology of the cells in any way, aliqouts of each cell line were placed 
in tissue culture flasks after passages 5 and 10 in spinner flasks. After a few days, 
morphologies of the resulting attached cells were examined under the microscope. The 
morphologies of cells examined after 5 passages in spinner flasks seemed unchanged. 
However, after 10 passages it appeared that the DLKP population had become 
homogenous with all the cells having the squamous phenotype of DLKP-SQ. DLKP-SQ 
itself appeared unchanged while DLKP-I appeared mixed, having colonies of both its 
own and the squamous phenotype (Figure 3.1.9). DLKP-M also appeared unchanged. 
It would thus seem that growth of these cells in suspension causes an interconversion 
towards the squamous phenotype represented by DLKP-SQ.
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Figure 3.1.8  Growth o f DLKP and clones in spinner flasks. Flasks were initially inoculated with 
4x10* cells/ml and growth was determined every 7 days by counting. Flasks were then re-seeded 
at original inoculating density.
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Figure 3.1.9 Appearance of A. DLKP, B. DLKP-I, C. DLKP-M and D. DLKP-SQ in monolayer 
culture after 10 passages growing in suspension in spinner flasks. xlOO.
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3.1.3.5 Growth factor assays
Enhanced sensitivity to stimulatory growth factors and/or reduced sensitivity to 
inhibitory growth factors, as mentioned in Section 3.1.3.4, is an aspect of altered 
growth control often found in tumour cells. To further explore the growth 
characteristics of DLKP and the clones, the proliferative responses of the cells to a 
selection of exogenous growth factors were examined.
TGFjS, EGF, IL-4, insulin, serotonin and histamine were all assayed for their effects 
on the growth of DLKP and its clones, as described in Section 2.9.6. However, no 
clear patterns of response were clear for any of the growth factors. Despite strict 
adherence to standard procedures before, during and after assays such as confluency of 
cells harvested to set up assays, feeding of cells on the day prior to harvesting, use of 
specific multichannel pipette to avoid inter-pipette differences, same stocks of serum 
and growth factors used during course of assays, same length of time assays incubated 
for and consistent staining procedure, extensive variation was found both in the nature 
of response i.e. stimulatory, inhibitory or no effect, and in the extent of such responses 
(results not shown). Various assays were carried out using 0.5% serum background, 0% 
serum background and 0% serum +  50ng/ml insulin background in an attempt to 
achieve more consistent results, but none were successful.
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3.1.4 Examination of Autocrine Growth Factor Production
As mentioned in Section 3.1.3.4, the inappropriate expression of growth factors and/or 
their receptors by tumour cells is one way in which such cells achieve enhanced growth 
and proliferate at faster rates than normal cells. In an attempt to detect any such 
autocrine growth stimulatory activity in the DLKP cell line or its clones, a range of 
conditioned medium (CM) assays were carried out. CM was collected as outlined in 
Section 2.10.
3.1.4.1 Initial detection of DLKP autocrine activity
Preliminary experiments with CM collected from DLKP cells grown in Hams F12 with 
1% L-glutamine and without serum (as outlined in Section 2.10), were carried out on 
DLKP cells plated at 2 different seeding densities (4X102 and 5X102 cells/ml) and with 
2 different background serum concentrations (1% and 2% serum). The results (Figure
3.1.10) suggested that a growth stimulatory activity was present in the CM. The 
stimulatory effect ranged from 51.7% to 14.6% increase in growth over control levels, 
depending on the assay parameters.
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3.1.4.2 Further examination of DLKP autocrine activity
In the light of the results found in Section 3.1.4.1, further work was carried out 
examining the apparent autocrine activity present in DLKP CM. Assays carried out with 
DLKP CM on another cell line, Hep 2 (a human cell line derived from a carcinoma of 
the larynx) consistently resulted in stimulation of the growth of the Hep 2 cells (Figure
3.1.11). In addition, neat CM collected from another cell line, RPMI 2650 (a human 
nasal carcinoma cell line) was capable of stimulating the growth of DLKP (Figure
3.1 .12). This assay was carried out with DLKP cells plated at 2 different densities 
3X102 and 7X102 cells/ml.
However, when DLKP CM was subsequently assayed for autocrine activity on DLKP 
cells, no stimulation of growth was seen, contrasting with initial experiments (Section 
3.1.4.1). In an attempt to detect any stimulatory activity, the DLKP CM was 
concentrated by ultrafiltration through an R1,000 membrane (see Section 2.10.1). 
Figure 3.1.13 shows the results of a typical experiment. Contrary to stimulation, 
inhibition of growth was seen with CM that was 10-fold more concentrated than 
untreated neat CM (lOx CM). Dilutions of the lOx CM were made with Hams F12 and 
the inhibitory activity was found to decrease with increasing dilution from 7x to l/10x.
CM collected from both flasks and roller bottles was assayed (Figure 3.1.14) to allow 
for possible differences in CM collection methods that may affect the CM, such as 
movement or greater cell numbers in roller bottles etc. No stimulation of growth was 
detected in CM collected by either method.
Up to this point, untreated Hams F12 had been used as a negative control (CM 
collected in Hams F12). An ultrafiltered Hams F12 control had not been assayed 
because the largest molecule present in this basal medium is phenol red (<  700kD) and 
as all molecules less than 1,000 kD should pass through the filtration membrane, the 
Hams F12 should merely reduce in volume (eg. 100ml -* 10ml) without becoming 
concentrated at the same time (i.e. lx  -* lx). However, when a sample volume of Hams 
F12 was ultrafiltered to a 10-fold reduction in volume and assayed in the DLKP CM 
assay, it was found to be inhibitory to the growth of the cells when compared with
121
Hams F12 that was not ultrafiltered (Figure 3.1.15). lOx-Hams F12 was also inhibitory 
to Hep 2 cells (Figure 3.1.15), compared with non-ultrafiltered Hams F12. It therefore 
appeared that the inhibitory effect of lOx-CM, concentrated through a 1,000 MW cut­
off filter, on DLKP cells was probably due, at least in part, to concentration of the 
Hams F12 basal medium.
An alternative explanation for the inhibitory activity of the ultrafiltered samples was that 
despite the pre-treatment of the membranes themselves (Section 2.10.2), contaminants 
were still present on them which entered the filtered samples and were either inhibitory 
or toxic to the cells. To examine this possibility, 2 separate batches of Hams F12 (‘A ’ 
and ‘B’) and a volume of a different basal medium, MEM, were ultrafiltered through 
a single membrane as follows:- after normal membrane pre-treatment, Hams F12 ‘A ’ 
was filtered, 100ml -> 10ml; 100ml ddH20  was then run through the membrane to clear 
it; MEM was filtered, 100ml -» 10ml; membrane was cleared with 100ml ddH20 ; Hams 
F12 ‘B’ was filtered, 100ml -> 10ml. The resulting lOx-media and dilutions thereof 
were assayed on DLKP cells (Figure 3.1.16). Both batches of Hams F12, ‘A ’ and ‘B \  
were found to be inhibitory to the growth of DLKP cells with the inhibition being 
diluted out at 5x and lx , while the lOx-MEM had no inhibitory effect on the cells 
compared with untreated MEM. It would therefore appear that the growth inhibitory 
effects were a characteristic of ultrafiltered Hams F12 samples and not of all basal 
media.
It was subsequently decided to focus attention on possibly improving the DLKP CM 
assay in an attempt to detect stimulatory activity in CM that was not concentrated i.e. 
neat or diluted.
Firstly, the DLKP seeding density was lowered. Normally, cells were seeded at 7x102 
cells/ml/well. When seeded at 5, 3 and lxlO2 cells/ml, increasing inhibition of growth 
was found with decreasing seeding densities in the presence of neat DLKP CM 
compared with neat Hams F12 controls (Figure 3.1.17).
The effect of increased seeding densities on CM activity was then examined. No 
difference was found between seeding densities up to 1.9X103 cells/ml (Figure 3 .1 .18 ).
122
Assays were carried out on DLKP CM which was diluted up to 1/1,000 to determine 
if it was necessary to dilute the autocrine activity before it became detectable. No 
difference in activity was seen over the range of dilutions tested (Figure 3.1.19).
The normal background serum levels for these asays was 1%. To determine if 
additional factors present in higher concentrations of serum were necessary to detect 
autocrine activity, the assays were carried out in 2.5, 5 and 7% serum but again, no 
stimulation was seen (Figure 3.1.20).
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Figure 3.1.12 Effect o f  RPMI 2650 CM on the growth o f  DLKP cells.
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Figure 3.1.13 Effect of varying DLKP CM concentration on growth o f DLKP cells.
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IFigure 3.1.14 Effect of mode of collection, roller bottle (RB) or flask (FL), on DLKP CM activity
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Figure 3.1.15 Effect o f lOx Hams F12 on the growth of DLKP cells and Hep 2 cells.
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Figure 3 .1.18 Effect of higher seeding densities on DLKP CM autocrine activity.
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Figure 3 .1 .20  Effect o f  serum concentration on DLKP CM autocrine activity
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3.1.4.3 Analysis of DLKP clones CM for autocrine activity
Serum-free CM was collected from each of the DLKP clones, as was collected from 
DLKP, and examined in monolayer assays for growth stimulatory activity (results not 
shown). The various CM were assayed on the cells from which they were collected and 
also on the other clones and on DLKP.
Again, as was found with the DLKP CM assays, the results varied with different 
batches of CM resulting in stimulation, inhibition or no effect in each assay carried out. 
No correlation was seen between modes of collection (roller bottle versus 75cm2 flask) 
or length of storage time of CM (always at 4°C) before assaying.
The relatively rapid and aggressive growth of DLKP and its clones in growth assays 
(Figure 3.1.3) and soft agar assays (Table 3.1.2), their ability to proliferate in the 
absence of serum (Figure 3.1.3), (particularly in the cases of DLKP and DLKP-I in 
defined serum-free medium (Figure 3.1.4)) led to the belief that some, if not all, of 
these cells were producing stimulatory autocrine growth factors. However, no such 
activity was detectable under the assay conditions described above in Section 3.1.4.
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3.1.5 Extracellular Matrix Adherence Assays
In vivo, normal tissue cells interact intimately with the ECM proteins that surround 
them through cell surface adhesion molecules. The ECM proteins not only anchor the 
cells and allow them to organise themselves spatially, but also act as important 
signalling molecules involved in the induction and maintenance of differentiated 
phenotypes. Tumour cells in vivo also interact with ECM proteins but often these 
interactions are deregulated and alterations in tumour cell adhesion molecules can result 
in a metastatic cell phenotype which is motile and capable of migration and invasion.
The attachment properties of DLKP and the clones to ECM substrates were compared 
to determine if differences in their adherence profiles existed. Wells in 24-well plates 
were coated with the various substrate proteins, after which uncoated sites were blocked 
with 0.1% BSA (described in Section 2.11). Cells were plated in medium without 
serum and attachment was determined after 15min. and 30min.
3.1.5.1 Adherence to plastic
The attachment of the cells to uncoated plastic blocked with 0.1 % BSA was determined. 
Here, as with the ECM-coated wells, wells without cells were used as controls. After 
each time point, all wells were stained with crystal violet dye which, after drying, was 
eluted with 33% acetic acid (as in CVDE assay, Section 2.9.2) and the absorbances of 
the resulting solutions were determined spectrophotometrically on an ELISA plate 
reader. Attachment was expressed as a percentage of control wells which did not 
contain cells (Figure 3.1.21).
After 15 min. incubation, it was found that the DLKP-M cells had attached to the 
plastic to a greater extent than the other 3 lines which themselves showed effectively 
no attachment at this time (Figure 3.1.21.A).
After 30 min., DLKP and DLKP-I showed increased attachment, while DLKP-SQ still 
showed little adherence (Figure 3.1.21.B).
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3.1.5.2 Adherence to collagen type IV
After 15 min. incubation in collagen type IV-coated wells, very little adherence was 
seen in any of the cell lines (Figure 3.1.21.A).
However, after 30 min., DLKP-M showed increased attachment (160% of control) 
while DLKP, DLKP-I and DLKP-SQ still remained unattached to the substrate (Figure 
3.1.21.B).
3.1.5.3 Adherence to fibronectin
Incubation of the cells in wells coated with fibronectin had the most dramatic effect on 
cell attachment. After 15 min., DLKP, DLKP-I and DLKP-SQ had each attached 200- 
250%, while DLKP-M had attached 450% compared with controls (Figure 3.1.21.A).
After 30 min., DLKP, DLKP-I and DLKP-SQ had continued to attach up to 300% 
compared with controls while DLKP-M showed decreased attachment (compared to 
15min.) at 340% (Figure 3.1.21.B).
3.1.5.4 Adherence to laminin
Little attachment was seen with any cell line after 15 min. incubation in laminin-coated 
wells (Figure 3.1.21.A).
However, after 30 min., DLKP, DLKP-M and DLKP-SQ had adhered up to 200% of 
control values, while DLKP-I still showed no great increase in attachment after this 
time (Figure 3.1.21.B).
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3.1.6 Sensitivity to Chemotherapeutic Drugs
Several multiple drug resistant (MDR) variants of the DLKP cell line have previously 
been selected by culturing the cells in increasing concentrations of chemotherapeutic 
drugs until highly resistant lines were established. These variants not only exhibit a 
marked increase in drug resistance compared with their sensitive parents but are also 
cross-resistant to a range of drugs that are structurally unrelated to the original selective 
agent. For example, the DLKP-A variant line, established by Dr.Alice Redmond, was 
selectively grown in increasing concentrations of adriamycin but is also several fold 
more resistant to vincristine and VP16 than DLKP (see Table 3.6.2). These variants 
have been established as models for the MDR phenotype which can occur in vivo 
following combination chemotherapy and are used to study mechanisms of MDR and 
possible modes of circumvention.
While it is considered likely that the MDR variants of DLKP arose via adaptation to the 
progressively increasing concentrations of selecting agent, it is possible that a 
subpopulation of the sensitive parental DLKP cells were inherently highly resistant and 
it was these which were selected out. To examine this possibility and to determine if 
variation existed between the DLKP clones with regard to their MDR profiles, the 
sensitivity of the clones to the 3 structurally different chemotherapeutic drugs, 
adriamycin, vincristine and VP16, was determined.
3.1.6.1 Sensitivity to adriamycin
DLKP, DLKP-I, -M and -SQ were exposed to concentrations of adriamycin in the 
range from 0.6ng/ml to 25ng/ml (see Section 2.12). This was the range over which the 
toxicity profile of DLKP had previously been determined. The IQ qS for DLKP and the 
clones are shown in Table 3.1.3. The results are the mean results from 4 separate 
experiments and each experiment was carried out in replicates of 8. Table 3.1.4.1(h) 
shows the mean fold difference of each clone w.r.t. the DLKP cell line.
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Taking standard deviations into account, no real difference was seen between DLKP, 
DLKP-M and -SQ. DLKP-I was the most sensitive of the clones to adriamycin w.r.t. 
DLKP, but the difference is less than 0.5-fold.
3.1.6.2 Sensitivity to vincristine
The vincristine toxicity assays were carried out over a range of concentrations from 
0.023ng/ml to 2.5ng/ml. The results shown in Tables 3.1.3 and 3.1.4 are the mean 
results from 3 experiments. In this case, DLKP-M had an IC*, value similar to that of 
DLKP, as did DLKP-I, although the standard deviation was rather high. DLKP-SQ was 
approximately 0 .5-fold more sensitive than DLKP.
3.1.6.3 Sensitivity to VP16
The toxicity assays with VP16 were carried out over a range of 2.4ng/ml to 250ng/ml 
VP16. The results shown in Tables 3.1.3 and 3.1.4 are the mean results from 6 
experiments. Once more, taking standard deviations into account, very little difference 
was seen between the 4 lines. DLKP-I had the lowest IQq but this was again less than 
0.5-fold sensitive w.r.t. DLKP.
The toxicity profiles of the DLKP clones were thus found to be very similar for the 3 
drugs examined and in addition, were found to vary less than 0.5-fold from those of 
DLKP. Therefore, putative highly resistant populations in DLKP were not represented 
by any of these clones.
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Cell line Adraimycin 
(ICjo, ng/m l)
Vincristine 
(IC sh ng/m l)
VP16 
(IC jo, ng/m l)
D LK P 11.78 ±  5.19 0.52 ±  0.17 30.7 ±  9.8
D L K P -I 5.71 ±  2.72 0.39 ±  0.31 19.2 ±  6.7
D LK P -M 8.67 ±  2.76 0.51 ±  0.26 22.5 ±  12.8
DLKP-SQ 9.55 ±  5.58 0.25 ±  0.09 33.5 ±  8.9
Table 3.1.3 Sensitivity o f DLKP and clones to M DR  drugs.
Cell line Adriam ycin 
(fold w .r.t.D L K P )
Vincristine 
(fold w .r.t.D L K P )
VP16 
(fold w .r.t.D L K P )
D LK P 1 1 1
D L K P -I 0.54 ±  0.14 0.65 ±  0.33 0.61 ±  0 .12
D LK P -M 0.83 ±  0.26 0.95 ±  0.16 0.74 ±  0 .34
| DLKP-SQ 0.96 ±  0.45 0.48 ±  0.11 1.10 ±  0 .29
Table 3.1.4  The fold differences in  IC *, values for each clone with respect to (w .r.t.) DLKP  
shown for each drug examined.
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Adriam ycin
Cell line B Assay 1 Assay 2 Assay 3 Blinded* Mean
J  (fold) (fold) (fold) (fold) (fold)
D LK P  1 1 1 1 1
D L K P -I |  0.50 0.48 0.78 0.42 0.54 ±  0.14
D L K P -M  0.69 0.72 1.28 0.65 0.83 ±  0.26
D LKP-SQ  || 1.05 0.64 1.67 0.50 0.96 ±  0.45
Table 3 .1.5  Results from individual assays carried out w ith adriamycin showing fold IQo 
values obtained for each clone w .r.t. DLKP.
Vincristine '
C ell line Assay 1 Assay 2 Blinded* Mean
(fold) (fold) (fo ld) (fold)
D LK P 1 1 1 1
D L K P -I 0.49 0.51 1.07 0.65 ±  0.33 I
D L K P -M 0.84 0.87 1.14 0.95 ± 0 . 1 6
D LKP-SQ 0.59 0.38 0.46 0.48 ± 0 . 1 1
Table 3 .1 .6  Results from individual assays carried out w ith vincristine showing fold IC ^  
values for each clone w .r.t. DLKP.
H Cell line | Assay 1 
(fold)
Assay 2 
(fold)
Assay 3 
(fold)
Assay 4  
(fo ld )
Assay 5 
(fold)
Blinded
(fold)
M ean
(fold)
D LK P 1 1 1 1 1 1 1
D L K P -I 0.78 0.68 0.57 0.39 0.65 0.62 0.61 ±  
0.12
D L K P -M 0.50 0.44 0.61 0.58 1.31 1.00 0.74 ±  
0.34
D LKP-SQ 1.31 0.84 1.50 0.77 1.31 0.84 1.10 ±  
0.29
Table 3 .1 .7  Results from individual assays carried out w ith VP16 showing fold ICg, values 
for each clone w .r.t. DLKP.
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3.2 CHARACTERISATION OF DLKP AND CLONES
If the DLKP cells were to be used as a model for lung cells, malignant or otherwise, 
it would be necessary to characterise the DLKP cells and each of the clones as 
thoroughly as possible. To fully understand the relevance and significance of any 
experiments carried out with these cells, it would be crucial to know as accurately as 
possible, what class of tumour the cells belonged to. In addition, knowledge of the stage 
of differentiation the DLKP cells were at before, during and after experiments would 
allow for a clearer perception of the behaviour of this particular tumour cell type, in  
v iv o  and in  v i t r o .
Therefore, to understand fully the cell system being examined, a broad characterisation 
study of the DLKP cells was carried out. This study encompassed functional, 
ultrastructural and biological aspects of lung epithelial cell biology.
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3.2.1 Electron Microscopy
Electron microscopy (EM) is the most definitive method presently available to study and 
characterise a cell type. The organelles contained by a cell can be determined and 
localised and staining procedures can be carried out to identify material contained 
within a cell. The organelle complement of a cell is specific to the function of that cell 
and therefore, EM allows accurate diagnosis of cell type.
Suspensions of each cell line - DLKP (P7), DLKP-I (P21), DLKP-M (P34) and DLKP- 
SQ (P34) - were fixed in glutaraldehyde (Section 2.13). Subsequent processing and EM 
analysis was carried out by Dr.David Dinsdale, University of Leicester.
The cells were found to contain no characterising organelles such as dense core granules 
or lamellar bodies which are indicative of NE cells and type II cells respectively (see 
Figure 3.2.1). In fact, the cells contained very little ultrastructural detail apart from the 
nucleus, mitochondria e tc . No differences were found between any of the 4 DLKP lines 
examined. Significantly, no difference was seen between the relatively early passage 
DLKP cells (P7) and the later passage numbers of DLKP-M and DLKP-SQ (P34). The 
results indicated that the cells were at a very early stage of differentiation, similar to 
basal or stem cells which would also lack differentiation-specific organelles.
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Figure 3.2.1 Ultrastructural features of A. DLKP, B. DLKP-I, C. DLKP-M and D. DLKP-SQ cells 
demonstrated by electron microscopic analysis. Arrows indicate possible dense core vesicles but these 
occurred extremely infrequently among all of the cells examined. (Magnification unknown).
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3.2.2 Electrical Resistance Studies
The cells in epithelial tissues are tightly bound together enabling the epithelium to 
function as a lining or barrier between the body and the outside world. The lining also 
facilitates compartmentalisation of cell and tissue types. Epithelial cells contain tight 
junctions which serve to maintain the selective barrier function of epithelial sheets. 
They also prevent diffusion of epithelial cell membrane proteins which results in the 
polarisation of epithelial cells.
To determine if DLKP cells or any of the clones were capable of forming an epithelial 
sheet with selective-barrier functions, the electrical resistances of confluent monolayers 
of the cells were determined as described in Section 2.14.2.
Cells were seeded onto millipore filters at confluent densities and grown in 12-well 
plates, as described in Section 2.14. Every 3-4 days, the electrical resistances of the cell 
monolayers were measured using an Endohm apparatus (electrical resistance 
measurements were determined by Stephen Keely and facilities provided by Dr. Alan 
Baird, Pharmacology Dept., University College Dublin). Increased electrical resistance 
was indicate of tight junction formation as the cells grew tighter together and the 
epithelial barrier formed. T84 cells, a human colonic cell line classically used in these 
experiments, were used as a positive control. The resistance of these cells was seen to 
increase over 8 days from 80 ohms to over 600 ohms (Figure 3.2.2). No increase in 
resistance was seen in any of the DLKP cells, indicating that these cells do not contain 
tight junctions and so are not polarised epithelial cells.
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Figure 3 .2 .2  Electrical resistance exhibited by confluent monolayers of A. DLKP-I, DLKP-M and
DLKP-SQ cells and B . DLKP, SKMES-1 and T84 cells.
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3.2.3 Immunocytochemical Analysis
An extensive immunocytochemical study was undertaken to determine the profile of 
protein markers expressed by DLKP cells. This profile would enable comparisons to 
be made between DLKP and their normal and malignant counterparts in  v iv o  and in  
v i t r o .  It would also serve as a means of qualitative analysis during experiments i .e .  did 
a particular treatment of the cells result in an up- or down-regulation of a marker, or 
switch on or off marker expression and allow for surmise on possible implications of 
such events. An additional aim was to detect differences in marker expression between 
the DLKP clones. Differences in growth, morphology and chromosome distribution had 
been established (Section 3.1) and detection of contrasting marker expression could 
identify possible differences in differentiation states of the 3 clones. It would also allow 
identification of specific clones in a mixed population and would enable the 
interconversion process to be observed more closely.
While some markers are not specific for particular cell types, especially tumour types, 
if a broad range of markers is examined, it is possible to substantially characterise 
tumour cells.
An immunocytochemical survey was therefore carried out on DLKP and its clones using 
specific Abs to determine the expression of protein markers. In some cases, the original 
paraffin-embedded tumour block was available for study.
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3.2.3.1 Epithelial markers
A number of markers exist which are specific for normal epithelial cells. It has been 
shown that of a possible 29 or more keratin proteins, each type of epithelial cell 
contains a characteristic combination of 2 to 10 cytokeratin intermediate filaments. 
Specific Abs are available which react with individual or subsets of cytokeratins, 
making it possible to determine cellular origins and degrees of differentiation of tumour 
cells. Several additional Abs which react specifically with epithelial cells have been 
raised but as yet their antigens remain unidentified.
Dr. Geraldine Grant had previously established the absence of cytokeratin expression in 
DLKP cells using an anti-pan keratin Ab.
3.2.3.1.1 Cam 5.2
Clone Cam 5.2 is a murine monoclonal antibody which reacts with keratin peptides 8 
and 18. These peptides are found in most epithelial cells with the exception of stratified 
squamous epithelium.
Sectioned agar blocks of cultured DLKP and clone cells and the original tumour block 
were examined for reactivity with Cam 5.2. All samples were found to be negative 
(Figure 3.2.3).
3.2.3.1.2 Pan cytokeratin
The reactivity of the cells with a pan cytokeratin antibody which reacts with 
cytokeratins 1, 4, 5, 6, 8, 10,13, 18 and 19 was also examined. The tumour block was 
not available for study here.
Again, DLKP and the 3 clones were all found to be negative for keratin expression 
(Figure 3.4.4 - Section 3.4).
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3.2.3.1.3 Epithelial membrane antigen
The epithelial membrane antigen (EMA) antibody is specific for epithelial cells but the 
antigen it recognises is as yet unknown.
Only the tumour block was examined with this antibody and was found to be negative 
(Figure 3.2.3).
3.2.3.1.4 EP16
The antigen which the EP16 antibody recognises is also unidentified but it is specific 
for epithelial cells.
The tumour block was not studied here. DLKP and each of the clones failed to react 
with this antibody (Figure 3.2.4).
3.2.3.1.5 Desmoplakin
Desmoplakin is a protein present in the desmosomes of epithelial cells. Desmosomes 
serve as anchoring sites for intermediate filaments and join epithelial cells together.
No desmoplakin was detected in DLKP cells or in any of the clones (Figure 3.2.5).
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Figure 3.2.3 Reactivity of Cam 5.2 anti-keratin Ab. with A. DLKP original tumour block and B. 
DLKP, passage 6 cells. In both cases, cells were negative. Also shown is reactivity of anti-EMA Ab. 
with C. DLKP tumour block. Again, cells were negative. xlOO.
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Figure 3.2.4 Reactivity of EP16 Ab. with A. DLKP, B. DLKP-I, C. DLKP-M, D. DLKP-SQ and
E. Hep 2 cells, all of which were negative. F. SCC-9 cells were used as a positive control. xlOO.
148
‘E
%  4* f t ; r. {
o f .
A' i*His Alfr > , - . : •
i
t ^ / / L L r A  |
f V
\  »/ .JBrtKtjLitt »«. i
'fir A
Figure 3.2.5 Reactivity of anti-desmoplakin Ab. with A. DLKP, B. DLKP-I, C. DLKP-M and
D. DLKP-SQ cells, all of which were negative. E. A549 cells were used as a positive control. xlOO.
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3.2.3.2 NSCLC markers
NSCLC is broadly sub-divided into squamous, adenocarcinoma and large cell carcinoma 
based on morphological and biochemical criteria. A marker specific for squamous 
differentiation and 2 antibodies which react with NSCLC and not with SCLC were 
examined.
3.2.3.2.1 Transglutaminase
Transglutaminases are a group of enzymes involved in the formation of cross-linked 
envelopes which are present in squamous differentiated cells.
DLKP and the 3 clones were negative for expression of this enzyme (Figure 3.2.6).
3.2.3.2.2 703D4/704A1
703D4 and 703D1 are antibodies which are believed to react only with NSCLC and not 
with SCLC, breast, colon, neuroblastoma or lymphoid tumours. Mulshine, e t a l . , who 
raised these antibodies believe that the antigen detected by the 703D4 antibody is 
expressed in cells early in the tumourigenic process, before any morphologic chage can 
be detected (personal communication, Dr.James Mulshine, National Cancer Institute, 
Rockville, Maryland, USA.).
DLKP and the 3 clones reacted positively with both of these antibodies (Figure 3.2.7).
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Figure 3.2.6 Reactivity of anti-transglutaminase Ab. with A. DLKP, B. DLKP-I, C. DLKP-M and 
D. DLKP-SQ cells, all of which were negative. E. SCC-9 cells were used as a positive control. xlOO
m-
Figure 3.2.7 Reactivity of 703D4 Ab. with A. DLKP, B. DLKP-I, C. DLKP-M, D. DLKP-SQ and
E. SKMES-I cells, all of which were positive. F. HTB 120 cells were used as a negative control. x200
3.2.3.3 SCLC markers
SCLCs can be characterised by the presence of neuroendocrine m arkers. A  com bination 
o f morphological examination and m arker expression can allow determ ination o f  the 
degree o f SCLC differentiation o f a tumour. H owever, the identity and num ber o f  these 
markers can vary and in addition, the markers are not confined to SCLC and are found 
in  other tum our types including NSCLC.
3.2.3.3.1 Neuron specific enolase (NSE)
N SE is a homophilic adhesion molecule. It exists as a homo or heterodim er o f alpha, 
beta or gamma subunits. The gamma subunit is expressed prim arily in  neurons and in 
neuroendocrine cells. Originally believed to be specific for SCLC, N SE reactivity has 
been found in other tum our types.
Only the tum our block was studied for NSE gam m a subunit expression and was found 
to be strongly positive (Figure 3.2.8).
3.2.3.3.2 Protein gene product 9.5 (PGP 9.5)
The PGP 9.5 antigen is as yet unknown, but the antibody has been shown to  react with 
SCLC.
The tum our block, DLKP and each o f the clones reacted strongly w ith this antibody 
(Figure 3 .2 .8).
3.2.3.3.3 Leu 7
Leu 7 is one o f 3 antibodies which com prise the CD57 cluster o f  leukocyte 
differentiation antigens corresponding to the NK3 cell-associated m olecule, HKN-1. In 
norm al tissue, CD57 is restricted to thick nerve fibres and can be expressed by some 
neural-related tumours.
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Only the tum our block was examined for reactivity to Leu 7 and some cells w ere seen 
to react positively (Figure 3.2.8).
3.2.3.3.4 Neurofilaments
Neurofilaments are intermediate filaments found only in  neural cells o f normal tissue. 
Their expression in  tum ours indicates neural origins or neural differentiation.
The tum our block was not examined here but D LKP and each o f the cells were strongly 
positive for neurofilam ent expression (Figure 3 .2 .9 ).
3.2.3.3.5 Neural cell adhesion molecule (NCAM)
NCAMs are a fam ily o f cell surface sialglycoproteins which mediate homotypic and 
heterotypic cell-cell interactions. They are expressed on nerve cells and glial cells and 
the antibody used reacts with the 125kD isoform.
No N CAM  expression was detected in DLKP cells or in any o f the clones (Figure 
3.2.10).
3.2.3.3.6 Serotonin (5-hydroxy-tryptamine, 5-HT)
5-HT is a monoam ine neurotransmitter which has m arked excitatory o r inhibitory 
actions on a variety o f  organs and physiologic functions through an action on sm ooth 
muscle and on glandular and neuronal tissue. N orm al tissues which contain 5-H T- 
positive cells include the central nervous system, adrenal medulla and neuroendocrine 
cells o f the bronchial epithelium.
DLKP and the clones contained no detectable levels o f 5-HT. SK-N-SK, a 
neuroblastoma cell line and H69, a SCLC cell line, w ere used as positive controls for 
this antibody. H ow ever, reactivity, while positive, was weak on the cells and was not 
visible when photographed. Therefore, no results are shown here for this antibody.
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3.2.3.3.7 Glial fibrillary acidic protein (GFAP)
Glial fibrillary acidic protein is a type II intermediate filam ent pro tein  p resent in 
astrocytes and some Schwann cells.
DLKP and the 3 clones were negative for expression o f this protein (F igure 3 .2 .11 ). 
3.2.3.3.8 C h ro m o g ran in  A
Chrom ogranin A is a m em ber o f the secretogranin/chrom ogranin class o f  p ro teins that 
occur in secretory granules o f a wide variety o f endocrine cells and neurons. In  norm al 
tissues, chrom ogranin A  is widely expressed in neuronal tissues and in  the secretory 
granules o f endocrine cells. Expression is also found in a variety o f  neuroendocrine 
tumours.
No chrom ogranin A  reactivity was detected in  DLKP or any o f  the clones. A s was 
found with the anti-serotonin antibody, reactivity was weak on positive control cell lines 
used with this antibody (SK-N-SH and H69) and it was not possible to  photograph  the 
results satifactorily. Therefore, the results are not shown.
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Figure 3.2.8 Shown here are:- A. the detection of NSE immunoreactivity in DLKP tumour block, x200; 
the detection of PGP 9.5 immunoreactivity in B. DLKP tumour block and C. DLKP-SQ cells, xlOO; 
the detection of D. Leu 7 and E. vimentin immunoreactivity in a small number of cells in the DLKP 
tumour block, xlOO;
and F. (he absence of LCA immunoreactivity from DLKP cells, xlOO.
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Figure 3.2.9 Positive neurofilament immunoreactivity in A. DLKP, B. DLKP-I, C. DLKP-M and
D. DLKP-SQ cells and negative reactivity in E. normal lung fibroblasts. xlOO.
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Figure 3.2.10 Negative NCAM immunoreactivity in A. DLKP, B. DLKP-I, C. DLKP-M and
D. DLKP-SQ cells and positive reactivity in E. SK-N-SH cells. xlOO.
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Figure 3.2.11 Negative GFAP immunoreactivity in A. DLKP, B. DLKP-I, C. DLKP-M and
D. DLKP-SQ cells and positive reactivity in E. SK-N-SH cells. xlOO.
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3.2.3.4 Other markers
DLKP cells were also examined for their expression o f several other m arker proteins.
3.2.3.4.1 Vimentin
Vimentin is a type II intermediate filament expressed in many cells o f mesenchymal 
origin including fibroblasts, blood vessel endothelial cells and white blood cells. 
Expression o f vim entin is also often induced in cultured cells.
The tum our block was examined for vimentin expression. Only scattered positives were 
present which were probably fibroblasts (Figure 3.2.8).
3.2.3.4.2 Leucocyte common antigen (LCA)
Leucocyte com m on antigen is a family o f 5 or m ore high molecular w eight 
glycoproteins present on  the surface o f the majority o f hum an leucocytes. N orm al 
lymphoid cells, macrophages and histiocytes express these proteins as do neoplastic B 
and T  cells in non-H odgkin’s lymphoma. Because the DLKP cell line was established 
from  a lymph node metastasis, it was necessary to eliminate the possibility that a 
lymphatic prim ary tum our was in  fact the source o f  DLKP.
The tum our block was not examined but DLKP and each o f  the clones showed no 
reacivity with the LCA  antibody (Figure 3 .2 .8 ).
3.2.3.4.3 P-Glycoprotein
P-glycoprotein is a m em brane drug efflux pum p which is highly expressed in  the 
D LK P-A cell line, a m ultiple drug resistant variant o f  DLKP. Previous work (Dr. A lice 
Redm ond, PhD thesis) had shown that the sensitive DLKP cells expressed very low 
levels o f this protein. H ere, the DLKP clones w ere exam ined for their expression o f  P- 
glycoprotein to determ ine if  a population o f  cells in  DLKP inherently expressed high
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levels o f P-glycoprotein which would suggest that these had been selected out to form 
the variant lines.
No expression o f P-glycoprotein was detectable in DLKP or any o f the clones (results 
not shown).
3.2.3.4.4 a-2 Integrin
The integrins are a  large family o f cell surface receptor molecules involved in cell-cell 
and cell-m atrix interactions. a2-integrin binds to collagen I and IV , lam inin and 
fibronectin and can  influence cell adhesion and motility.
a -2  integrin expression was detected in DLKP cells and in each o f the clones (Figure 
3 .2 .12). D LK P-M  cells appeared to have higher levels o f expression than the 2 other 
clones and DLKP.
A  summary o f the immunocytochemical reactivities o f DLKP and the clones is 
presented in Table 3 .2 .1 .
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Figure 3.2.12 Positive os-integrin immunoreactivity in subpopulations of A. DLKP, B. DLKP-I,
C. DLKP-M and D. DLKP-SQ cells and positive reactivity in SKMES-1 cells. xlOO.
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Marker Tumour
block
DLKP
(P6)
DLKP
(P29)
DLKP-I DLKP-M DLKP-SQ
Epithelial
Cam 5.2 - - - - - -
Pan ker. - - - - -
EMA -
EP16 - - - - -
Desmopl. - - - - -
NSCLC
Transgl. - - - - -
703D4/ 
704A1
✓ ✓ ✓ ✓ ✓
SCLC
NSE ✓
PGP 9.5 ✓ ✓ ✓ / ✓ ✓
Leu 7 ✓
N.fils ✓ ✓ ✓ ✓
NCAM - - - -
5-HT - - - -
GFAP - - - -
Crg.A - - - -
Others
Vimentin -
LCA - - - - -
P-gly. - - - - -
a2-intgr. ✓ / ✓ ✓
Table 3.2.1 Expression of biological markers in DLKP cells and clones. (Pan ker. = pan anti- 
keratin, EMA = epithelial membrane antigen, Desmopl. = desmoplakin, Transgl. = transglutaminase, 
NSE = neuron specific enolase, PGP 9.5 = protein gene product 9.5, N.fils. = neurofilaments, NCAM 
= neural cell adhesion molecule, 5-HT = serotonin, GFAP = glial fibrillary acidic protein, Crg.A = 
chromogranin A, LCA = leucocyte common antigen, P-gly.= P-glycoprotein and a2-intgr. = a2- 
integrin).
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3.3 PRODUCTION OF MONOCLONAL ANTIBODIES
During the characterisation studies carried out on the D LK P clones described in Section 
3.2, no measureable feature had emerged, biological o f  im m unological, that would 
allow for actual identification o f any 1 clone in a m ixed population i.e. no differential 
marker(s) had been identified. The presence o f one o r m ore m arkers on  any o f the 
clones would mean that the interconversion o f  the cells occurring in  culture, which up 
to this point had only been observed morphologically under the m icroscope, could be 
analysed m ore closely and quantitated. Knowledge o f  differences in  the expression o f 
specific proteins betw een the clones may also give insight into the respective 
differentiation states o f  the cells and could be used in  experim ents w ith differentiating 
agents to explore the differentiating capacities o f the cells. The presence o f m arkers on 
1 or m ore o f the clones would also aid in comparisons between those particular cells 
and possible corresponding cells in vivo, normal and/or malignant. F or these reasons, 
it was decided to raise monoclonal antibodies (MAbs) to the cells to aid in the search 
for markers for the clones.
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3.3.1 Immunisation with DLKP Cells
M ice were immunised w ith D LK P whole cells. The parental population was chosen for 
immunisations because, in theory at least, this mixture o f cells should possess the entire 
complement o f antigens expressed by all the indivivual clones, plus any that m ay not 
be represented by the clones. F o r the same reasons, DLKP cells w ere used  in  the 
preliminary screening assays to identify antibody-producing hyrbridom as. In  later 
screening assays, the DLKP clones w ere examined for differential expression o f 
antigens.
Three immunisations w ere carried out over 7 weeks, followed by a  final boosting 
injection 3 days prior to sacrifice o f  the animals at week 9. 2 weeks after the 3rd 
immunisation, sinus bleeds w ere carried out on the mice. The sera from  these samples 
were analysed for im munoreactivity w ith DLKP cells by ELISA as outlined in  Section 
2 .16 .3 . Immunoreactivity w as detected in  all samples indicating that the im m une 
systems o f the mice had responded to  the foreign DLKP cells by producing antibodies 
specifically directed against D LK P antigens.
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3.3.2 Fusion and Selection of DLKP-immunoreactive MAb Clones
Fusion of splenocytes from the immunised mouse with mouse myeloma Sp2 cells was 
carried out as described in Section 2.16.2. A successful fusion would mean that the 
resulting hybridomas were immortalised cells capable of producing and secreting Abs. 
The fused cells were plated into 96-well plates and incubated undisturbed for 7 days. 
After this time, the plates were examined under the microscope and any wells 
containing colonies of cells were marked. Approximately 50% of the wells examined 
contained colonies of varying sizes.
The marked wells were allowed to become confluent until the supematent had turned 
from red/purple to yellow/orange, indicating cell proliferation and metabolism and thus 
possible Ab secretion. The supematent was them removed and analysed for 
immunoreactivity with DLKP cells (see Section 2.16.3). The first batch screened 
consisted of 45 supematents and these were tested 11 days after the initial fusion. Those 
supematents which resulted in absorbance readings greater than approximately 20% 
those of control wells ( i .e .  without Ab) were designated positive and their 
corresponding clones were marked for further culture and were subsequently grown up 
into 6-well plates and then into 25cm2 flasks. Of the 45 supematents tested in the first 
batch, 15 were positive. The remaining 30 clones were thus discarded.
Six such preliminary screenings of supematents were carried out using DLKP cells as 
positive indicators of reactivity. More than 200 supematents were analysed and of 
these, 28 appeared to consistently react positively with DLKP cells. It was noted that 
the reactivity of the Abs produced by some of the hybridomas appeared to diminish 
with time.
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3.3.3 Screening Against the DLKP Clones
Supematents from the 28 selected hybridomas were collected and their 
immunoreactivities with the DLKP clones were examined. Because a marker which 
could differentiate between the clones was being sought, only those supematents which 
differentially reacted with the clones were of interest i .e .  those which reacted with 1 or
2 clones only or which reacted more strongly with 1 clone than another. After 7 
screenings of the clones, no Ab was found to react specifically with only 1 or 2 of the
3 clones. However, 2 Abs, named 4D2 and 3E1, appeared to consistently react more 
strongly with DLKP, DLKP-M and DLKP-SQ than with DLKP-I. Further work was 
carried out to characterise these 2 Abs and to determine their efficacy as markers for 
subpopulations of DLKP cells.
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3.3.4 Isotyping of MAbs
It was important to determine the isotypes of the 4D2 and 3E1 Abs. In humans, there 
are 5 classes of Abs, IgA, IgD, IgE, IgG and IgM, which are classified according to 
the nature of their antigen-binding chains. IgM is the first class of Ab produced by 
immune cells in response to a foreign antigen (Ag). The presence of 10 binding sites 
on these Abs gives them a high affinity for their specific Ag. However, an increase in 
the affinity of Abs produced with time after immunisation is often seen due to mutations 
in the genes which code for the Ag-binding sites. Therefore, IgG Abs, which are the 
major class of Ab in the blood and are produced during secondary immune responses, 
are more desirable for use as analytical tools.
Isotyping of the 4D2 and 3E1 Abs was carried out using a Serotec kit, described in 
Section 2.16.4. During the ELISA screenings with these Abs, it appeared that 4D2 had 
a stronger reaction with the DLKP cells than 3E1. Therefore, for the isotype analysis, 
4D2 was tested at dilutions of 1/50, 1/100 and 1/200 while 3E1 was tested at 1/10, 
1/50 and 1/100.
The results of the indicated that the 4D2 Ab was an IgG molecule while the 3E1 Ab 
was an IgM molecule. These results were consistent with the 4D2 Ab having a stronger 
reaction with the DLKP cells than the 3E1 Ab in the ELISAs.
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3.3.5 Western Blot Analysis
In order to determine the molecular weights of the antigens which reacted with the 4D2 
and 3E1 Abs, Western blots were carried out (see Section 2.17 for techniques). Western 
blots also allow semi-quantitative analysis as either the protein concentrations or cell 
numbers that are loaded onto a gel are pre-determined and equal, thus allowing the size 
of the resulting bands to be compared to each other. For these Westerns, whole cells 
were run on the gels (1X104 cells per lane).
The 3E1 Ab failed to produce a band on any Western attempted using the following 
cells:- DLKP, DLKP-I, -M, -SQ, DLKP-A, DLKP-A-2B, DLKP-A-5F and SKMES- 
ADR (Figure 3.3.1). It was therefore not possible to estimate a size for the Ag which 
had reacted with 3E1 in the ELIS As.
When the blots were probed with the 4D2 Ab, a single band resulted for each cell line 
examined. When compared with the standard molecular weight markers run 
simultaneously, the band produced had an apparent size of 58kD and the band was this 
size in all the cell lines analysed.
Consistently i . e .  on each of 8 separate Westerns carried out, the band produced by 
DLKP-SQ cells was stronger than those produced by DLKP, DLKP-I and -M, 
indicating a higher level of expression of the 4D2 Ag in the DLKP-SQ cells (Figure
3.3.2).
Several other cell lines were examined with the 4D2 Ab - DLKP-A, DLKP-A-2B, 
DLKP-A-5F, SKMES-1, SKMES-1-ADR, SKLU-1 and A549 - and all produced a 
single band of approximately 58kD. The SKMES-1-ADR cells appeared to produce the 
strongest band of all the lines examined, including DLKP-SQ (Figure 3.3.3).
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Figure 3.3.1 Western blot examined with 3E1 Ab. No reactivity was seen with any cell lines examined.
Figure 3.3.2 Western blot examined with 4D2 Ab resulting in a band of approximately 58kD in lanes
containing DLKP and each of the clones. This Ab. consistently reacted most strongly with DLKP-SQ
cells.
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Figure 3.3.3 Western blot examined with 4D2 Ab. A single band of approximately 58kD was produced 
for all cell lines examined.
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3.3.6 Immunocytochemical Analysis
The 4D2 and 3E1 Abs had been selected on the basis of their reactivities in ELISAs 
where the intensity of colour produced by a soluble substrate was used as an indicator 
of positivity. In order to examine more closely the nature of the interaction of the Abs 
with the cells, immunocytochemical analysis with the 3 stage DAB-ABC staining 
technique was carried out as prevoiusly described in Section 2.15.2. This results in an 
insoluble colour precipitate where the primary Ab reacts with its specific Ag and thus 
gives an indication of the location and distribution of the Ag within the cell e g . 
membranous, nuclear, cytoplasmic, filamentous, vesicular e tc . While this is an 
imprecise analysis, it can be helpful in ruling in or out likely candidates for the identity 
of the Ag. It is also possible that a single Ag may have different distributions in 
different cells.
3.3.6.1 DLKP and clones
The reactions of 4D2 and 3E1 with DLKP, DLKP-I, -M and -SQ were examined by 
the DAB-ABC method. Neat conditioned media from the hybridomas were used in all 
experiments.
The 4D2 Ab had a strong reaction with DLKP and the 3 clones, appearing to be 
strongest in DLKP-SQ (Figure 3.3.4). Staining was localised to the cytoplasm in each 
of the cell lines and inasmuch as was possible to determine under the microscope, the 
staining appeared to be uniform throughout the cytoplasm i . e .  not localising in 
structures of any kind such as vesicles or networks.
The 3E1 Ab had a similar reaction with DLKP and the clones, but the staining was 
much less intense than that seen with the 4D2 Ab (results not shown). Again, the 
staining was cytoplasmic and general, as observed with 4D2.
Cytospins were made of both subconfluent and confluent DLKP cells and these were 
analysed to examine the possibility that the Ag(s) was expressed only in either actively
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growing cells or in contact inhibited cells. No difference was seen in Ab reactivity with 
such cells and all cells were positive (Figure 3.3.5).
3.3.6.2 Screening of other cell types
A wide range of cell types, normal and malignant, were screened to determine the 
specificity of the Abs and to assess their suitability for use as markers for any specific 
cell type e g . lung cells, tumour cells, epithelial cells e tc . The cell types examined are 
listed in Table 3.3.1. The 4D2 and 3E1 Abs were found to react positively with every 
cell type examined. Examples of some of these results are shown in Figures 3.3.6 and 
3.3.7.
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Figure 3.3.4 Positive 4D2 immunoreactivity in A. DLKP, B. DLKP-I, C. DLKP-M and 
D. DLKP-SQ cells. Staining appears to be cytoplasmic. xlOO.
Figure 3.3.5 Positive 4D2 immunoreactivity in A. subconfluent and B. confluent DLKP cells. No 
difference in reactivity was apparent. xlOO.
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Figure 3.3.6 Positive 3E1 immunoreactivity in A. DLKP and B. Hep 2 cells. xlOO.
Figure 3.3.7 Positive 4D2 immunoreactivity in A. DLKP, B. SKLU-1, C. T84, D. Hep 2, 
E. RPMI 2650 and F. normal lung fibroblast cells. xlOO.
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Table 3.3.1 Reactivity of a range of cell types with 4D2 and 3E1
Cells Tumour
cells
Normal
cells
Origin 4D2
reactivity
3E1
reactivity
DLKP(P8) / Lung ✓ ✓
DLKP-A(P70) ✓ Lung ✓ ✓
SKMES(P38) ✓ Lung ✓ /
F.blast(P5)* / Lung / ✓
A549(P7) ✓ Lung ✓ ✓
SKLU-1(P31) ✓ Lung ✓ ✓
T84 ✓ Colon ✓ ✓
Hep 2 ✓ Larynx ✓ ✓
RPMI 2650 ✓ Nasal ✓ ✓
DLKP-A-2B
(P61)
✓ Lung ✓ ND
DLKP-A-2B
(P61)
/ Lung ✓ ND
SKMES-1
ADR(P73)
✓ Lung ✓ ND
Human 
Type II
/ Lung ✓ ND
Rat 
Type II
✓ Lung ✓ ND
Pig 
Type II l i
✓ Lung ✓ ND
Note: figures in parenthesis refer to passage number of cells eg.P8 = passage 8 
*F.blast =  normal fibroblasts 
ND =  not determined.
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3.4 DIFFERENTIATION STUDIES ON DLKP AND ITS CLONES
The characterisation studies carried out on DLKP and the clones and described in 
Section 3.2 indicated that each of the lines was poorly differentiated with no 
ultrastructural or biochemical features detected that would be indicative of any 
particular differentiated phenotype in the lung. In an attempt to gain further insight into 
the nature of the DLKP cells and each of the clones i . e .  what normal and/or abnormal 
cells they may represent in  v iv o ,  differentiation studies were carried out.
2 principal aims were perceived. Firstly, the effects, if any, of differentiating agents on 
the interconversion of the clones was to be observed. The ability to control the 
interconversion may allow the process to be studied more closely and possible 
m echanism s to be elucidated. Secondly, the effects of these agents on marker expression 
in the cells may provide information on potential differentiation pathways available to 
each cell type and enable comparisons and contrasts to be made between these 
malignant cells and normal lung epithelial differentiation. Concerning the first aim here, 
no differential marker for the clones emerged during the characterisation work and the 
MAb study also failed to produce such a marker. Therefore, morphological appearance 
remained the criterion for identification and classification of the clones.
2 agents known to affect the differentiation of many cell types, 5-bromodeoxyuridine 
and retinoic acid, were examined for their effects on morphology and marker expression 
in DLKP and the clones. The entire experiments, including exposure to differentiating 
agents and immunocytochemical analysis were carried out in 6-well tissue culture plates 
as outlined in Section 2.18.
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3.4.1 Bromodeoxyuridine
The effect of BrdU, a thymidine analogue, on the morphology and marker expression 
of DLKP and its clones was examined. BrdU is capable of both blocking and inducing 
expression of differentiated phenotypes but its mechanism of action is not understood. 
(For discussion see Section 4.8).
3.4.1.1 Morphological effects on DLKP and clones
Preliminary differentiation experiments were carried out with 1/xM, 10/zM and 50/iM 
BrdU which was added to the cells in normal growth medium (5 % serum) 24hrs after 
plating (as outlined in Section 2.18.2). Cells were fed with fresh BrdU-containing 
medium every 2-3 days. The toxic effect of BrdU on DLKP cells had been determined 
in a previous experiment (Section 3.5.3). The toxic effect of BrdU seen here reflected 
the previous findings. 10/xM and 50/iM BrdU were quite toxic to the cells resulting in 
approximately 75% and 90% kill respectively.
Table 3.4.1 lists brief descriptions of the effects of each BrdU concentration on the 
morphology of DLKP, DLKP-I, -M and -SQ after 14 days exposure to the compounds. 
1/xM BrdU had little effect on the morphology of any of the cells. Occasionally, larger 
than normal cells were evident, but apart from these and the slightly lower number of 
cells present compared with untreated controls (80-90%), no other morphological effects 
were apparent. At the higher BrdU concentrations (10/iM and 50/iM), fewer cells were 
present (25% and 10% of controls respectively) and these grew as single cells, not in 
colonies. The surviving cells were 4-6 times larger than the control cells and their 
cytoplasm had a stretched, fibrous appearance (Figures 3.4.1 and 3.4.2).
No interconversion of clonal morphologies was observed at any BrdU concentrations 
examined.
To determine if the change in morphology observed after BrdU treatment was 
permanent or reversible, cells treated for 2 weeks in 10/tM and 50/iM BrdU were fed
178
with normal medium without BrdU, and their morphologies were observed over 4 
weeks. After this time, colonies had reformed and each clone resembled its original 
morphology before BrdU treatment (see Figure 3.4.3).
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Cell line Control 50/tM BrdU 10/iM BrdU 50/iM RA 10/iMRA
DLKP - -50% 
confluent
- some very 
big colonies
- very few 
cells alive
- flattened 
& stretched
- -10% of 
controls
- flattened 
& stretched
- -30% of 
controls
- not as 
distorted as 
BrdU
- similar % 
to controls 
-morphology 
normal
DLKP-I - -40% 
confluent
- T colonies 
& some ‘SQ’ 
colonies
- very few 
cells alive
- flattened 
& stretched
- -10% of 
controls
- flattened 
& stretched
- -10% of 
controls
- normal 
colonies 
of 3-4 cells
- similar % 
to controls
- colonies 
smaller but 
normal
DLKP-M - -90% 
confluent
- cells look 
normal
- very few 
cells alive
- flattened 
& stretched
- -10% of 
controls
- flattened 
& stretched
- -40% of 
controls
- most cells 
normal
- similar % 
to controls
- looks like 
control well
DLKP-SQ - -40% 
confluent
- normal 
‘SQ’ colonies
- -40% of 
controls
- stretched 
& elongated
- -80% of 
controls
- stretched 
& elongated
- -10% of 
controls
- normal 
squamous
- -80% of 
controls
- squamous 
colonies with 
cells more 
dispersed
Table 3.4.1 Summary table of morphological effects of bromodeoxyuridine (BrdU) and retinoic acid 
(RA) on DLKP and the clones.
180
Figure 3.4.1 Effect of A. 10/xM BrdU and B. 10/xM RA on morphology of DLKP cells compared with 
C. untreated DLKP cells and effect of D. 10^ M BrdU and E. 10/zM RA on morphology of DLKP-I cells 
compared with F. untreated DLKP-I cells. xlOO.
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Figure 3.4.2 Effect of A. 10/xM BrdU and B. lOftM RA on the morphology of DLKP-M cells compared 
with C. untreated DLKP-M cells and effect of D. lOftM BrdU and E. 50/iM RA on the morphology of 
DLKP-SQ cells compared with F. untreated DLKP-SQ cells. xlOO.
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Figure 3.4.3 Recovery of A. DLKP, B. DLKP-I, C. DLKP-M and D. DLKP-SQ cells which had been 
fed in 10/xM BrdU-containing medium for 2 weeks and then in BrdU-free growth medium for 4 weeks. 
xlOO.
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3.4.1.2 Determination of marker expression
Cells in each of the DLKP lines had appeared enlarged, flattened and squamous-like 
following exposure to BrdU. These cells were now examined for their their expression 
of several markers whose presence/absence had previously been determined (Section 
3.2.3). Emphasis was placed on epithelial markers because of the squamous appearance 
of the treated cells.
3.4 .1 .2 .1  K eratins
Cells not exposed to BrdU had already been shown to express no epithelial markers 
including cytokeratins (Dr.Geraldine Grant, PhD thesis). Cells exposed to 1/xM and 
10/iM BrdU for 7 days were fixed with methanol and examined for keratin (ker.) 
expression by immunocytochemistry (for details of methods see Section 2.15.1 -
2.15.2). An anti-pan cytokeratin Ab was used. This Ab was a broad spectrum reagent 
specific for kers. 1, 4, 5, 6 , 8, 10, 13, 18 and 19, and would thus react with simple, 
comity mg and non-comifying squamous epithelia and pseudostratified epithelia. 
Approximately 20% and 50% of cells were found to react positively with this Ab 
following treatment with 1/iM and 10/zM BrdU respectively. Staining was very strong 
in IOjiM BrdU-treated cells.
Expression of individual keratins is limited to specific epithelial cell and tissue types. 
It is therefore possible to identify likely origins of a cell by determining its keratin 
profile (for discussion see Section 4.8). Five keratin proteins were selected for analysis 
and BrdU-treated cells were found to be positive for ker. 8, 18 and 17 expression and 
negative for ker. 10 and 14 expression (Figure 3.4.4).
The time course for appearance of keratin proteins in DLKP, DLKP-I, -M and -SQ 
cells was determined. Multiple plates were set up and cells were grown in the presence 
of 10/xM BrdU and fixed after 2, 6, and 8 days. Ker. 17, 18 and anti-pan cytokeratin 
Abs were used to probe the cells. Each Ab reacted faintly with cells exposed to BrdU 
for 2 days and the reactivity increased at days 6 and 8 (results not shown).
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The ability of cells to retain keratin expression following removal of BrdU from the 
medium was examined. Cells were treated for 7 days with 50/iM BrdU and then fed for 
another 8 days with growth medium without BrdU. Cells were then analysed for keratin 
expression and found to exhibit continued expression of kers. 17, 18 and also reacted 
positively with the anti-pan cytokeratin Ab (results not shown).
3 .4 .1 .2 .2  N eurofilam ents
DLKP and the clones were exposed to 1/*M BrdU for 7 days and then analysed for 
expression of neurofilaments which had previously been demonstrated in untreated cells 
(Section 3.2.3.3.4).
Neurofilament reactivity was found to be retained in all of the BrdU-treated cells 
(Figure 3.4.5).
3 .4 .1 .2 .3  T ransg lu tam inase
To determine if other epithelial markers were now being expressed in the BrdU-treated 
cells, cells which were grown in 10/xM BrdU for 7 days were examined for expression 
of transglutaminase, a squamous cell marker.
No transglutaminase reactivity was detected in any BrdU-treated cells (Figure 3.4.6).
3 .4 .1 .2 .4  D esm oplakin
Cells exposed to l^M BrdU for 7 days were analysed for desmoplakin expression, a 
protein found in the desmosomes of epithelial cells.
All cells were negative for desmoplakin reactivity (Figure 3.4.7), as they had been 
shown to be in untreated cells in previous experiments in Section 3.2.3.
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Figure 3.4.4 BrdU-induced keratin expression in DLKP cells, A. No inimunoreactiviiy with anti-pan 
keratin Ab was detected in untreated cells .Cells treated with 5/iM BrdU were found to react positively 
with anti-B. pan keratin, C. ker.8 D. ker.17 and E. ker.18 Abs. and negatively with F. anti-ker.10 Ab.
xlOO.
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Figure 3.4.5 Neurofilament immunoreactivity is retained in DLKP cells treated with A. l^ M BrdU and 
lO^iM RA. Results with DLKP clones were similar. xlOO.
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Figure 3.4.6 DLKP cells remained negative for transglutaminase immunoreactivity following treatment 
with A, 10/jM BrdU and B. 20/xm RA. Results with DLKP clones were similar. xlOO.
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Figure 3.4.7 DLKP cells remained negative for desmoplakin immunoreactivity following treatment with
A. 1/xM BrdU and B. 10^ M RA. Results with DLKP clones were similar. xlOO.
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3.4.1.3 Effects of BrdU on keratin expression in other cell types
To ascertain whether the phenomenon of BrdU-induced keratin expression was unique 
to DLKP cells or not, a number of cell types from lineages both similar and different 
to that of DLKP were analysed. These cells were treated with BrdU as the DLKP cells 
had been and their keratin profiles before and after treatment were determined. In all 
assays with these lines, DLKP cells were assayed simultaneously as a positive control 
for the BrdU effect.
3 .4 .1 .3 .1  H82
H82 is a human cell line and is classified as variant SCLC. As such, this line expresses 
no cytokeratin proteins under normal growth conditions (see Table 2.5.1 for growth 
media), despite being presumably derived from lung epithelial cells. H82s do express 
a small number of NE markers such as NCAM and Leu 7, allowing them to be 
classified as NE cells. These cells are therefore similar to DLKP cells which also may 
be classified as SCLC-V, although some of the NE markers expressed by DLKP differ 
from those found in H82. It was therefore of interest to determine if BrdU was capable 
of inducing keratin expression in H82 cells.
The H82 cells were exposed to l^M and 10/xM BrdU for 7 days and the medium was 
replenished 3 times during that time, as was standard procedure in these assays. H82 
cells grow in aggregates in suspension so it was necessary to harvest the cells each time 
the medium was changed. The cells were then resuspended in fresh medium. As with 
all cells that were grown in the presence of BrdU, decreased growth was noted with 
increasing BrdU concentration.
After 2 days’ exposure to BrdU, it was observed that cells in the presence of BrdU had 
begun to attach to the surface of their wells. A greater number had attached in the 
10pM wells than in l^M BrdU (Figure 3.4.8). No cells had attached in the control 
wells which contained no BrdU. Attachment of H82 cells occurs in flasks under normal 
culture conditions i .e .  without BrdU, but this is ususlly after more than a week in 
culture and less than 5 % of the cells are seen to attach. After 7 days exposure to BrdU,
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1/xM and 10/xM BrdU resulted in >50% and >90% attachment of surviving cells. 
Some attached cells had also begun to spread (Figure 3.4.8).
Following treatment with BrdU for 7 days, the supematents from all H82 wells were 
collected, centrifuged and any cells harvested were cytospun onto glass slides and fixed 
(methanol as before, Section 2.15) for immunocytochemical analysis. All wells were 
also fixed and along with the cytospins, were tested for keratin expression.
Cytospins of control H82 cells (without BrdU) were negative for keratin expression 
when examined with the anti-pan cytokeratin Abs (Figure 3.4.9). None of these cells 
had attached to their wells during the 7 days of the assay.
Cytospins of H82s exposed to l^M BrdU were found to be negative when analysed 
with anti-pan, ker.17 and ker.18 Abs. Attached cells also failed to react with these Abs 
(results not shown).
A very small number of H82 suspension cells were harvested from 10/iM BrdU wells. 
These were negative when probed with anti-pan, ker.17 and ker.18 Abs. The cells 
which had attached to the wells in the presence of IO^ iM BrdU (>90%  of population) 
were examined with anti-pan and ker.18 Abs. A small number of the cells (<5% ) 
reacted positively with the anti-pan cytokeratin Ab and also with the anti-ker.18 Ab 
(Figure 3.4.9).
3.4.1.3.2 SK-N-SH
SK-N-SH is a human neuroblastoma cell line. These cells were examined because they 
are derived from the neural crest and therefore should not normally express keratin 
intermediate filaments.
The SK-N-SH cells were exposed to 5/zM BrdU for 7 days. Unlike the H82 cells, these 
cells do not grow in suspension but attached to a substratum. Decreased growth was 
seen in the presence of BrdU. After 7 days, the cells were fixed and keratin expression 
was determined.
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Unexpectedly, it was found that untreated SK-N-SH cells contained keratin proteins as 
they reacted positively with the anti-pan and ker.18 Abs. No reactivity was seen with 
the anti-ker.17 Ab (Figure 3.4.9).
Cells treated with 5/iM BrdU appeared to have increased reactivity with the pan and 
ker.18 Abs. These cells also reacted with a ker.8 Ab but did not express keratins 10, 
14 or 17 (Figure 3.4.9).
3.4.1.3.3 HL60
HL60 is a human nonlymphatic leukemic cell line and therefore is derived from a 
lineage distinct from epithelial and neural crest lines. These cells are a classical model 
for studying differentiation in  v i t r o  as they can be induced to undergo terminal 
differentiation along either the myeloid or monocytic pathway. These cells do not 
express keratin intermediate filaments.
HL60 cells grow in suspension and therefore, during the BrdU assays, they were 
handled as the H82 cells had been. During exposure to l i^M and 10/zM BrdU, no 
attachment of the cells to their wells was seen. Following 7 days treatment, all cells 
were harvested, made into cytospins and fixed for keratin analysis.
When control HL60 cells (without BrdU) were analysed, no keratin reactivity was seen 
with the anti-pan cytokeratin Ab (Figure 3.4.10).
No reactivity was seen either with those cells which had been exposed to 1/*M or 10/xM 
BrdU (Figure 3.4.10).
3.4.1.3.4 A549
A549 cells are classified as human lung adenocarcinoma cells. They are therefore 
derived from the epithelium and they express keratin proteins. These cells were 
examined to determine the effects of BrdU on cells which already contain keratins.
190
The A549 cells were exposed to 5/iM BrdU for 7 days. After this time, untreated 
control cells reacted positively with anti-pan and ker.18 Abs (Figure 3.4.10).
The cells which were exposed to BrdU showed increased reactivity with the same Abs. 
They also reacted strongly with anti-ker.8 and ker. 17 Abs but no expression of keratins 
10 or 14 was detected (Figure 3.4.10).
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Figure 3.4.8 Effect of A. 1/xM BrdU and B. 10/xM BrdU on the morphology of H82 cells compared 
with C. untreated H82 cells. Increased adherence and decreased cell growth was seen with increasing 
BrdU concentration. xlOO.
192
o
 ^, 
(f
t \  y J S  y
•  mt ,  V* v A * V  -
¥ ♦ ■» i j
i k
A *
Figure 3.4.9 Induction of A. keratin expression (anti-pan keratin Ab.) and B. ker. 18 expression in H82 
adherent cells following exposure to lO^ iM BrdU. C. Untreated suspension H82 cells remained negative 
for keratin expression (anti-pan keratin Ab.). xlOO.
Increased expression of D. ker.8 and E. ker. 18 in SK-N-SH cells following exposure to 5/xM BrdU 
compared with F. ker. 18 expression in untreated SK-N-SH cells. xlOO.
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Figure 3.4.10 Reactivity of anti-pan keratin Ab. with HL60 cells A. before and B. after treatment with 
10/xM BrdU. No keratin was detected in either case. xlOO.
An apparent increase in expression of C. ker.8, D. ker.17 and E. ker 18 was detected in A549 cells 
which had been exposed to 5/iM BrdU compared with F. untreated A549 cells. xlOO.
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3.4.2 Retinoic Acid
Vitamin A and its analogues, the retinoid family, have been shown to modulate 
epithelial cell differentiation both in  v iv o  and in  v i t r o .  These agents inhibit squamous 
cell differentiation and squamous metaplasia can result from vitamin A deficiency. 
Retinoids interact with nuclear retinoid receptors but as yet, their mechanism of action 
on differentiation processes is not understood. The effect of all-trans retinoic acid (RA) 
on the interconversion of the clones and on their marker expression was examined.
3.4.2.1 Morphological effects on DLKP and clones
DLKP and the clones were grown in 6-well plates in the presence of 10/xM and 5 0 /jlM  
RA. The medium was replaced every 2-3 days and after 14 days exposure, the cells 
were viewed under the microscope. The observations made are summarised in Table 
3.4.1.
Only slight differences between control cells and 10/iM RA-treated cells were apparent. 
There were approximately 10% fewer cells in the treated wells. These cells were 
growing in colonies which were slightly smaller than control colonies. The cells in these 
R.A.-treated colonies were not as tightly packed as control cells and the cells appeared 
separated from each other. The morphologies of each of the DLKP clones were 
apparently unchanged and no interconversion was observed. Very few cells remained 
in the 50/iM RA-treated wells ( <  5 % controls). Some colonies of cells were present and 
morphologically the cells resembled their normal, untreated counterparts. No giant or 
stretched cells similar to BrdU-treated cells were seen.
3.4.2.2 Determination of marker expression
DLKP, DLKP-I, -M and -SQ were treated with RA and then analysed for alterations 
in marker expression.
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3.4.2.2.1 Keratin
The DLKP lines were grown in 20/xM RA for 7 days and then analysed for keratin 
expression.
All cells reacted positively with the anti-pan cytokeratin Ab (Figure 3.4.11). More cell 
survival was seen in these RA-treated cells compared with BrdU-treated cells. In 
addition, the cells were growing in colonies and were apparently normal in size. Keratin 
reactivity appeared to be present in every cell.
3 .4 .2 .2 .2  N eurofilam ents
Cells were exposed to 10^M RA for 7 days and then analysed for neurofilament 
expression.
Neurofilament reactivity was seen in all cells of each DLKP line (Figure 3.4.5).
3 .4 .2 .2 .3  T ransg lu tam inase
Cells treated with 20pM RA were examined for expression of transglutaminase.
No transglutaminase was detected in any of the lines (Figure 3.4.6).
3 .4 .2 .2 .4  Desm oplakin
Expression of desmoplakin was analysed in cells grown in 10/iM RA for 7 days.
No desmoplakin reactivity was detected (Figure 3.4.7).
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Figure 3.4.11 Detection of induction of keratin expression using anti-pan keratin Ab. in A. DLKP,
B. DLKP-I, C. DLKP-M and D. DLKP-SQ cells which had been exposed to 20/xM RA. xlOO,
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3.5 COMPARISON OF GROWTH OF DLKP AND DLKP-A
DLKP-A is a MDR variant of DLKP which was selected in increasing concentrations 
of the chemotherapeutic drug adriamycin and is several-fold more resistant than DLKP 
to a range of toxic compounds (see Table 3.5.1). Biological differences between DLKP 
and DLKP-A have previously been detected.For example, DLKP-A expresses high 
levels of P-glycoprotein, a transmembrane pump, which is probably one of the 
mechanisms of its resistance. This protein is expressed at extremely low levels in DLKP 
and is often indetectable, even by RT-PCR analysis (Lorraine O’Driscoll, PhD thesis).
The growth rates and responses to growth factors of DLKP and DLKP-A were 
compared to determine if the aquisition of the MDR phenotype had altered the growth 
characteristics of DLKP-A w.r.t. DLKP ie . was development of the MDR phenotype 
accompanied by enhanced or depleted growth capabilities, or neither.
Drug DLKP-A 
(fold w .r.t. DLKP)
Adriamycin 322.2
Vincristine 79.5
VP 16 36.2
Table 3.5.1 Fold resistances of DLKP-A w.r.t. DLKP to several chemotherapeutic 
agents. From Clynes e t a l . , C y to te c h n o lo g y  10:75-89, 1992.
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3.5.1 Growth Responses to Serum
The rate of the growth of DLKP and DLKP-A in different serum concentrations over 
9-10 days was examined.
No significant difference in growth rates between the 2 lines was apparent up to 7 days 
in culture. After 7 days however, the rate of growth of DLKP-A appeared to decrease 
relative to that of DLKP (Figure 3.5.1).
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Figure 3.5 .1  Proliferation o f DLKP and DLKP-A cells in monolayer culture in the presence o f  0%, 5 % 
and 10% serum (as indicated in parentheses), using CVDE end-point.
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3.5.2 Responses to Growth Factors
The effects of 6 growth factors (IL-1, IL-6, TGF/3, EGF, PDGF-A and PDGF-B) on 
the growth of DLKP and DLKP-A cells were determined. 2 end-points were employed; 
(i) crystal violet dye elution after 7 days in culture (see Section 2.9.2) and (ii) 3H- 
thymidine incorporation after 24 hr in culture (see Section 2.9.7).
3 .5 .2 .1  C ry sta l violet end-po in t
The effect of the above 6 growth factors on the growth of DLKP and DLKP-A after 7 
days in culture was determined. Assay to assay variation in the extent of responses of 
both lines was common but the response itself ie .  stimulatory, inhibitory or neither, was 
reasonably constant. Assays were carried out in 1% background serum because 
negligible growth occurred in the absence of serum. The concentrations of growth 
factors used were within the biologically active ranges for each growth factor. The 
results presented are the mean results from at least 3 separate experiments, therefore 
error bars are often large. Each individual experiment also consisted of 8 replicates. 
Growth was determined by CVDE assay as outlined in Section 2.9.2. The results are 
expressed as percentage growth over control where the control is medium without 
growth factor.
3 .5 .2 .1 .1  PD G F-A
PDGF-A appeared to have a slight stimulatory effect on the growth of DLKP-A cells 
over the range of concentrations examined (Figure 3.5.2). Maximum stimulation in the 
region of 130% of control was seen at concentrations of l-25ng/ml PDGF-A. A 
decrease in stimulation was seen at 50ng/ml. A lesser degree of stimulation was seen 
for DLKP with a maximum effect at lower concentrations of PDGF-A, but large error 
bars are also noted here.
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3.5.2.1.2 PDGF-B
PDGF-B also appeared to stimulate the growth of DLKP-A up to approximately 130% 
of control (Figure 3.5.3). Again, little effect was seen for DLKP at the concentrations 
of PDGF-B assayed.
3 .5 .2 .1 .3  TGF/3
TGF/3 had a small stimulatory effect of up to 115% of control on the growth of DLKP- 
A (Figure 3.5.4). In contrast, this growth factor had an inhibitory effect on DLKP. 
Error bars are large making an accurate assessment of the extent of inhibition difficult. 
Nonetheless, inhibition of growth was seen at each concentration of growth factor 
examined, with a maximum effect of close to 65% growth of control ie . 35% 
inhibition.
3 .5 .2 .1 .4  E G F
EGF was also stimulatory to DLKP-A cells to about 140% of controls (Figure 3.5.5). 
Again, the extent of stimulation varied between assays resulting in large standard 
deviations, but the overall effect was stimulation at concentrations from l-20ng/ml. 
EGF appeared to have no real effect on the growth of DLKP cells.
3 .5 .2 .1 .5  EL-1
IL-1 stimulated the growth of DLKP-A cells up to approximately 125% of controls 
(Figure 3.5.6). Again, no effect was seen with DLKP cells, except inhibition to 
approximately 80% of controls at 20ng/ml IL-1 which was the highest concentration 
examined.
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3.5.2.1.6 IL-6
IL-6 had a slight stimulatory effect on DLKP-A growth, up to approximately 125 % of 
controls, again with large standard deviations (Figure 3.5.7). As was the case with most 
of the other growth factors, no effect was observed with the DLKP cells, except at 
75U/ml where stimulation up to 120% of controls was seen.
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Figure 3 .5 .2  Effect of PDGF-A on the growth o f DLKP and DLKP-A cells using CVDE end-point.
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Figure 3 .5 .3  Effect of PDGF-B on the growth o f DLKP and DLKP-A cells using CVDE end-point.
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Figure 3 .5 .4  Effect o f  TGF/S on the growth o f DLKP and DLKP-A cells using CVDE endpoint.
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figure 3 .5 .5  Effect o f  EGF on the growth o f DLKP and DLKP-A cells using CVDE end-point.
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Figure 3 .5 .6  Effect o f IL-1 on the growth o f DLKP and DLKP-A cells using CVDE end-point.
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Figure 3 .5 .7  Effect of IL-6 on the growth o f DLKP and DLKP-A cells using CVDE end-point.
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3.5.2.2 3H-Thymidine incorporation
The incorporation of exogenous radio-labelled thymidine (Td) into the DNA of 
replicating cells, and so indicating DNA synthesis, was used as an alternative 
measurement of cell proliferation. As outlined in Section 2.9.7, cells were serum- 
starved for 24 hr prior to addition of growth factor in order to decrease cells 
proliferation and thus DNA synthesis. Growth factors were then added to the cells in 
serum-free medium and 4hrs later, 3H-thymidine C’H-Td) was added. Any stimulatory 
or inhibitory effects of the growth factors on the cells should be represented by an 
increase or a decrease in radio-labelled Td present in the cells. This was determined by 
liquid scintillation counting. As with the crystal violet end-point determinations (Section
3.3.2.1), results are presented as the mean results of at least 3 separate experiments, 
and each experiment contained 8 replicates.
As was the case with the crystal violet end-point assays, variation was seen between 
assays in the size of responses, but not in actual responses ie .  stimulatory, inhibitory 
or neither. It was noted during the course of these experiments that ^ -T d  incorporation 
by positive control cells ie . in presence of 5 - 10% serum, was usually less than 200% 
and never more than 300% that incorporated by negative control cells, ie .  in presence 
of 0% serum. Therefore, the ‘window’ of stimulation produced by individual growth 
factors was also likely to be relatively narrow and would not be expected to be greater 
than that produced by whole serum.
3 .5 .2 .2 .1  PDG F-A
PDGF-A caused an increase in DNA synthesis in DLKP cells, with increased synthesis 
occurring with increasing concentrations of PDGF-A from l-50ng/ml (Figure 3.5.8). 
At 50ng/ml, a maximum incorporation of 3H-Td of 180% of control was seen. In 
contrast, PDGF-A had no effect on DNA synthesis in DLKP-A cells at the same 
concentrations.
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3.5.2.2.2 PDGF-B
DNA synthesis in DLKP cells was also stimulated to 160% of controls by PDGF-B 
(Figure 3.5.9). Again, increased incorporation of 3H-Td was found with increasing 
concentrations of PDGF-B up to 50ng/ml where levels began to decrease. No 
stimulation of DNA synthesis was seen with DLKP-A, and indeed, slight inhibition 
seemed to be occurring.
3 .5 .2 .2 .3  T G F 0
TGF/3 was found to increase DNA synthesis in DLKP cells up to 150% of control 
values, in the range of concentrations assayed (Figure 3.5.10). DNA synthesis in 
DLKP-A was reduced in response to TGF/3. Reduction to 80% of controls was seen in 
these cells.
3 .5 .2 .2 .4  E G F
The response of the cells to EGF varied in this assay (Figure 3.5.11). DLKP seemed 
to be stimulated by lower concentrations of EGF (0.1-5ng/ml) where 3H-Td 
incorporation up to 140% of controls was found. The response of DLKP-A cells was 
erratic with inhibition of DNA synthesis occurring at lng/ml and stimulation at 
20ng/ml.
3 .5 .2 .2 .6  IL -1
3h-Td incorporation in DLKP and DLKP-A cells varied from assay to assay (Figure
3.5.12). An increase in DNA synthesis in DLKP was found across the range of IL-1 
concentrations examined, but as with all of the growth factor assays, the magnitude of 
the response varied, reaching a maximum of 160% of controls at 5ng/ml. The response 
of DLKP-A cells also varied with no real increase in 3H-Td incorporation occurring at 
lower concentrations and up to 150% occurring at 20ng/ml.
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Increased DNA synthesis in DLKP cells occurred in response to IL-6, particularly at 
high concentrations where incorporation of up to 150% of controls was found (Figure
3.5.13). Again, slight inhibition of DNA synthesis was apparent in DLKP-A cells at 
50U/ml IL-6.
3.S.2.2.6 IL-6
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Figure 3 .5 .8  Effect o f PDGF-A on ^ -T d  incorporation in DLKP and DLKP-A cells.
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Figure 3 .5 .9  Effect o f PDGF-B on ^ -T d  incorpo ration in DLKP and DLKP-A cells.
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Figure 3.5 .10 Effect o f  TGF/3 on 3H-Td incorporation in DLKP and DLKP-A cells.
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Figure 3.5.11 Effect o f  EGF on 3H-Td incorporation in DLKP and DLKP-A cells.
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Figure 3.5.12 Effect o f  IL-1 on 3H-Td incorporation in DLKP and DLKP-A cells.
175 DLKPDLKP-A
150
P<W 
►O
z
2  125 HH
Pi O
O *  100
SUH 
P < £
OO 
u u 75
QH
W
«*>
50
25 -
i i  i i i ~  
0 25 50 75 100 125
CONC.[U/ML]
Figure 3.5.13 Effect o f  IL-6 on ^ -T d  incorporation in DLKP and DLKP-A cells.
G ro w th
fac to r
D L K P D LK P-A
PD G F-A + / 0 +
PD G F-B 0 +
TGF/3 0 / - +
E G F 0 +  +
IL-1 + / 0 +
IL -6 + / 0 +
Table 3 .5 .2  Summary table o f  growth responses o f DLKP and DLKP-A to growth factors as 
determined in the crystal violet dye elution (CVDE) assay.
+  +  +  is stimulation >175%  of control 
+  +  is stimulation -150-175%  o f control 
+  is stimulation —100-150% of control 
0 is no effect 
- is inhibition
Growth
factor
DLKP DLKP-A
PDGF-A +  +  + 0
PDGF-B +  + 0 / -
TGF0 +  + -
EGF + +
IL-1 +  + +  [
IL-6 + 0 / -  1
Table 3 .5 .3  Summary table o f  DNA synthesis responses o f DLKP and DLKP-A to growth factors 
as determined by ’H-thymidine incorporation assay. ( +  + + ,  + +  etc. as for Table 3 .5 .1 .).
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3.5.3 Bromodeoxyuridine Toxicity Assay
The responses of DLKP-A cells to growth factors determined after 7 days in culture 
(CVDE end-point) indicated that the growth of these cells was capable of being 
stimulated by the growth factors examined but the 3H-Td incorporation assays indicated 
otherwise. It was possible that the DLKP-A cells were responding to the growth factors 
and synthesising DNA but the cells were not taking up the exogenous Td to do so. 
During the biosynthesis of DNA precursors, cells can utilise a d e  n o v o  route for 
synthesis of thymidylate (TMP) from deoxyuridylate (dUMP) via thymidylate synthetase 
(TS) or a salvage route from thymine and thymidine via thymidine kinase (TK) 
(Komberg, 1974). Decreased levels of TK can prevent cells using the salvage pathway, 
thus decreasing the incorporation of exogenous Td. It was possible that DLKP-A cells 
lacked, or expressed reduced levels of, TK and so failed to incorporate 3H-Td in the 
growth factor assays.
In order to examine the possibility that decreased levels of TK had caused the DLKP-A 
cells to incorporate very little exogenous 3H-Td compared with DLKP, a BrdU toxicity 
assay was carried out. If DLKP-A cells contained lower levels of of TK than DLKP, 
BrdU may be less toxic to DLKP-A than DLKP as less BrdU would be incorporated 
via the salvage pathway. Such a decrease in TK activity could explain why growth was 
seen in response to growth factors in the crystal violet assays (Section 3.5.2.1) while 
no incorporation of exogenous Td was detected in the 3H-Td assays (Section 3.5.2.2).
As can be seen in Table 3.5.3, less than a 2-fold difference in IG*, values between 
DLKP and DLKP-A was found in the BrdU toxicity assay. This would suggest that 
there was little difference in TS activity between the 2 cell lines and so these results do 
not explain the failure of DLKP-A cells to respond to growth factors in the 3H-Td
assays.
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Cell line BrdU l e »  
G*M)
DLKP 2.6
DLKP-A 1.7
Table 3.5.3 Sensitivity of DLKP and DLKP-A to BrdU toxicity.
215
3.6 M D R  1 RIBOZYME TRANSFECTIONS
The development of cross-resistance to a number of structurally and functionally 
unrelated drugs, a phenomenon termed multiple drug resistance (MDR), is a major 
problem in cancer chemotherapy, as discussed in Section 1.7. Overexpression of P- 
glycoprotein (pgp, p i70), a drug efflux pump, is one mechanism by which MDR 
occurs. The P-glycoprotein drug efflux pump is encoded by a gene called M D R  1. 
Reduction of cellular levels of P-glycoprotein has become one of the routes explored 
in the quest for reversal of MDR. Inhibition of protein expression can be targetted at 
gene, mRNA or protein level. Ribozymes are catalytic RNA molecules which can be 
used as tool to target specific mRNA sequences. mRNAs may thus be cleaved at critical 
sites, rendering the resulting fragments non-functional. No functional protein molecules 
are then created.
DLKP-A is an MDR variant of the DLKP cell line and expresses high levels of P- 
glycoprotein. DLKP expresses little to no P-glycoprotein. During a study of 
heterogenicity in sub-populations of MDR cell lines, a number of clones were 
established from the DLKP-A cell line (Dr.Mary Heenan, PhD thesis). These clones 
display varying cross-resistance profiles to MDR drugs and also express varying levels 
of P-glycoprotein. A study was carried out here on the effect on toxicity profiles of 
transfection of an M D R  1 mRNA-specific ribozyme (Rz) into clonal populations of the 
sensitive DLKP cells and the resistant DLKP-A cells, DLKP-I and DLKP-A-2B 
respectively.
A plasmid containing a specific M D R  1 Rz gene was transfected into DLKP-I and 
DLKP-A-2B cells using a calcium phosphate and glycerol shock technique as described 
in Section 2.19. The plasmid also contained a gene encoding geneticin resistance, 
allowing for selection of plasmid-containing cells by growth in geneticin-containing 
medium.
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3.6.1 Transfection and Selection of Ribozyme-containing Clones
DLKP-I and DLKP-A-2B cells were transfected with plasmids containing the M D R  1 
Rz and geneticin resistance genes (plasmids stocks amplified by Dr.Carmel Daly). 2 
days after the transfection, selection in geneticin-containing medium (400/ig/ml) 
commenced. 11 days after this, the level of geneticin was increased to 600/ig/ml. 
Untransfected cells of both lines were concurrently grown in geneticin-containing 
medium to serve as indicators for when any untransfected cells would be dead. 17 days 
after the transfection, these cells were dead. It was therefore assumed that any cells 
remaining on transfected plates contained the Rz.
The selected cells were then cloned out in a limiting dilution assay ie .  seeded at a 
density of 1 cell/2 wells of a 96-well plate (see Section 2.7.1), and cultured routinely. 
The cloning resulted in 7 DLKP-I transfectants (1A9, 1B10, 1C9, 1G8, 2D4, 2F7 and 
2G3) and 2 DLKP-A-2B transfectants (1A5 and 1C7).
3.6.2 Detection of Ribozyme DNA by PCR
The DLKP-I and DLKP-A-2B transfectants were resistant to geneticin so it could be 
assumed that the cells contained the plasmid. However, to prove that the plasmid was 
indeed present in the cells, DNA PCR was carried out. Primers specific for the plasmid 
were used to amplify a product of 221 base pairs. PCR was carried out on crude DNA 
extracted from each of the transfectants plus untransfected DLKP-I and DLKP-A-2b 
controls, as outlined in Sections 2.20 and 2.22.
The Rz was found to be present in all of the transfected cells and absent in the 
untransfected controls (Figure 3.6.1).
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Figure 3.6.1 PCR products resulting from amplification of DNA extracted from DLKP-I and DLKP-A- 
2B ribozyme transfectants and their respective untransfected, parental lines. The primers selected for 
ribozyme DNA amplification produced a band of 221 base pairs as indicated. Ph/3 is plasmid which did 
not contain ribozyme DNA and therefore produced a smaller PCR product. Rz refers to plasmid 
containing ribozyme DNA which was amplified as a positive control.
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3.6.3 Determination of Ribozyme Expression by RT-PCR
It was necessary to shown not only that the plasmid was present in the cells, but also 
that it had been incorporated into the hosts genome and was being properly transcribed.
RT-PCR was carried out on RNA extracted from the transfected cells and from control 
untransfected DLKP-I and DLKP-A-2B cells, as described in Sections 2.21 and 2.23. 
Primers specific for a sequence in the plasmid and a sequence in the Rz were used to 
amplify a product of 118 base pairs.
The appropriate Rz RNA band was demonstrated in all of the transfected lines 
indicating transcription of the Rz gene (Figure 3.6.2). No bands were seen in the 
DLKP-I and DLKP-A-2B untransfected controls.
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Figure 3.6.2 RT-PCR products resulting from amplification of ribozyme RNA extracted from DLKP-I 
and DLKP-A-2B ribozyme transfectants and their respective untransfected, parental lines. The primers 
selected for ribozyme RNA amplification produced a band of 118 base pairs as indicated.
3.6.4 Effect of Ribozyme on M D R  1 Gene Expression
The purpose of the Rz transfections was to target and reduce the levels of M D R  1 RNA 
in MDR cells, thus reducing the amount of protein expressed and reversing the drug 
resistance of the cells. To examine the effect of the Rz on M D R  1 RNA levels in 
transfected cells, RT-PCR was carried out on RNA extracts using primers specific for 
M D R  1. A product of 157 base pairs is produced by these primers.
DLKP-I untransfected control cells were found to contain no detectable M D R  1 RNA 
(Figure 3.6.3). The DLKP-I transfectants also produced no M D R  1 band.
Untransfected DLKP-A-2B cells were shown to express M D R  1 RNA as a band of the 
appropriate size was present. The DLKP-A-2B 1A5 transfectant had slightly lower 
levels of M D R  1 RNA as shown by the presence of a smaller band than that of DLKP- 
A-2B. The 1C7 transfectant contained no detectable levels of M D R  1 RNA as no band 
was produced by these cells.
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Figure 3.6.3 RT-PCR products resulting from analysis of MDR 1 RNA extracted from DLKP-I and 
DLKP-A-2B ribozyme transfectants and their respective untransfected, parental lines. The primers 
selected for MDR 1 analysis produced a band of 157 base pairs. This band was absent in DLKP-I and 
its transfectants and was present in DLKP-A-2B but was reduced in DLKP-A-2B 1A5 and absent from 
DLKP-A-2B 1C7 transfectants. /3-Actin RNA was amplified as an internal control using specific primers 
to amplify a band of 383 base pairs.
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3.6.5 DLKP-I Transfectants Toxicity Assays
Toxicity tests were carried out on the transfected cells to determine the ultimate effect 
of the Rz on the cells i . e .  reversal of drug resistance.
The toxicity profiles of 3 MDR drugs - adriamycin, vincristine and VP16 - for DLKP-I 
and its transfectants were determined.
These cells express no detectable M D R  1 (Section 3.6.4) and so the IC» values, shown 
in Table 3.6.1, were found to be relatively low, as expected. There was no more than 
a 2-fold difference in ICJ0 values between the untransfected DLKP-I cells and any of 
the transfected cells. Results shown are mean values from 3 separate experiments.
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3.6.6 DLKP-A-2B Transfectants Toxicity Assays
The toxic effects of adriamycin, vincristine and VP16 on DLKP-A-2B cells and their 
transfectants were determined to establish if the reduction in M D R  1 levels found in the 
RT-PCR analysis (Section 3.6.4) correlated with a decrease in resistance to MDR 
drugs.
The IQo values for DLKP-A-2B, 1A5 and 1C7 are shown in Table 3.6.2 and 3.6.3 and 
are the mean values from at least 3 experiments. Transfectant 1A5 which showed a 
slight reduction in M D R  1 RNA expression by RT-PCR, showed no increase in 
sensitivity to the MDR drugs compared with DLKP-A-2B. In fact, these cells were 
more resistant to the 3 drugs. In contrast, transfectant 1C7 showed increased sensitivity 
to each drug. The greatest effect was seen for vincristine with an 26-fold increase in 
sensitivity compared with DLKP-A-2B. A 4.7-fold increase and a 1.3-fold increase was 
seen for adriamycin and VP 16 respectively.
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Cell line Adriamycin 
(ICjo, ng/ml)
Vincristine 
(ICso, ng/ml)
VP 16 
(ICjo, ng/ml)
DLKP-I 5.33 ±  0.47 
(1.00)
0.275 ± 0.100 
(1.00)
51.00 ±  2.94 ! 
(1.00)
1B10 4.08 ±  0.31 
(1.31)
0.275 ±  0.025 
(1.00)
31.67 ±  4.71 
(1.61)
1C9 9.42 ±  2.20 
(0.57)
0.615 ±  0.015 
(0.05)
84.00 ±  17.28 
(0.61)
1G8 9.42 ±  1.42 
(0.57)
0.390 ±  0.065 
(0.71)
78.00 ±  18.40 
(0.65)
2D4 6.33 ±  1.12 
(0.84)
0.462 ±  0.137 
(0.59)
51.67 ±  10.27 
(0.99)
2G3 3.58 ±  0.32 
(1.49)
0.275 ±  0.025 
(1.00)
29.00 ±  2.94 
(1.76)
Table 3.6.1 Sensitivity o f  DLKP-I transfectants to MDR drugs. Results shown are mean results from 
3 experiments. Values in parentheses refer to  fold increase in sensitivity w .r.t. DLKP-I cells.
Cell line Adriamycin
(IC^, n g / m l )
Vincristine 
(ICjo, ^g/ml)
VP16
(ICjo, Mg/ml)
DLKP-A-2B 0.160 ±  0.08 
(1.00)
0.049 ±  0.005 
(1.00)
0.43 ±  0.11 
(1.00)
1A5 0.330 ±  0.05 
(0.49)
0.111 ±  0.027 
(0.48)
0.58 ±  0.16 
(0.74)
1C7 0.034 ±  0.015 
(4.71)
0.0019 ±  0.0012 
(25.79)
0.32 ±  0.019 
(1.34)
DLKP-A* — 2.5 -1 .0 0 0 -1 .0 0 0
DLKP* -0 .0 1 0 -0.00075 -0 .0 7 5
Table 3.6.2 Sensitivity o f  DLKP-A-2B transfectants to MDR drugs. Results shown are mean values 
from at least 3 experiments. Values in parentheses refer to fold increased sensitivity w .r.t. DLKP-A-2B
cells.
* Previously determined by D r.A lice Redmond and shown here to allow comparison with ribozyme 
transfectants.
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Assay No. Adriamycin 
(ICjo, Mg/ml)
Vincristine 
(ICjo, /i/ml)
VP16
(1 ^ 50) /t/ml)
DLKP-A-2B
n 0.280 0.055 0.59
n 0.100 0.050 0.37
n 0.100 0.043 0.34
1A5
n 0.340 0.072 0.54
n 0.380 0.130 0.41
#3 0.260 0.130 0.79
1C7
#1 0.026 0.0021 0.60
n 0.055 0.0006 0.26
#3 0.021 0.0012 0.18
u - 0.0038 0.25
Table 3.6.3 Results from  individual toxicity assays (assay #1, #2 etc.) showing IC^s determined for 
each cell line in the presence o f MDR drugs.
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DISCUSSION
population again. It is therefore possible that the ratio of clonal morphologies present 
in the parental DLKP population (which is relatively consistent itself) is the steady-state 
ratio for these particular cells and that clones isolated from DLKP will always 
ultimately recreate the mixed DLKP population.
No alteration in the treatment of the clones was knowingly made which would cause 
them to interconvert. Media, serum, culturing techniques e tc . were all standard and 
this, when considered with the fact that the interconversion occurred consistently after 
20-25 passages in culture, suggests that the interconversion was determined within the 
cells and not a result of a sudden change in external factors.
Interconversion was not observed between DLKP-SQ and DLKP-M, while both of these 
morphologies appeared relatively quickly in cultures of DLKP-I, the latter being the 
most morphologically unstable clone. Colonies of DLKP-I cells also appeared in DLKP- 
SQ and -M cultures. This seems to suggest that DLKP-I is behaving as a stem cell-like 
population which can give rise to DLKP-SQ and -M cells (see Figure 4.1.1). These 
cells can also revert to DLKP-I cells to give rise to the parental DLKP population 
again. Such phenotypic reversion and interconversion has been observed in tumour cells 
in  v iv o  and in  v i t r o  (reviewed in Nicolson, 1987).
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DLKP-SQ DLKP-M
DLKP-1
Figure 4.1.1 Proposed m odel for interconversion o f  DKLP clones. DLKP- 
SQ  and DLK P-M  cells appear to interconvert with DLKP-1 cells, but no 
interconversion has been observed between DLKP-SQ  and DLKP-M cells.
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4.2 CHROMOSOMAL ANALYSIS OF DLKP CLONES
The karyotype of DLKP, passage 5, had previously been determined (Law e t a l . , 1992) 
and was found to consist of a hyperdiploid subpopulation (65% of cells) and a 
hypertetraploid subpopulation (35% of cells). In the present study, the chromosome 
distributions of DLKP (passage 22), DLKP-I (passage 26), DLKP-M (passage 32) and 
DLKP-SQ (passage 29) were examined.
40% of DLKP cells were found to be hypertetraploid with 100-110 chromosomes and 
approximately 12 and 15% of cells had 30-39 and 90-99 chromosomes respectively. The 
remaining cells contained anywhere between 40 to 130 chromosomes. 36% of DLKP-I 
cells were found to contain 90-99 chromosomes ( i .e .  near tetraploid), with chromosome 
numbers from 40 to 110 being distributed almost equally throughout the remaining 
population. DLKP-M was found to be the most homogenous population with respect to 
chromosome number with 60% of the population having 50-59 (near diploid) 
chromosomes. 15% of the population had 100-109 while 12% had 40-49 chromosomes. 
DLKP-SQ exhibited 3 large chromosomal populations with 36%, 27% and 16% of the 
cells having 90-99, 100-110 and 80-89 chromosomes respectively. No DLKP-SQ cells 
examined contained less than 60 chromosomes.
The chromosomal distributions of the 3 clones reflected their morphological distribution 
in DLKP as the DLKP-M phenotype and karyotype are not substantially represented in 
the DLKP population, while DLKP-SQ and -I account for the majority of DLKP cells 
in terms of both morphology and chromosome number.
Thus, the morphological diversity of the clones was reflected in their respective 
chromosome numbers and indeed may be explained by them. The karyotypic evolution 
of several cultured undifferentiated large cell lung carcinoma lung cell lines has been 
found to follow an orderly and predictable pattern. Burholt e t a l.  (1989a and 1989b) 
reported that while one such cell line exhibited extensive heterogeneity with respect to 
both numerical and structural chromosomal abnormalities, their results suggested that 
the genetic evolution of this cell line followed an orderly and predictable sequence of
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events. The sequence consisted of a relatively rapid doubling of chromosome number, 
creating a tetraploid population, followed by a gradual loss of chromosomes and 
accounted for most of the observed variability in chromosome numbers per cell over 
time. This could explain the different chromosome distribution found in this study using 
DLKP passage 22 cells compared with that found by Law e t a l .  (1992) using DLKP 
passage 5 cells. In addition, the 3 DLKP clones, with their distinct chromosomal 
profiles, may represent different stages of a similar process where a continuous cycle 
of chromosome doubling and subsequent chromosome loss is occurring. The changes 
in balance of gene expression accompanying the fluctuating chromosome populations 
could result in the diverse yet interconverting morphologies observed in the clones. 
Determination of chromosome distributions in the clones at various passages over the 
time in which interconversion is seen to take place could reveal if such changes are 
occurring in DLKP cells and thus give an insight into possible mechanisms by which 
diversity among phenotypes of tumour subpopulations can occur.
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4.3 GROWTH CONTROL IN DLKP CLONES
During normal development and tissue maintenance, a balance exists between cell 
proliferation and differentiation. As outlined in Section 1.6, a limited number of 
multipotent stem cells are laid down during embryogenesis. These stem cells give rise 
to a much larger population of more developmentally restricted progenitor cells which 
become committed to differentiation. The stem cells are also capable of self-renewal to 
replace those which differentiate. Uncoupling of these coordinated processes of 
proliferation and differentiation leads to tumourigenesis.
The proliferation potential of a cell decreases with increasing differentiation (see Figure
1.7.1) and the most aggressive tumour cells are poorly differentiated and highly 
proliferative (Warren e t a l . , 1990). The growth properties and potentials of the isolated 
DLKP clones were examined to determine what roles individual tumour subpopulations 
may play in the progression of malignant disease i .e . did all DLKP subpopulations have 
comparable proliferative capabilities under various conditions or not? If not, did this 
correlate with increased differentiation and could poorer-performing clones adapt with 
time to assay conditions and increase proliferation and if so, how did they adapt? Also 
of interest was how the proliferative capabilities of the isolated clones compared with 
those of the parental DLKP cells.
4.3.1 Growth Assays
When assayed in monolayer culture in the presence of 0%, 1% and 5% serum, the 
parental DLKP cells proliferated faster than any of the clones (Section 3.1.3.1). DLKP- 
I were found to be the fastest growers of the clones in this assay, with DLKP-M and - 
SQ proliferating relatively poorly over the first 4 - 5  days. DLKP-M and -SQ appeared 
to be density-dependent as their growth increased rapidly after 5 days of the 8 day 
monolayer assay.
The growth of the cells in serum-free conditions reflected the monolayer assay results 
(Section 3.1.3.2). The sole mitogen present in the defined serum-free medium was
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insulin and only DLKP and DLKP-I were found to be capable of proliferation in this 
medium. While all 4 lines attached readily to the flask surface, only DLKP and DLKP-I 
formed colonies (see Figure 3.1.5). This suggested either that these 2 cell lines could 
proliferate in the presence of insulin alone, or, what is more likely, that additional 
growth factors are being produced by these populations, allowing them to expand more 
aggressively than the other clones and relatively independently of their environment.
The colonies formed by DLKP-I in SFM were morphologically similar to those formed 
by this cell line in serum-supplemented medium. While approximately 75 % of DLKP 
cells appeared to proliferate without forming colonies, remaining rounded and loosely 
attached, the remaining 25% also formed DLKP-I-like colonies. Presumably, these 
represented the DLKP-I-like cells present in the mixed parental population.
These results and observations indicate that, of the 3 clonal populations, DLKP-I was 
the most independent of exogenous growth and attachment/adherence signals because 
these cells were capable of forming characteristic colonies in the presence of either 
serum or insulin alone. This also would explain why the growth rate of DLKP-I in 
defined SFM usually exceeded that of DLKP, as in the mixed DLKP population, these 
self-sufficient growers account for only approximately 30% of the total population.
With regard to DLKP-M and -SQ, while all cells in each line appeared to attach 
successfully in this SFM, only a small percentage were seen to divide and when 
harvested, cell counts were always below those of initial seeding densities. In the 
monolayer assays (Section 3.1.3.1), the growth of these 2 lines appeared to be density 
dependent in the presence of 5%, 1% and 0% serum, with little proliferation occurring 
at the early stages of the culture, i .e .  low cell numbers, followed by a late surge. These 
assays were carried out in 96-well plates with cells seeded initially in serum- 
supplemented medium at lxlO3 cells/well and growth was determined by CVDE assay. 
Thus, cells were not harvested and re-seeded at any stage. In contrast, in the SFM 
assays, cells were seeded at 2.5x10s cells/25cm2 flask, which is a similar density to the 
96-well plate assay, but cells were plated in SFM and so did not spread and were fed 
or harvested by trypsinisation every 6-7 days. This time span was adequate to observe 
proliferation in DLKP and DLKP-I and may have been too short to see growth in
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DLKP-M and -SQ. However, the assay succeeded in demonstrating important growth 
differences between the clones.
DLKP and DLKP-I cells which had been cultured in SFM were placed back into serum- 
supplemented medium to determine if their morphologies had altered. While no change 
was observed in cells which had been passaged 5 times in SFM, cells at passage 10 
appeared altered when plated in the presence of serum (Figure 3.1.6). DLKP cells had 
become more homogenous with >90% of cells being squamous-like in appearance, 
similar to the DLKP-SQ morphology. DLKP-I cells also appeared changed, being more 
heterogenous, with large numbers of squamous cells present (up to 30%).
Culture in serum-free medium thus seemed to influence the morphologies of these cell 
lines but the squamous-like cells which appeared are probably not identical to DLKP-SQ 
cells as the latter failed to proliferate in SFM. It would be interesting to compare the 
chromosome numbers of DLKP-SQ and the serum-free squamous cells to determine if 
they are similar. Increasing numbers of unattached and rounded cells had been observed 
in later passages of serum-free DLKP and DLKP-I cells and it was probably these 
which attached and became squamous-like when the serum-free cells were placed back 
into serum-containing medium. The emergence of a squamous cell phenotype in cell 
lines has been previously reported by Terasaki e t a l .  (1987) who demonstrated that 
delipidised serum-supplemented medium ( i .  e. retinoic acid deficient) induced squamous 
cell characteristics in a small cell lung cancer cell line. The changes were reversible 
upon addition of retinoic acid to the medium. The inhibition of squamous differentiation 
by retinoic acid is well established (Section 1.6) and so it is possible that the absence 
of this agent from the defined SFM used to culture DLKP and DLKP-I caused the cells 
to differentiate towards a squamous phenotype which was discernable only when the 
cells were able to attach in serum-supplemented medium. It is also possible that the lack 
of attachment factors in the SFM caused the cells to differentiate into a phenotype 
which no longer required such factors, hence the increased numbers of cells observed 
in suspension in later serum-free passages. In the presence of serum, these cells then 
attached and spread and were squamous in appearance.
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The ability to form colonies in soft agar is a characteristic of many malignant cells and 
is a measure of their clonogenic potential. The end-point in such assays is often based 
on colony number or colony diameter and varies widely from 50 cells (Hay e t a l . ,  
1991) to 120/mi (Bepler e t a l . ,  1987c) to 250/an (Tonita e t a l . ,  1992). When it was 
found that DLKP-I cells formed effectively no colonies in this assay (Section 3.1.3.3), 
a relatively low diameter width of 20/am (approximately 25-30 cells) was chosen to 
score colonies. This resulted in high CFEs for DLKP, DLKP-M and -SQ of 
approximately 38%, 27% and 13% respectively.
The inability of DLKP-I cells to form colonies in soft agar was unexpected in the light 
of their high growth rates in serum-supplemented and serum-free medium. The 
possibility that these cells had been adversely affected by the high temperatures during 
plating of the cells was discounted (Section 3.1.3.3 and Figure 3.1.7), leaving the 
surprising conclusion that these cells had a very low CFE compared with the 2 other 
clones and the parental DLKP cells. It is possible that the DLKP-I cells require 
attachment to a substratum for optimum proliferation and colony formation and so did 
not perform well in suspension in the soft agar. Classic SCLC cell lines generally have 
a lower cloning efficiency in soft agar than variant types (Kiefer e t a l . ,  1987 and 
Carney e t a l . , 1985) so it is possible that the DLKP-I cells express a phenotype closer 
to that of SCLC than DLKP-M and -SQ. Cell-cell attachment molecules also influence 
anchorage independent growth (Doyle e t a l . , 1990 and Carbone e t a l . , 1991) and the 
complement of attachment molecules and receptors expressed by DLKP-I may differ to 
those of the 2 other clones and may not facilitate colony formation in semi-solid agar.
The ability of the clones to grow in suspension in spinner flasks was inferior to that of 
DLKP (Section 3.1.3.5). The growth of the parental cells often exceeded that of any 
of the clones by over 100%. With some week-to-week variation, the DLKP-SQ clone 
proliferated best under these assay conditions. The rate of proliferation of each clone 
increased slightly most weeks, indicating adaptation to the conditions.
Observations of changes in cell morphology when re-seeded into normal tissue culture 
flasks again after 10 passages in spinners appeared to confirm an adaptive process. As 
was the case in the SFM medium assays, alteration towards a squamous morphology
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was evident in DLKP and DLKP-I after 10 passages in suspension. DLKP-SQ and 
DLKP-M appeared unchanged, both resembling their respective original morphologies. 
The time-frame over which the adaptation took place was similar to the serum-free 
assays where no change was apparent after 5 passages but were so after 10 passages. 
In addition, the enforced growth in suspension in spinner flasks resembles the situation 
in the serum-free medium assays where attachment factors would have been absent, 
save those, if any, produced by the cells themselves. Therefore, when anchorage- 
independent growth was either enforced (spinners) or induced (SFM), the resulting 
phenotype was squamous-like, suggesting that this was an adaptation to allow 3- 
dimensional growth in suspension. These interconversions support the theory that 
DLKP-I is a stem cell-like population which can give rise to the other clonal 
phenotypes. The DLKP-I cells may be basal-like cells which in  v iv o  would be attached 
to the basement membrane. These then could give rise to various daughter cell types 
including DLKP-M and -SQ, the latter of which forms the bulk of the 3-dimensional 
tumour (thus causing the biopsy to be diagnosed as ‘poorly differentiated squamous’). 
Possible roles of the DLKP-M cells are discussed later in Section 4.4.
It appears that the combined growth properties of the different DLKP clones span the 
range of growth conditions examined here - soft agar, suspension, serum free and 
monolayer. Thus, in  v iv o , these cells may readily adapt to changing environmental 
conditions and situations, conferring plasticity on the tumour as an entity and facilitating 
continuous growth.
In all growth assays except the defined serum-free medium assays, the parental DLKP 
cells proliferated faster than each of the clones. It would thus appear that the balance 
of phenotypes present in the DLKP population was the best for most growth conditions. 
This could explain why interconversion of the clones seemed to tend towards recreation 
of this mixed population. Adaptation of all lines apart from DLKP-M was evident in 
serum-free and spinner assays and it would be interesting to determine if continued 
culture of adapted cells in normal, serum-supplemented conditions would bring about 
a return to original clonal morphologies.
The responses of DLKP and the clones to a range of exogenous, purified growth factors
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were examined but no consistent effects were seen (Section 3.1.3.6). DLKP cells are 
stimulated by even trace amounts of serum (0.1%) so assays were carried out in the 
absence of serum to avoid masking any growth factor effects. However, no repeatable 
responses, stimulatory, inhibitory or no effect, were obtainable. When insulin was 
included with the growth factors to determine if the cells could be ‘primed’ or prepared 
for growth factor responses similar results were obtained. Therefore, no conclusions 
could be drawn regarding the exogenous growth factor requirements of the cells 
following these growth factor experiments.
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4.3.2 Autocrine Growth Regulation
The ability of DLKP and DLKP-I to proliferate successfully in 0 %  serum (Section
3.1.3.1) and in defined serum-free medium (Section 3.1.3.2) suggested that these cells 
were producing autocrine growth factors capable of stimulating their own growth. 
However, despite the initial apparent detection of DLKP autocrine activity (Section
3.1.4.1), no substantial autocrine effects, stimulatory or otherwise, were demonstrable. 
A wide range of assay conditions were examined but none were suitable to detect 
autocrine growth activity in either DLKP cells or any of the clones.
It is possible that the autocrine activity was not a soluble factor secreted into the 
medium, thus rendering the collection of CM futile. The putative factor(s) may have 
been transmitted v ia  mechanisms such as gap junctions or membrane-membrane contact, 
or may be an extracellular matrix protein which stimulated growth from the substratum 
(see Section 1.5).
If the factor(s) was a soluble, secreted molecule, it may have been extremely labile and 
as no CM was assayed on the day of its collection, activity may have been lost before 
it was assayed. A secreted factor may also exert its effect by accumulating locally and 
becoming concentrated around neighbouring cells, thus increasing the signal seen by 
these cells while overall levels of the factor remain low. This effect would also be lost 
during the collection and subsequent assaying of CM.
It may be necessary to utilise antisense or neutralising antibody ‘knock-out’ approaches 
to identify autocrine growth factors in DLKP cells. These would cover most of the 
aforementioned possibilities but knowing which molecules to target would be a problem. 
‘Transwell’ assay systems are another possibility. These consist of multi-well plates 
with mini, well-shaped inserts suspended in each well (see Section 2.14) and the culture 
of 2 cell monolayers in a single well allows 1 cell line to be used as indicator cells 
which respond to factors released by the other. This could solve the problem of the loss 
of activity during storage as a factor could act on the target cells as soon as it diffuses 
through the medium.
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4.4 EXTRACELLULAR MATRIX
The adherence properties of DLKP cells and the clones to a number of ECM proteins 
were found to differ from each other (Section 3.1.5). Of the 4 lines, DLKP-M attached 
most rapidly to plastic, fibronectin and collagen type IV. In the case of laminin, DLKP, 
DLKP-M and -SQ all attached at the same rate while DLKP-I attached more slowly. 
Interestingly, while the attachment of DLKP, DLKP-I and -SQ to fibronectin increased 
with time, DLKP-M cells appeared to detach from this substrate after an initial rapid 
rate of adherence. The DLKP-M cells have a mesenchymal-like appearance. They do 
not form colonies but grow in a scattered manner and have an elongated, irregular 
shape, with many neurite-like processes. When studied by time-lapse videomicroscopy 
(results not shown), DLKP-I and -SQ cells were found to be relatively immobile once 
attached to the substrate. DLKP-M cells however, were quite motile and though not 
travelling long distances, moved in a circular fashion about the substrate and often, cells 
were seen to move around each other and between other cells. The attachment 
properties of DLKP-M cells therefore appear to be quite complex and different to those 
of the 2 other clones.
As discussed in Section 1.5, the invading, migratory cells found at tumour invasion 
fronts often loose their epithelial morphology and appear more mesenchymal, becoming 
spindle-shaped and fibroblast-like. The down-regulation of epithelial cell-cell 
attachments and altering of normal cell-matrix interactions enables metastasising cells 
to migrate and invade the basement membrane. DLKP-M cells appear to possess many 
characteristics of metastasising cells including their appearance and their unusual 
attachment properties. The finding that these cells attached rapidly to fibronectin and 
then appear to detach possibly reflects their migratory nature which allows them to 
attach to and derive traction from a substrate but does not render them immobile.
The DLKP-M clone may therefore represent a metastatic-like subpopulation which is 
present at low levels in the parental DLKP population. The fact that a degree of 
interconversion is evident between DLKP-M and DLKP-I suggests that this metastatic 
phenotype is capable of evolving or devolving, depending on conditions. The DLKP-M
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clone proliferated relatively slowly in the monolayer and soft agar growth assays and 
not at all in defined serum-free conditions suggesting that clonal expansion is not the 
inherent function of these cells. The relative stability of morphology of this clone 
compared with DLKP-I and -SQ which interconvert more readily and the failure of 
growth in suspension in spinner flasks to affect the morphology of DLKP-M while those 
of DLKP-I and -SQ were altered, indicates that this may be a more specialised, 
differentiated phenotype which does not readily convert back to the DLKP-I 
morphology.
Invasion assays and the determination of expression of matrix-degrading enzymes by 
DLKP-M cells could support their status as metastatic cells. Unfortunately, DLKP and 
each of the clones failed to form tumours when injected subcutaneously into nude mice, 
therefore the metastatic ability of DLKP-M cells in  v iv o  is currently unknown. 
However, if the cells could be made to form such tumours e g . by injection directly into 
the lung, demonstration of metastasis formation by DLKP-M cells would be persuasive 
evidence that DLKP and its clones could serve as a good model for tumour progression, 
invasion and metastasis. In the interim however, quantification of the motility of DLKP- 
M cells by time-lapse videomicroscopy, further analysis of their ECM attachment 
capabilities and characterisation of their membrane adhesion molecules and receptors, 
in comparison with those of the non-motile DLKP-SQ and -I clones, could be useful in 
our understanding of tumour progression.
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4.5 SENSITIVITIES OF CLONES TO CHEMOTHERAPEUTIC DRUGS
A number of multidrug resistant variants of the DLKP cell line have been established 
for the investigation of drug resistance in tumour cells. These include DLKP-A, a 
variant which was selected in adriamycin and DLKP/VP-3 and DLKP/VP-8 (established 
by Dr.Mary Heenan) which were selected in VP-16. These variants are not only 
resistant to their selective agents but also to other, unrelated, chemotherapeutic drugs.
The sensitivities of the DLKP clones to 3 such drugs - adriamycin, vincristine and 
VP 16 - were determined and found to be similar to the sensitive parental DLKP cells 
(Section 3.1.6). This finding supports the theory that MDR is an acquired phenotype 
which occurs as a result of exposure to drugs, rather than the selection of an inherently 
resistant subpopulation. It is still possible however, that additional phenotypes are 
present in the DLKP population which are not represented by the 3 clones and which 
are highly multidrug resistant.
No significant differences were found in the sensitivities of the clones with each of the 
drugs examined. Thus, the different modes of action of the 3 drugs were equally 
effective on each of the clones suggesting that the topoisomerase II activities, RNA 
transcription, spindle formation e tc . which the drugs effect (see Section 1.7) are broadly 
similar in the clones, i .e .  if one or more of the drugs had a significantly different IC50 
value for one or other of the clones, it could indicate differences in some of these 
cellular processes as well as differences in drug resistance.
It had been anticipated that the slower growing clones, DLKP-M and -SQ might have 
slightly lower IC50 values than DLKP and DLKP-I because many of the effects of the 
MDR drugs occur during DNA replication. Therefore, a cell line with a high turnover 
rate may be effected to a greater extent than one which divided at a slower rate. There 
was no evidence for this in the toxicity assays carried out here. It may however be 
possible to see such differences if the cells were exposed to the drugs for shorter 
lengths of time than the standard 7 day incubation period used in this study. Another 
alternative would be to use lower, less toxic drug concentrations with longer incubation
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times. These approaches may reveal more subtle differences in sensitivities between the 
clones.
Also of interest would be the establishment of MDR variants of the DLKP clones. 
Multidrug resistant phenotypes are heterogeneously expressed in tumours (Barranco e t 
a l . ,  1988) and the DLKP-A cell line has been shown to contain subpopulations with 
varying levels of drug resistance. Investigations into the acquisition of this phenotype 
by the individual DLKP clones could give insight into the subpopulations of tumours 
in  v iv o  most likely to adopt this phenomenon and how and why they do so. In addition, 
the putative links between multidrug resistance and differentiation (Biedler, 1994) could 
also be further examined in the light of the differentiation studies carried out here on 
the DLKP clones.
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4.6 CHARACTERISATION OF DLKP CLONES
One of the main aims of the work described here was to characterise the DLKP cells 
and each of the clones as fully as possible to determine what type of lung tumour cells 
DLKP resembled and whether individual phenotypic roles could be assigned to the 
isolated clonal subpopulations. To achieve this, ultrastructural, functional and biological 
features of the cells were examined.
4.6.1 Electron Microscopic Analysis
Electron microscopic analysis of cells at the ultrastructural level is one of the most 
useful methods currently available for examining cell structure and content, allowing 
cells to be characterised and classified accordingly. As mentioned in Section 1.2, it was 
EM studies which first revealed the overlapping features within NSCLC and SCLC cells 
(McDowell e t a l . , 1981), observations which have ultimately led to the now widely held 
‘common stem cell’ theory of the origins of lung tumours.
Ultrastructural analysis frequently reveals neuroendocrine features in cells, such as 
dense core granules, which may otherwise be undetectable. (Hammer e t a l . , 1989). In 
many cases, EM analysis is the only definitive method of cell identification eg. 
determination of the presence of lamellar inclusion bodies in lung type II cells, and 
studies employing this technique have yielded much information on the structure and 
function of lung epithelial cells (Baldwin, 1994 and Have-Opbroek e t a l . , 1988).
DLKP, DLKP-I, -M and -SQ were examined by EM and were found to contain no 
organelles characteristic of any differentiated lung epithelial cell types (Section 3.2.1). 
Features such as dense core granules and lamellar bodies are indicative of NE cells and 
type II cells respectively, but no such features were present. The 4 lines were found to 
be similar to each other in their lack of cell type-specific organelles and no differences 
were apparent between the cells.
It therefore appears that each of the clones is poorly differentiated, containing few
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ultrastructural features apart from those necessary for replication. As mentioned earlier, 
lack of differentiation is typical of aggressively growing tumours, and differentiation 
inversely correlates with proliferation. It cannot be determined however, if these DLKP 
tumour cells arose from already poorly differentiated cell types or dedifferentiated from 
a slightly more differentiated cell type. The common stem cell theory implies that the 
former is the case.
The EM analysis here was carried out on cells which had been harvested i.  e. not on 
growing, attached cells. Examination of DLKP cells and clones in  s i tu  could yield 
significant additional information about these cells eg . determining the presence of cell­
cell attachments such as desmosomes, the location of the nucleus in each clonal cell 
type (central, basal or apical), the cross-sectional shape of the cells (columnar, cuboidal 
or pyramidal) e tc . Such information could be of significant benefit in further 
characterising the clones.
4.6.2 Electrical Resistance
Polarised epithelial cells line all body cavities in adult mammals and are also found in 
tissues which carry out specialised absorptive and secretory functions. These cells are 
characterised by a) the polarised distribution of the cytoskeleton and cytoplasmic 
organelles, b) the formation of 3 distinct membrane domains, apical, lateral and basal, 
brought about by the ordered distribution of plasma membrane proteins and lipids, c) 
the presence of tight junctions which separate apical and lateral membrane domains and 
form barriers to the intercellular diffusion of ions and macromolecules and d) cohesive 
cell-cell interactions formed by cell adhesion molecules and a highly developed 
junctional complex (reviewed in Rodriguez-Boulan and Nelson, 1989).
Bronchial epithelial cells are polarised and serve as a barrier to the movement of water 
and solutes between the airways and the interstitial compartments of the lung (Boucher 
e t a l . ,  1988). Cultured Clara cells have been shown to actively transport Na+ in an 
apical to basolateral (lumen to interstitial compartment) direction (Van Scott e t a l . , 1987 
and 1989). Transport functions such as these are important in maintaining the depth and 
composition of the layer of liquid lining the airway surfaces. Abnormalities in these
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pathways can result in lung diseases such as cystic fibrosis which involves defects in 
the transport of Na+ and Cl' that result in accumulation of mucoid secretions and 
occlusion of the small airways (Anderson and Welsh, 1991).
The colonic tumour cell lines T84 and Caco-2 have been employed extensively for 
physiological studies on epithelial ion transport (reviewed in Dharmsathaphom and 
Madara, 1990). These cells can form tight junctions with high resistance which separate 
their apical and basolateral membranes and confer on them their electrolyte transport 
properties. Measurements of tight junction formation may be made by determining the 
electrical resistance across monolayers of cultures cells (Yu e t a l . ,  1994). Electrical 
resistance increases over time (days) in concert with the number of tight junctions 
formed in a confluent monolayer. The failure of a monolayer to exhibit increased 
electrical resistance is indicative of the absence of tight junctions and such cells cannot 
be polarised and thus do not carry out vectorial secretory or absorptive functions.
Neither DLKP nor its 3 clones formed tight junctions when cultured in confluent 
monolayers as determined by their failure to demonstrate increased electrical resistance 
compared with T84 cells. Therefore, none of the 4 DLKP lines appeared to form 
polarised monolayers as normal lung epithelial cells would do in  v iv o  and in  v i t r o  (Yu 
e t a l . , 1994) and so cannot perform electrolyte secretory functions similar to Clara cells 
of the bronchial epithelium. SKMES-1, a human lung squamous carcinoma cell line, 
also also appeared to lack tight junction formation when examined for comparative 
purposes and so too could be considered to be non-polar. These results indicate that 
none of 3 DLKP clones represent a cell type similar to differentiated Clara cells capable 
of electrolyte transport functions.
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4.6.3 Biological Marker Expression
The importance of the correct diagnosis of lung tumour type was outlined in Sections
1.2 and 1.7. NSCLC and SCLC respond differently to chemotherapy (Gazdar and 
Linnoila, 1988) and can have different rates of progression with implications for 
prognosis (Lequaglie e t a l . ,  1991 and Warren e t a l . ,  1990). Clinically, the distinction 
between NSCLC and SCLC is still largely made on the basis of morphological, light 
microscopic examination. The development of antibodies which are specific for protein 
markers in normal and tumour cell types has resulted in a greater precision in tumour 
classification and has also demonstrated the frequent overlap between the standard 
classifications. In addition, tumour-specific markers may be useful for antibody-directed 
therapy. The Third International Workshop on lung tumour and differentiation antigens 
reported recently (Stahel e t a l . ,  1994) on their progress in identifying clusters of 
antibodies based on similar reactivities against cell lines and tissues, in an effort to 
define antigens associated with lung tumours and lung differentiation. It is hoped that 
this internationally coordinated study will identify antibodies which can be used as tools 
in the elucidation of normal and tumourigenic lung cell processes.
DLKP cells were examined for the expression of a number of markers (Section 3.2.3) 
which it was hoped would give an insight into the tumour type from which DLKP was 
derived, as well as the respective differentiation states of the DLKP clones.
The finding that neither DLKP cell lines (examined at varying passage numbers from 
6 to 30), nor the tumour from which they were established, expressed the epithelial 
markers examined was unexpected given that the tumour had been diagnosed as a 
poorly differentiated squamous cell carcinoma. While the antigens of EM A and EP16 
are as yet unknown, both antibodies exhibit widespread reactivities with epithelial cells, 
but not with DLKP cells. The lack of desmoplakin reactivity indicated the absence of 
desmosomes and hemidesmosomes from DLKP cells, which epithelial cells would also 
be expected to contain. Transglutaminase expression was examined to determine if the 
squamous morphology exhibited by the cells could be shown to reflect underlying 
squamous differentiation, but no reactivity was detected.
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DLKP cells were also examined for the expression of 7 of the most commonly 
occurring keratins with an anti-pan cytokeratin antibody. No reactivity was detected. 
Human fetal lungs at the pseudoglandular stage (10-16) weeks are positive for both 
keratin and EM A reactivity (Yousem e t  a l . ,  1990), so DLKP may represent cells that 
are either more poorly differentiated than 10 week old fetal epithelial cells, or cells 
which have dedifferentiated from more well-differentiated epithelial cells. The only lung 
epithelial tumour cells which have been shown to lack keratin expression are SCLC-V 
cells (Broers e t a l . , 1985) and these have been shown to express neurofilament proteins, 
as have DLKP cells. SCLC-V cells are thought to arise from the progression of classic 
SCLC cells to the more aggressive variant phenotype (Carney e t a l . , 1983 and Doyle 
e t a l ,  1991). SCLC-C cells usually contain keratin filaments and not neurofilaments. 
Keratins form complex skeletal networks throughout the cytoplasm of epithelial cells 
and appear to attach to the intercellular desmosomal plaques which play an important 
role in epithelial cell adhesion (reviewed in Steinert and Roop, 1988). Thus, the 
downregulation of cell-cell attachment seen in the loosely aggregated colonies of SCLC- 
V cells (Gazdar e t a l . , 1985, Carney e t a l . , 1985 and Bepler e t a l . , 1987b) may reflect 
the loss of desmosomal cell-cell attachments and the replacement of keratin proteins 
with neurofilament proteins, allowing a less restricted, more aggressive phenotype to 
emerge.
The 703D4 and 704A1 antibodies reacted positively with DLKP cells and each of the 
clones. These antibodies were believed to distinguish NSCLC from SCLC (Mulshine 
e t a l . , 1983) but are now thought to identify an antigen which is expressed in cells very 
early, before clinical features of neoplasia are evident, in the tumourigenic process 
(personal communication, Dr.J.Mulshine, NCI, Maryland, USA and Tockman e t a l . ,  
1988). Therefore, reactivity with these antibodies may not indicate NSCLC 
differentiation but may reflect the presence of an early marker for lung cancer.
The DLKP tumour block showed strong positivity for NSE expression and moderate 
Leu 7 immunoreactivity. The tumour block and all DLKP cell lines examined were also 
positive for PGP 9.5 expression. These results, along with the demonstration of 
neurofilament reactivity, are indicative of neuroendocrine differentiation. GFAP and
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NCAM proteins were not detectable in any DLKP cells, nor were 5-HT and 
chromogranin A reactivities discemable. This correlates with the absence of dense core 
granules demonstrated in the electron microscopic analysis (Section 3.2.1). The 
expression of a limited number of NE markers including NSE, Leu 7 and 
neurofilaments but not dense core granules is characteristic of SCLC-V cells (de Leij 
e t a l . , 1985, Watanabe e t a l . , 1988, Deftos e t a l . , 1988 and Carbone e t a l . , 1991). As 
described in Section 1.1, neuroendocrine cells are the first mature cell type to appear 
in the developing lung and NSE immunoreactivity is one of the earliest markers 
observed in these cells, appearing in immature NE cells at 8 weeks before most 
neuropeptides can be detected (Cutz e t a l . ,  1982). Therefore, the presence of NSE 
positivity in cells which do not contain neuropeptides or APUD elements, as is the case 
with DLKP, may indicate that such cells are at a very early stage of differentiation and 
theoretically can progress towards several distinct phenotypes. Maintaining this 
plasticity is of obvious benefit to tumour cells as they remain uncommitted to any single 
differentiation pathway and so are free to adapt to a changing environment.
The complement of marker expression determined in DLKP lines suggests that the cells 
should be classified as either NSCLC-NE or SCLC-V. The former subtype is defined 
as the expression of 2 or more NE markers in otherwise NSCLC cells while the latter 
is considered to be the absence of expression of some NE markers in otherwise SCLC 
cells which are tending towards large cell morphology. The fact that DLKP cells 
express NSE and neurofilaments and do not express keratins slightly favours 
classification as SCLC-V.
Vimentin intermediate filament proteins were not detected in the tumour block, 
confirming that the tumour was probably not mesenchymal in origin (Steinert and Roop, 
1988) and the absence of leucocyte common antigen (LCA) reactivity suggested it was 
unlikely that the tumour was a lymphatic primary tumour. The fact that the biopsy was 
taken from a lymph node metastasis made this confirmation necessary.
None of the clones, nor parental DLKP cells (passages 6 and 29) were found to express 
detectable levels of P-glycoprotein, the membrane drug efflux pump. This correlated 
with the high sensitivities of the cells to MDR drugs (Section 3.1.6) and leant support
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to the theory that the MDR phenotype, which in the case of the DLKP-A variant cells 
includes overexpression of P-glycoprotein, is acquired as a result of drug exposure 
rather than the selection of an inherently multidrug resistant subpopulation.
DLKP and each of the clones were found to express a 2-integrin. However, the 
reactivity appeared strongest in DLKP-M cells. These cells had exhibited unusual 
extracellular matrix attachment properties (Section 3.1.5) and the difference in 
expression of this integrin compared with the other clones could be one of the reasons 
for this. Metastatic cells exhibit altered integrin expression and the overexpression of 
a 2 integrin, which can bind collagens, laminin and fibronectin (Rouslahti, 1991), in 
DLKP-M cells may play a significant role in the behaviour of this mesenchymal-like 
cell type. Alternatively, there may be a downregulation of a 2-integrin expression in 
DLKP, DLKP-I and -SQ cells. Normal bronchial and alveolar epithelial cells express 
high levels of this integrin (Damjanovich e t a l . , 1992 and Mette e t a l . , 1993) and others 
which allow them to adhere strongly to their basement membrane and resist the shear 
forces and airway turbulence caused by normal breathing and coughing e tc . Antibodies 
directed against specific integrins can be used to determine their roles in attachment and 
migration of different cell types (Adams and Watt, 1991). Determination of the array 
of integrins and other attachment molecules expressed by the DLKP cells and clones, 
along with the examination of the effects of neutralising antibodies, could reveal 
differences in the physiology and behaviour of the individual DLKP clonal 
subpopulations.
The characterisation studies of DLKP thus indicated that the cells were poorly 
differentiated with no evidence for differentiation towards any normal mature lung cell 
type. The absence of keratin and the presence of neurofilaments and the early fetal lung 
marker NSE suggested that the cells resembled immature, multipotent fetal epithelial 
cells with very slight neuroendocrine differentiation. The tumour type which DLKP 
resembles most closely appears to be variant SCLC, or perhaps NSCLC-NE, but the 
presence of neurofilaments and the lack of keratin, desmosomes and other epithelial 
markers favours the former category. No evidence was found here to support the theory 
that DLKP-I represented a stem cell-like population from which DLKP-M and -SQ arise 
because no such indicative differences in function or markers were found.
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4 .7  SPECIFIC M ARKERS FO R DLKP CLONES
While the determination of marker expression in DLKP cells yielded much information 
on the tumour cell types they were similar to in  v iv o ,  no markers had emerged that 
could be used to distinguish between the individual DLKP clones. The immunological 
characterisations had been carried out using immunocytochemical methods which are 
not quantitative, as for example Western blot analysis could be. Therefore, there may 
have been quantitative differences in the levels of marker expression between the 
clones. However, using differences such as these as markers for the individual clones 
would not have been satisfactory as it would not allow in  s i tu  qualitative or quantitative 
examination of clonal phenotypes in mixed populations such as in interconversion or 
differenation studies. Only the identification of a marker which was expressed on 1 or 
2 of the clones and not on all 3 would enable such studies to be carried out.
Therefore, in an attempt to identify specific markers for the clones, monoclonal 
antibodies were raised to the parental DLKP cells (Section 3.3.1). The rationale was 
that this population should contain the sum of the markers expressed by the individual 
clones, possibly along with some additional markers, and so the resulting monoclonal 
antibodies may react differentially with the clonal subpopulations. However, of the 28 
hybridomas which produced antibodies directed against DLKP antigens, all were found 
to react to some extent with each of the clones in ELIS As, although 2 antibodies, 4D2 
and 3E1, appeared to be less reactive with DLKP-I than the 2 other clones.
When the 4D2 and 3E1 monoclonal antibodies were used in Western blot analyses, 3E1 
failed to produce a band for any cell lines examined. This was probably due to the 
antigen it recognised being altered in the reducing conditions of the SDS gel. 4D2, 
however, produced a tight band in Western blots which had an apparent molecular 
weight of approximately 58kD. The intensity of this band was consistently stronger in 
DLKP-SQ cells than in DLKP, DLKP-I or -M cells. The 4D2 antibody not only reacted 
with DLKP cells in Western blots, but also with several other lung lines examined, all 
of which resulted in a single band of 58kD also. Immunocytochemical analysis revealed 
that the 4D2 and 3E1 antigens were expressed in effectively all tissue types, both 
normal and tumour, and also in non-human species (Tables 3.3.6.2 - 3.3.6.4). The
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staining patterns produced by both antibodies indicated that the antigen was 
cytoplasmic.
It would therefore appear that the 4D2 and 3E1 antibodies, far from being specific 
DLKP clone markers, detect ubiquitous markers for all cell types. The demonstration 
that the 4D2 antigen was expressed at a higher level on DLKP-SQ cells than the other 
clones was not sufficient to enable the antibody to be used in clone identification 
studies.
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4.8 EFFECTS OF DIFFERENTIATION-INDUCING AGENTS ON DLKP 
CELLS
The effects of differentiation-inducing agents on the morphologies and marker 
expression of DLKP and its clones were examined in an attempt to manipulate the 
apparently spontaneous clonal interconversions observed in culture and also to elucidate 
the differentiation pathways open to the clones by determining changes in marker 
expression. Many differentiaion-inducing agents are described in the literature and of 
these, BrdU and RA were selected for study, the former partly because of the 
demonstration of its effect on SCLC cell morphology (Feyles e t a l . ,  1991) and the latter 
partly because of its well-established involvement in the regulation of squamous 
differentiation (Terasaki e t a l . ,  1987).
The 3 distinct subpopulations which have been identified in many neuroblastoma cell 
lines (Ciccarone e t a l . , 1989) serve as an interesting comparison to the DLKP clones 
and interconversion of these subpopulations has been demonstrated in response to RA 
and BrdU (Ross e t a l . ,  1994). The neuroblastoma subpopulations consist of (i) a cell 
type termed ‘N ’ which is neuroblastic in appearance with a rounded cell body and 
numerous neurite-like processes and possesses APUD features, (ii) a cell type termed 
‘S’ which is larger, flattened, highly substrate-adherent and resembles epithelial cells 
and exhibits Schwannian rather than neuronal properties and (iii) a cell type termed ‘I’ 
with a morphology intermediate between that of N and S cells. The N and S cell types 
are descended from a common precursor cell type and both are capable of spontaneous 
interconversion to the other cell type (Ross e t a l . , 1983). The I cell type may represent 
a cellular intermediate in the N- and S-cell transdifferentiation process or may be a stem 
cell from which both N and S cells arise. Studies by Ross e t a l. (1994) found that BrdU 
treatment induced differentiation of I cells to S-type morphologies while RA treatment 
resulted in N-type colonies. However, not all neuroblastoma lines respond in this 
manner and some have been shown to differentiate towards an S-type morphology 
following RA treatment (Ross e t a l . , 1991).
The spontaneous interconversions of the DLKP clones mirrored those of neuroblastoma
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subpopulations and both appeared to occur v ia  an intermediate cell type. However, no 
interconversion was seen between the DLKP clones in response to BrdU or RA (Section 
3.4). In fact, RA had very little effect on morphology except that cells in colonies 
seemed less tightly packed together. BrdU, in contrast, had more obvious effects on 
morphology and the effect increased with increasing BrdU concentration. The treated 
cells no longer grew in colonies but became larger and more stretched in appearance. 
This increase in cell surface area in response to BrdU has been previously reported for 
SCLC cells (Feyles e t  a l . ,  1991), melanoma cells (Valyi-Nagy e t a l . ,  1993) and 
neuroblastoma cells (Ross e t a l ., 1994), all using similar concentrations of 
approximately 10/xM BrdU.
Increasing the lengths of exposure time to RA and BrdU may lead to interconversions 
between the DLKP clones. The longest exposure time used here was 14 days whereas 
the interconversions in neuroblastoma subclones is observed after 21 days or more 
(Ross e t a l . ,  1994). Alternatively, the DLKP clones may have greater differentiating 
potential than neuroblastoma cells and RA and BrdU treatment may be inducing 
expression of additional phenotypes rather than just inducing interconversion between 
2 or 3 morphologies.
The finding that keratin expression had been strongly induced in BrdU- and RA-treated 
DLKP cells was surprising. While reports of alterations in keratin expression in 
response to differentiation-inducing agents exist in the literature (Terasaki e t a l . , 1987 
and Stellmach e t a l . , 1991), no reference has yet been found to the induction of keratin 
expression in cells which previously contained no keratin filaments. BrdU and RA 
appeared to induce differentiation of DLKP cells towards a new phenotype which was 
not already present in the parental population, rather than causing clonal 
interconversion. This supports the proposal above that DLKP cells are multipotent and 
capable of differentiation along several pathways. This also indicates that the cells 
possess undifferentiated stem cell-like phenotypes which corroborates the poor 
differentiation demonstrated in immunocytochemical and electron microscopic analyses. 
It appears that DLKP cells may be cycling between restricted, undifferentiated stem cell 
phenotypes, incapable of advancing along normal differentiation pathways due to 
unknown blocks and as a result are tumourigenic. It is possible that BrdU and RA
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overcame these blocks and caused the cells to differentiate along as yet unidentified 
pathways. Determination of the proliferative capacities of these new phenotypes may 
indicate if this hypothesis is accurate. Reduced growth rates and colony forming 
efficiencies in treated cells would strongly suggest that the malignant phenotype 
exhibited by untreated DLKP cells was being reverted to a less malignant state.
BrdU was found to effect other cell lines in a similar manner to that of DLKP (Section 
3.4.1.3). A549, an adenocarcinoma cell line and SK-N-SH, a neuroblastoma cell line, 
both exhibited an increase in cell surface area. Keratin expression appeared to be 
increased in these cells after BrdU treatment (not examined with RA) and it was 
unexpected to find that SK-N-SH expressed keratins prior to treatment. It had been 
hoped to use these cells as a negative control to determine the effect of BrdU on other 
cell lineages which did not express keratin inherently. However, HL60, a leukemic cell 
line which grows in suspension, did not express keratin proteins before or after BrdU 
treatment. The cells also remained in suspension throughout the exposure time.
H82, a SCLC-V which also grows in suspension and does not express keratins, has 
previously been shown to differentiate towards a more tightly aggregated, classic 
morphology in the presence of RA (Doyle e t a l . , 1989), however, differences in marker 
expression were still found between the RA-treated cells and SCLC-C cells. The BrdU- 
treated H82 cells in this study were found to behave differently to the RA-treated cells 
of Doyle e t a l. (1989) and attached increasingly with increasing BrdU concentration. 
The attached cells spread and were epithelioid in appearance. The H82 cells which 
remained in suspension during BrdU treatment did not express keratins, but keratin 
positivity was apparent in some attached cells (Figure 3.4.9). BrdU has been shown to 
have similar effects in a SCLC-C cell line, H69, with floating cell aggregates becoming 
attached and epithelioid in appearance (Feyles e t a l . ,  1991). It therefore appears that 
BrdU and RA each have distinct differentiation effects in multipotent cell populations 
such as neuroblastoma, H82 and DLKP cells.
The differentiation studies here indicate that BrdU induces keratin expression in keratin- 
negative SCLC-V cells such as DLKP and H82 and increases keratin content in cell 
lines which inherently express keratin proteins. However, keratin induction does not
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occur in non-epithelial cells such as HL60 which themselves are induced to differentiate 
by BrdU (Yen and Forbes, 1990) suggesting that the control of keratin expression in 
non-epithelial cells differs significantly from that of epithelial-derived cells, which is 
to be expected as only epithelial cells normally express keratin. BrdU and RA thus 
appear to be capable of inducing cell differentiation along lineage specific pathways and 
will not, for example, induce keratin expression in a non-epithelial cell type.
The phenotypes induced in DLKP by BrdU and RA treatment are as yet unclear. The 
agents had distinct effects on cell morphology suggesting that the resulting phenotypes 
were not identical and that BrdU and RA had induced differentiation along different 
pathways. The expression of neurofilaments, transglutaminase and desmoplakin 
remained unchanged in treated and untreated DLKP cells, thus giving no further insight 
into the identity of the new phenotypes. Retention of neurofilament proteins along with 
keratin expression meant that BrdU-treated cells were expressing 2 sets of intermediate 
filament proteins. Co-expression of 2 and even 3 types of intermediate filaments can 
occur in both normal and tumour tissues (Virtanen e t a l . , 1989, Van Muijen e t a l . , 
1987 and Lehto e t a l . , 1985) and keratin and neurofilament proteins are often co­
expressed in neuroendocrine tumours (Virtanen e t a l . ,  1985).
The proteins of the keratin family, which comprises at least 20 different proteins not 
including hair keratins, are expressed in a very cell-specific manner in epithelial tissue 
(Moll e t a l . ,  1982). A particular epithelium or epithelial cell can be characterised by 
its specific pattern of keratin expression and this means that identification of the keratins 
being induced in DLKP cells could aid in understanding the differentiation pathways 
involved.
The family of keratin molecules is subdivided into type I keratins (Ker 9 - Ker 20) 
which are small and acidic and type II keratins (Ker 1 - Ker 8) which are large and 
neutral to basic (reviewed in Schaafsma and Ramaekers, 1994). All keratin intermediate 
filaments are heteropolymers composed of at least one type I and one type II chain both 
in  v iv o  and in  v i t r o  (reviewed in Steinert and Roop, 1988). The profiles of keratin 
expression in normal and malignant lung epithelial tissues are shown in Table 4.8.1 
(Broers e t a l . ,  1988). Elias e t a l .  (1988) proposed that the overlapping expression of
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keratin filaments in SCLC, NSCLC and normal tissue further supports the concept of 
a stem cell origin of lung cancers.
Logistically, it was not feasible to determine the expression of each keratin protein 
induced in DLKP. 5 keratins were selected for immunocytochemical analysis of BrdU- 
treated DLKP cells and clones. Individual keratin expression was not examined in RA- 
treated cells. The keratins selected were keratins 8, 10, 14, 17 and 18. Keratins 8 and 
18 are the major keratins expressed in simple epithelia, keratin 10 is expressed in 
comifying epithelia, keratin 14 is found in myoepithelial cells and basal cells and 
keratin 17 is expressed in transitional and pseudostratified epithelia, basal and 
hyperproliferating cells (Schaafsma and Ramaekers, 1994).
Keratin 10 and keratin 14 induction was not detected in DLKP cells and clones exposed 
to BrdU. Keratin 14 is expressed in poorly differentiated squamous cell carcinomas but 
not in adenocarcinomas or SCLCs (Schaafsma and Ramaekers, 1994) and its absence 
along with that of keratin 10 suggests that differentiation was not towards squamous or 
myoepithelial cell types.
Strong induction was apparent, however, in the case of keratins 8 and 18 and weaker 
induction of keratin 17 was also evident. Keratins 8 and 18 are expressed in normal 
simple epithelia and their expression has been shown to increase during the progression 
of malignancy (Broers e t a l . ,  1988). These 2 keratin types are also expressed in 
squamous, adenocarcinoma and SCLC cells, therefore no real conclusions as to the 
identity of the new DLKP phenotypes can be drawn from their appearance, except 
perhaps confirming that the cells were simple, undifferentiated epithelial cells and thus 
are likely to be highly malignant. The absence of these 2 keratins would have been 
indicative of a more specialised cell type which would have been unusual in poorly 
differentiated cells.
The detection of keratin 17 expression was more informative. This keratin is expressed 
in normal basal cells and in hyperproliferating cells (Schaafsma and Ramaekers, 1994). 
It is also present in squamous cell carcinomas but the strong expression of keratin 14 
in squamous cell carcinomas also, which was absent in DLKP cells, suggests that
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Keratin
No.
Normal Tissue Tumour Tissue
Columnar
Epithelium
Basal
Cells
Mixed
Glands
Lung
Alveoli
Adeno­
carcinoma
Squamous
carcinoma
SCLC
4 ± ± - ± + +
5 + + + +
7 + - + + + + -
8 + - + - + + +
10 - - - - - + -
13 ± - - - - + -
14 + +
15 +
17 +
18 + ± + + + + +
19 + + + + + + +
Figure 4.8.1 Expression o f keratin proteins in normal and tumour lung tissues from Broers et al, (1988)
squamous differentiation is not as likely to be occurring here as the expression of a 
basal cell phenotype. The absence of transglutaminase reactivity in BrdU-treated cells 
also supported this likelihood.
Determination of the expression of other keratin and protein markers will give a clearer 
insight into the differentiation induced in DLKP cells. Identification of the keratin types 
and other markers induced in the RA-treated cells will determine if the pathways of 
differentiation resulting from RA exposure differ from those of BrdU exposure. 
Examination of other epithelial cell type markers and electron microscopic analysis 
should aid in the identification of the new phenotypes. Differences between the BrdU- 
/RA-treated DLKP clones may also be revealed in such studies.
The novel induction of keratin expression in keratin-negative cells also raises interesting 
questions about the mechanisms of action of BrdU and RA. The information currently 
available on RA-induced gene expression, and specifically keratin gene expression, is 
more substantial than that on BrdU (see Section 1.6). Most RA-induced alterations in 
keratin expression occur at the transcriptional level (Kim e t a l . ,  1987 and Kopan and 
Fuchs, 1989) and effects can occur as early as 6hr after exposure, increasing over 24- 
48hr (Stellmach e t a l . ,  1991). The literature on BrdU-induced differentiation is sparse 
and no reports of its effects on keratin expression could be found. The mechanism of 
action of BrdU in differentiation is unknown but the induction of keratin expression in 
DLKP cells may afford an excellent opportunity to investigate this mechanism. 
Techniques such as DNA footprinting could determine if BrdU acts v ia  the specific 
mechanism of induction of transcription factors. This technique would involve 
extracting protein from treated and untreated cells and mixing them with DNA extracts 
from the cells. Any induced transcription factors will bind to their specific regions of 
DNA and upon incubation with DNase, will protect that region from digestion and will 
create a gap or footprint when the digested DNA fragments are run on a gel. 
Reproducible footprints would indicate that BrdU was inducing transcription of specific 
genes by activation of transcription factors.
Determination of the effects of other differentiation-inducing agents on DLKP and its 
clones would also be valuable in determining the differentiation potentials of the cells.
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Agents such as butyric acid (Chen and Breitman, 1994), vasoactive intestinal peptide 
(Pence and Shorter, 1990), TGFjS (Masui e t a l . ,  1986 and Jetten e t a l . ,  1986), 
interferon-a, interleukin 6 and insulin (McCormick e t  a l . ,  1995), phorbol esters and 
diacylglycerol (Jetten e t a l . , 1989), sodium butyrate, dimethyl sulfoxide and dimethyl 
formamide (Mickley e t a l . , 1989 and Khan e t  a l . , 1993) and forskolin (Ross e t a l . , 
1991) have all been found to be differentiation-inducing agents in many cell systems 
including lung epithelial cells and could be used with DLKP cells to assist in the 
elucidation of tumour cell potentials.
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4.9 COMPARISON OF GROWTH OF DLKP AND DLKP-A
As outlined in Section 1.7, alterations in phenotype and growth control such as reduced 
growth proliferative potential, reduced oncogenic potential and altered morphology are 
often evident in MDR variants of tumour cell lines (Biedler e t a l . ,  1981 and 1975). 
These observations led to the proposal that acquisition of the MDR phenotype may be 
related to cell differentiation (Biedler, 1994), The growth of DLKP and one of its MDR 
variants, DLKP-A, was examined in the presence of serum and a range of growth 
factors to determine if there was evidence of altered differentiation in this MDR variant 
(Section 3.5).
No difference was found between the proliferation rates of DLKP and DLKP-A in the 
presence of 0% serum in the 9 days over which the assays were carried out. In the 
presence of 5% and 10% serum, the growth rates of the 2 lines were similar up to day 
7, after which time, the proliferation of DLKP exceeded that of DLKP-A at both serum 
concentrations. The fact that the growth rates of the 2 lines were comparable for the 
first 7 days of the assays indicates that the cells respond similarly to the growth signals 
present in serum. The increase in growth of DLKP over DLKP-A after day 7 suggests 
that the DLKP cells may be secreting additional growth stimulatory molecules 
themselves that are produced in sufficient amounts to stimulate growth only at the cell 
densities reached by day 7. Alternatively, DLKP-A may be producing growth inhibitory 
factors which decrease its growth with respect to DLKP. Thus, the difference in growth 
responses of the 2 cell lines to serum may be indicative of a reduced growth potential 
of the MDR variant compared with its sensitive counterpart.
However, the responses of DLKP and DLKP-A to growth factors, PDGF-A, PDGF-B, 
EGF, TGF/3, IL-1 and IL-6, in the 7 day monolayer assay produced evidence contrary 
to this. In these assays, the growth of DLKP-A cells was stimulated by each of the 6 
growth factors examined. While much assay-to-assay variation was apparent in both cell 
lines, a trend towards stimulation in DLKP-A cells was nonetheless evident. DLKP, in 
contrast, showed little responsiveness to the growth factors. It is possible that a longer 
incubation period would have affected the responses of DLKP , as was the case in the
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serum response assays, or that combinations of growth factors, rather than single 
agents, would stimulate DLKP growth. However, it is not clear at the moment why 
individual growth factors succeeded in enhancing the growth of DLKP-A cells while 
serum failed, and why the reverse occurred with DLKP cells.
The 3H-thymidine incorporation assays in turn seemed to contradict the monolayer 
assays. Here, DNA synthesis appeared to be increased in DLKP cells in response to 
growth factors while little effect was seen with DLKP-A cells. In these assays, 
responses were determined after only 24hr exposure to the growth factors which was 
much shorter compared with the 7 days of the growth assays. It is possible that the time 
scale over which the growth factors exerted their effects on the 2  lines differed and that 
while DLKP responded within 24 hr to growth factor signals, DLKP-A responded more 
slowly and so DNA synthesis had not begun before incorporation of 3H-thymidine was 
determined. However, no such delay in DLKP-A responses to growth signal was 
apparent in the 7 day growth assays which would seem to rule out this possibility. The 
finding that DLKP and DLKP-A had similar toxicity profiles for BrdU seemed to 
eliminate the possibility that DLKP-A cells expressed lower levels of thymidine kinase 
than DLKP cells and failed to incorporate exogenous 3H-thymidine as a result.
The growth factor assays carried out here are therefore inconclusive, both as regards 
differences in growth regulation between MDR variants and their sensitive counterparts 
and the theory that acquisition of an MDR phenotype correlates with increased 
differentiation.
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4.10 RIBOZYME TRANSFECTANTS
Ribozyme gene transfection is a relatively novel approach to the reversal of MDR in 
cancer cells but to date, no lung cell lines have been successfully reverted to a sensitive 
phenotype by this technique (see Section 1.7). In this study, clonal populations of 
DLKP and DLKP-A, DLKP-I and DLKP-A-2B respectively, were chosen to transfect 
with an MDR-1-specific ribozyme in an attempt to overcome multidrug resistance 
(Section 3.6). Clonal subpopulations were opted for because it was envisaged that a 
more homogenous population would take up the plasmid, express it and be affected by 
it in a more uniform manner than mixed parental populations and thus would be more 
beneficial as models during the initial establishment of the procedure. Mixed parental 
populations would obviously be closer to the in vivo situation and possibly more 
relevant in the long term and these were indeed successfully transfected with the MDR-1 
ribozyme also (work carried out by Dr.Carmel Daly), but clonal populations were 
considered to facilitate a more precise initial assessment of the possibilities of this 
approach.
The ribozyme plasmid contained a geneticin-resistance gene and so, following 
transfection, survival of cells in geneticin-containing selection medium indicated that 
the cells had been successfully transfected and were expressing at least the geneticin- 
resistance gene in the plasmid. PCR and RT-PCR analyses confirmed that the ribozyme 
gene was present in the transfected cells and not in control untransfected cells, and was 
being transcribed.
The MDR-1 ribozyme was to exert its effect by enzymatically degrading MDR-1 RNA, 
thus preventing P-glycoprotein expression. DLKP-I untransfected cells contained no 
MDR-1 RNA by RT-PCR analysis and no expression was seen in DLKP-I untransfected 
cells either. DLKP-A-2B untransfected cells, in contrast, exhibited overexpression of 
MDR- 1 RNA when examined by RT-PCR. The level of RNA expressed in DLKP-A-2B 
1A5 transfectants was lower than in DLKP-A-2B parental cells, and no RNA expression 
was detected in the 1C7 transfectant. It thus appears that the MDR-1 ribozyme was 
successfully downregulating the expression of MDR-1 RNA to some extent in
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transfectant 1A5 and apparently completely in transfectant 1C7.
The MDR-1 ribozyme was therefore capable of decreasing P-glycoprotein expression 
at the RNA level but it was necessary to determine what effect, if any, this had on the 
drug resistance of DLKP-A-2B cells. As expected, the toxicity profiles of the DLKP-I 
transfectants were largely unchanged from those of DLKP-I for the 3 MDR drugs, 
adriamycin, vincristine and VP16. Two of the transfectants, 1C9 and 1G8, appeared to 
have approximately a 2-fold increase in IC50 values over those of untransfected DLKP-I 
cells.
Interestingly, the DLKP-A-2B 1A5 transfectants were also found to exhibit increased 
resistance to each drug when compared with DLKP-A-2B cells, similar to that which 
had been observed in DLKP-I 1C9 and 1G8 transfectants. In the cases of adriamycin 
and vincristine, approximately a 2-fold increase in resistance was seen in the 1A5 cells, 
with a smaller increase evident in response to VP16. The transfection procedure 
involves cloning of the transfected cells (Section 2.19) and it is possible that inherently 
more resistant clones were selected at this stage from both the DLKP-I and DLKP-A-2B 
populations. Despite being clonal subpopulations, it is possible that variations in 
resistance were present. Thus, in the case of DLKP-A-2B 1A5, the ribozyme may have 
been having an effect on P-glycoprotein expression and indeed appeared to be doing so 
in the analysis P-glycoprotein RNA levels (Figure 3.6.3), but it cannot be determined 
if drug resistance was reduced in these cells. Alternatively, the site at which the plasmid 
was incorporated into the genome may have had significant ramifications for the drug 
resistance profiles of the cells. Incorporation at a site involved in any aspect of MDR 
biology could result in altered resistance and this possibility cannot be avoided.
The sensitivity of the DLKP-A-2B 1C7 transfectant was markedly increased compared 
with the untransfected DLKP-A-2B cells, revealing that the MDR-1 ribozyme had 
successfully affected the drug resistance of these cells. The greatest effect was in 
response to vincristine where a 26-fold reduction in resistance to this drug compared 
with DLKP-A-2B was found. When compared with sensitive DLKP parental cells, the 
IC50 value of 1C7 cells was only twice that of DLKP, indicating that the ribozyme had 
effectively abolished resistance to vincristine in 1C7 cells.
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The resistance of 1C7 cells to adriamycin was also decreased with a 5-fold reduction 
evident when compared with DLKP-A-2B cells. This corresponded to approximately 
a 3.5-fold increase in resistance over the sensitive DLKP cells and compares with a 16- 
fold increase in resistance of DLKP-A-2B cells over DLKP cells. The smallest effect 
was seen in response to VP16 where 1C7 cells were only approximately 1.5-fold more 
sensitive than DLKP-A-2B cells.
The patterns of altered resistances of 1C7 cells to the 3 drugs correlated with the extent 
to which P-glycoprotein is involved with their respective mechanisms of action. 
Overexpression of P-glycoprotein is the major mechanism involved in resistance to 
vincristine (Clynes et a l., 1990). Therefore, downregulation of MDR-1 RNA should 
result in a significant decrease in resistance to this drug. This was found to be the case 
in the 1C7 tranfectants. Adriamycin and VP16, in contrast, operate via topoisomerase 
II inhibition, in addition to other mechanisms including to a lesser extent overexpression 
of P-glycoprotein (Osheroff et al. , 1994). In agreement with this, the MDR-1 ribozyme 
was less effective in reducing resistance to these drugs in the 1C7 cells. However, it 
is not necessary to confer on a cell sensitivity to every drug. Reversal of resistance to 
one drug may be sufficient to restore the benefits of chemotherapy.
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C O N C LU SIO N
5.0 CONCLUSION
The DLKP cell line appears to represent a poorly-differentiated lung epithelial 
population which is similar to the omnipotent cell type expressed at early stages (before 
8  weeks) of fetal lung development. The absence of cell type-specific markers from the 
cells, as determined by electron microscopic and immunocytochemical analyses, in 
addition to the lack of differentiation-associated functions inferred from the inability of 
the cells to form polarised monolayers, indicates a low level of differentiation, typical 
of aggressive tumour cells.
The presence of morphologically heterogenous subpopulations within the DLKP cell line 
was confirmed by the establishment of the 3 clonal populations DLKP-I, -M and -SQ. 
The morphologies of the individual clones are distinct from each other and are 
homogenous for up to 20 passages after isolation. DLKP-I possesses the least 
morphologically stable morphology and appears to behave as a stem cell-like population 
by giving rise to the 2 other clonal cell types. The DLKP-I cells morphologically 
resemble basal cells in terms of their small size and low nuclear-to-cytoplasmic ratio 
and their inability to form colonies in soft agar may reflect a requirement for attachment 
to the basement membrane for optimum, 3-dimensional proliferation. In vivo, basal cells 
are the only epithelial cells which form attachments to the basement membrane (Tandler 
et al., 1981).
The spontaneous conversion of DLKP-I cells towards a squamous morphology during 
normal culture conditions and when cultured in SFM and in suspension flasks, the 
observation that up to approximately 65% of parental DLKP cells are squamous in 
appearance and the diagnosis of the original biopsy as a poorly differentiated squamous 
carcinoma suggests that differentiation from DLKP-I, stem cell-like cells, towards 
DLKP-SQ, squamous-like cells, may be the main pathway followed by these tumour 
cells, both in vitro and in vivo.
In contrast, the DLKP-M phenotype appears to be more stable and this, in addition to 
the slower proliferation rates of these cells in the growth assays and their failure to
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proliferate in SFM, suggests that the DLKP-M cells may be more differentiated or may 
have a more specialised function than DLKP-I and -SQ cells. Also in support of this 
theory are the observed similarities between DLKP-M cells and metastatic cells with 
regard to properties such as such as their morphology, motile behaviour, distinct ECM 
attachment properties and apparent altered c^-integrin expression.
The DLKP cell subtypes may therefore serve as a useful model for examining tumour 
cell interactions and conversions. The ability to study isolated, characterised clonal 
populations with apparently distinct roles should advance our understanding of tumour 
cell biology.
While most tumour types contain overlapping features, it is necessary to define any 
tumour cell model as completely as possible to enable extrapolations to be made with 
other in vitro models, in addition to the in vivo situation. The biological marker profile 
of the DLKP cell line is consistent with that of variant small cell lung carcinoma cells. 
DLKP cells may now therefore be used more effectively to study aspects of the 
tumourigenic process with a clearer understanding of how information obtained from 
these cells may be applied in vivo.
While the DLKP clones are morphologically distinct and have different growth 
properties, no marker has been identified which is capable of distinguishing between 
the clones. The identification of such a marker is important in terms of confirming 
phenotypic differences between the clones and also to serve as a quantitative marker in 
interconversion and differentiation studies.
The failure of the differentiation-inducing agents, BrdU and RA, to induce clonal 
interconversion but to instead induce apparent differentiation indicates that these agents 
are capable of overcoming the supposed ‘block’ that causes the DLKP cells to remain 
in a poorly differentiated state and also confirms the multipotent nature of the DLKP 
cells. It remains to be determined if these new phenotypes are less malignant than their 
untreated counterparts and future characterisation work should shed light on the 
pathways of differentiation open to DLKP tumour cells. These cells could possibly be 
used in studies examining the efficacy of differentiation-inducing agents as anti-tumour
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agents.
The observation that BrdU and RA are capable of inducing keratin expression in 
keratin-negative epithelial cells is a novel finding with important implications for both 
normal and abnormal differentiation processes. Further studies with DLKP cells may 
aid in the elucidation of control of keratin gene expression as well as facilitating 
investigations into the mechanisms of action of BrdU and RA as differentiation-inducing 
agents.
Lung cancer is the leading cause of cancer death and new treatment regimes are 
urgently required. MDR 1 ribozyme transfection experiments carried out here were 
successful in reversing multidrug resistance in a DLKP-A clonal population, DLKP-A- 
2B 1C7. No such reversal has been reported in a lung cell line to date. Therefore, while 
these studies are still in preliminary stages, the 1C7 cells should allow, not only further 
investigations of the role of P-glycoprotein in multidrug resistance, but also the 
assessment of ribozyme gene therapy as a strategy in the treatment of lung cancer.
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